ࡱ>  0bjbj .?!!!55559 t 51C+////bbbh?j?j?j?j?j?j?$1FH?]!fV bff?//%'Bfd0/!/h?fh?j )^;/@rY50T?C01C1 WIl WId;;WI!T=bcrde}bbb??)bbb1CffffWIbbbbbbbbb : Practicals Lab. Practical 1Blood Glucose Estimation Lab. Practical 2 Oral Glucose Tolerance Lab. Practical 3Glycated Hemoglobin Estimation Lab. Practical 4Measurment of Triglycerides Lab. Practical 5Measurement of Total Cholesterol , HDL and LDL Lab. Practical 6Renal Function Tests: BUN and Creatinine estimation Lab. Practical 7Creatinine Clearance Estimation Lab. Practical 8Liver Function Tests 1: Bilirubin ; Total and Direct Lab. Practical 9Liver Function Tests 2: Enzymes; ALT, AST and GGT Lab. Practical 10Albumin and Total Protein Estimation Lab. Practical 11Bone profile Testes Lab. Practical 12Cardiac profile testes Lab. Practical 13 15 Tutorials  Introduction To Applied Biochemistry General Comments about testing There are so many different methods used to analyze different chemical compounds that to state one method over another is unfair. Another issue is that your body chemistry changes throughout the day in response to external conditions such as exercise and internal conditions such as kidney function. This makes comparisons among various tests difficult to do. One method to lessen these variables is to try to have your tests done by the same laboratory so that comparisons of test values are possible. It is also beneficial then to have your tests drawn under the same conditions (fasting/non fasting, early morning/late afternoon, etc.) so that you can eliminate these interferences when you look at your results. Practices of Clinical chemistry Estimation of Blood Glucose Introduction: The importance of testing the blood glucose level comes from the fact that the brain cells are very dependent on the extracellular glucose concentration for their energy supply; hypoglycemia is likely to impair cerebral functions as well as do the hyperglycemia especially of rapid onset, which can cause cerebral dysfunction by affecting extracellular osmolarity. Objectives: -To know the different methods for estimation of blood glucose -To know the precautions needed to get accurate results and better interpretation of glycemic status in relation to disease condition. Methods: Many methods were developed to estimate the glucose level in body fluids among which the commonly used nowadays, the enzymatic methods. These methods can be summarized and categorized into A) Reduction methods: These methods depend on the reductive property of glucose(aldose) 1-Ferriccyanide( Hoffmans) method: using ferricyanide which is reduced by the glucose .  Fe+++ Fe++ (color change from yellow to colorless solution that will diminish the absorbance measured photometerically ) 2-Copper sulfate methods: Benedict: The reagent contains Na-citrate &Na carbonate with CuSO4. It gives color acc. To conc. of glucose (green-----yellow-----brown-----red). Fehling : using KOH &Na/K tartrate with CuSO4  Folin- Wu : Alkaline Cu SO4 +Phosphomolybdic acid molybdenum blue  by reducing Cu2O CuO2 3-Smogi-Nelson method: using Arsenomolybdate N.B. The reduction methods need alkaline medium &heat These methods are qualitative & semi-quantitative. B) Aromatic amines method:  O-toludine +glucose (aldhyde) heat &acidity glucosamine (colored ) C) Enzymatic methods: 1-Hexokinase methods(The reference method). With pre-deproteinization of sample or without. Glucose +ATP +HK(ADP+G6P G6P +NAD +G6PD (6 P-gluconolactone +NADH+H (measured at 340) 2- Glucose oxidase methods: -Trinders (Enz.-Dye Colorimetric ) method: which is colorimetric either by spectrophotometer or refractrometer (refractrometeric methods either in a film form [kodak Ectachem] or a strip form [Dry chemistry] ). -Kinetic method: by measuring the increase in absorbance through increase in NADH+H N.B. GOD/POD method can not used for detection of urine glucose because the urine contains interfering substances for peroxidase (POD) . To use this method treatment of the urine sample either by Somogi Nelson filtrate or Ion Exchange Resin is taken before running . Also, using GOD/POD method in urine with modification like , Polarigraphic determination with post-reaction elimination of H2O2 by: ethanol & catalase or Iodide & molybdate. 3- Glucose Dehydrogenase Method: Glucose +NAD GDH Gluconolactone +NADH+H (measured at 340) Glucose Oxidase for blood glucose estimation (Experiment #1) PRINCIPLE OF THE METHOD Glucose oxidase (GOD) catalyses the oxidation of glucose to gluconic acid. The formed hydrogen peroxide (H2O2), is detected by a chromogenic oxygen acceptor, phenol-aminophenazone in the presence of peroxidase (POD): Principle: (Trinders method ) (-D-glucose Mutarotase (-D-glucose (-D-glucose +H2O+O2 Glucose oxidase D-gluconic acid+H2O2 H2O2+ 4-aminophenazone+phenol Peroxidase Quinonemine +4 H2O The intensity of the color formed is proportional to the glucose concentration in the sample. CLINICAL SIGNIFICANCE Glucose is a major source of energy for most cells of the body; insulin facilitates glucose entry into the cells. Diabetes is a disease manifested by hyperglycemia; patients with diabetes demonstrate an inability to produce insulin. Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. PREPARATION Working reagent (WR): Ready for use Signs of reagent deterioration: - Presence of particles and turbidity. - Blank absorbance (A) at 505 nm 0.10. Requirements: Samples: -Blood samples Whole blood Serum Plasma (with Ca.oxalates/NaF), which is the preferred sample -Fresh urine by double void collection technique.? -CSF collected in sterile clean container and to be done immediately or centrifuged to get cell free fluid. Instrumentation: -Photometer adjusted on wavelength 540 nm -Cuvette (light path) 1 cm -Water bath at 37 C -Automatic pipettes, disposable test tubes , racks and disposable tips for the dispensers. PROCEDURE 1. Assay conditions: Wavelength: . . . . . . . . . . . . . .. . 505 nm (490-550) Cuvette: . . . . . . . . . . . . . . . . . . . . .. 1 cm light path Temperature. . . . . . . . . . . . . . . . . . . 37C / 15-25C 2. Adjust the instrument to zero with distilled water. 3. Pipette into a cuvette: BlankStandardSample WR (mL) 1.0 1.0 1.0 Standard (L) -- 10 -- Sample (L) -- -- 10  4. Mix and incubate for 10 min at 37C or 15-20 min at room temperature (15-25C). 5. Read the absorbance (A) of the samples and standard, against the Blank. The colour is stable for at least 30 minutes. CALCULATIONS (A) Sample x 100 (Standard conc.) = mg/dL glucose in the sample (A) Standard Conversion factor: mg/dL x 0.0555= mmol/L. *Linearity of the test = 400 mg/dl (Samples give higher level must be retested with dilution by suitable buffer or dist. H2O) Result: Abs. Of the Standard ~ 0.3 As the concentration of glucose standard = 100 mg/dl The Glucose concentration in the sample = 333 X Abs. Of the Sample Normal Range: Blood glucose Fasting= 70 - 110 mg/dl & 2 hrs. Postprandial = 110 - 140 mg/dl Urine glucose .. < detectable limit (Nil) CSF glucose ~ 60 - 90 mg/dl N.B. To express the result in mmol/L divide by 18 ( MW of Glucose =180) Interpretation: I -Hypoglycemia : The patient considered critically hypoglycemic if: Whole Blood glucose level < 40mg/dl Serum/Plasma glucose level < 45mg/dl A- Well Fed State Hypoglycemia : 1- Excessive Insulin Release: Reactive Hypoglycemia Alimentary Hyperinsulinism Leucine Hypersensitivity 2- Inherited Enzyme Defect: Galactose -1- Phosphate Fructose -1- Phosphate 3- Fed Status Functional Hypoglycemia: B- Fasting Hypoglycemia: 1-Organic Hypoglycemia: a-Pancreatic B-Cell disease/CA b-Non-Pancreatic Tumors c-Anterior Pituitary Hypo-function d-Adrenocortical Hypo-function e-Ingestion of Akee Fruit 2- Functional Fasting Hypoglycemia PPPPPPP a- On specific hepatic enzyme deficiency: Genetic Deficiency or Delayed Maturation of Enzymes in Pre- mature Babies 2- Glycogen Storage Disease b- Induced by Exogenous Agents: 1-Alcohol Intake 2-Excessive Insulin Administration 3-Excessive Sulfonylurea Administration II - Hyperglycemia : Diabetes Mellitus Hemochromatosis Hypokalemia Stress Pheochromocytoma Anesthesia Pregnancy Hyperthyroidism Cushing disease Hyperpituitarism (gigantism) Discussion: *Physiological & Biochemical Background: Glucose metabolism, Insulin action and other hormonal effects on glucose in the human body. *Pathological & Disease Correlation: Diabetes Mellitus, Cushing disease ,Hyperthyroidism ..etc Questions: What is the basis of reduction methods for glucose estimation ? Give short notes on Trinders method for glucose estimation. When does a person considered hypoglycemic? What are the types of hypoglycemia ? Give an account on the principle of glucose oxidase method for glucose estimation. ORAL GLUCOSE TOLERANCE TEST Introduction: On standard oral glucose dose, the response of the body regarding the absorption and metabolism of glucose said to be tolerant on meeting the normal elevation and return. Whereas abnormal and improper glucose metabolism is termed glucose intolerance. This used to diagnose diseases where the glucose metabolism is impaired as in Diabetes mellitus. Oral glucose tolerance test (OGTT) has been widely used as the golden standard for diagnosing diabetes mellitus in clinically doubtful cases. Lately, thought, the use of OGTT in primary care has been questioned for several reasons. It has low reproducibility and is very expensive. However, for the detection of diabetes in pregnant women, it is still recommended. Objectives: It is to practice the OGTT and knowing the uses and interpretation regarding the diagnostic benefits of this laboratory test. Indications: Borderline fasting blood sugar for >2 times (~ 110 125mg/dl) Diagnosis of Gestational Diabetes (GDM) at 24 28 weeks of gestation especially for those have a family history of diabetes. After delivery for those was suffering from GDM. OGTT (Experiment # 2): *Patient preparation (Perquisites) ;  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET  Activity--Don't smoke or exercise strenuously for 8 hours before the test or during the test.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Diet--Eat a high-carbohydrate diet (> 150 g/day) for 3 days, then fast for 10 to 12 hours before the test. Don't drink coffee or alcohol for 8 hours before the test.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Drugs (medicines)-Inform the person performing the test to omit any medications listed, as under taking these drugs the test results may differ (contraceptives to be stopped one cycle before the performance of OGTT).  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET The test must be performed at daytime (morning). * General description of test  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Test usually takes 3 hours but can last as long as 6 hours (extended OGTT).  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Drink water frequently during the test (the only allowed fluid to drink).  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET The first blood sample and the first urine sample are collected between 7 A.M. and 9 A.M., after you have fasted for 12 hours.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Operator gives a test load of glucose, usually 75 100 gram dextrose / 300 ml water, lemon flavored . Drink the entire solution in 5 minutes.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Blood and urine samples are collected at 30 min., 60 min., 90 min.,120 min. and 3 hours and sometimes immediately after drinking oral glucose solution. Dose of Oral Glucose: Dextrose: 1 1.75 g/kg. body wt. (for adults0 and not exceeds 100 g. It is to be dissolved in 250 300 ml lemon flavored water. Fortical : 113 ml completed to 300 ml water Lucozade: 350 ml. (ready to use) *Samples: Blood samples ; fasting(basal) sample, 30min. after oral glucose load, 60min, 90min, 120min. (in extended OGTT another 2 samples will be taken at 2hour and 3 hours). Urine samples ; first fasting urine and the hourly collected urine samples. Calculation: there are different methods to calculate and interpret the glucose levels (mg/dl)in OGTT: Glucose sampleWilkerson CriteriaFajan-conn criteriaRevised SummationFasting> 130 (1 point-*If  of results (F + 60min. + 90 min. + 120 min.) > 600 mg/dl = Diabetic *If  of results < 600 = non diabetic30 min.--60 min.>190 ( point>190 ( +190 min.-> 165 ( +1120 min.>140 ( point> 140 ( +12 hour>130 ( 1 point-Calculation of Results2 3 point (Diabetic - 1 point ( Suspect Zero ( Non diabetic3 ( Diabetic 1 2 (Suspect Zero ( Non diabetic Results and Diagnosis: Glucose tolerance tests may lead to one of the following diagnoses: Normal Response A person is said to have a normal response when the 2-hour glucose level is less than or equal to 110 mg/dl, or following this normal levels. Time Pregnancy Other AdultsChildFasting<100<110<13030, 60 & 90 minutes<200<200<200120 minutes<145<140<140Impaired Fasting Glucose When a person has a fasting glucose equal to or greater than 110 and less than 126 mg/dl, they are said to have impaired fasting glucose. This is considered a risk factor for future diabetes, and will likely trigger another Impaired Glucose Tolerance A person is said to have impaired glucose tolerance when the 2-hour glucose results from the oral glucose tolerance test are greater than or equal to 140 but less than 200 mg/dl. This is also considered a risk factor for future diabetes. There has recently been discussion about lowering the upper value to 180 mg/dl to diagnose more mild diabetes to allow earlier intervention and hopefully prevention of diabetic complications. Diabetes A person has diabetes when oral glucose tolerance tests show that the blood glucose level at 2 hours is equal to or more than 200 mg/dl. This must be confirmed by a second test (any of the three) on another day. There has recently been discussion about lowering the upper value to 180 mg/dl to diagnose more people with mild diabetes to allow earlier intervention and hopefully prevention of diabetic complications. Gestational Diabetes A woman has gestational diabetes when she is pregnant and has any two of the following: a fasting plasma glucose of more than 105 mg/dl, a 1-hour glucose level of more than 190 mg/dl, a 2-hour glucose level of more than 165 mg/dl, or a 3-hour glucose level of more than 145 mg/dl.  INCLUDEPICTURE "http://www.cabrillo.cc.ca.us/~dscott/bio5/homeostasis/img013.gif" \* MERGEFORMATINET   INCLUDEPICTURE "http://www.cabrillo.cc.ca.us/~dscott/bio5/homeostasis/img015.gif" \* MERGEFORMATINET  Discussion: Drugs may affect OGTT results  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Amphetamines.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Arginine.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Benzodiazepines.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Beta-adrenergic blockers.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Chlorthalidone.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Clofibrate.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Corticosteroids.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Dextrothyroxine.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Diazoxide.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Epinephrine.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Furosemide.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Glucose I.V.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Insulin.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Lithium.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET MAO inhibitors.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Nicotinic acid (large doses).  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Oral contraceptives (estrogen-progestogen combination).  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Oral hypoglycemics.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Phenolphthalein.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Phenothiazines.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Phenytoin.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Thiazide diuretics.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Triamterene. Other factors that may affect test results  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET  Ethanol.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Caffeine.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Recent infection.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Fever.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Pregnancy.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Acute illness.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET People over age 50 tend toward decreasing carbohydrate tolerance, which may cause conflicting results.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Cushing's disease, hemochromo-cytosis, pheochromocytoma, injury to central nervous system, tumor of pancreas islet cells, malabsorption, Addison's disease, hypothyroidism, hypopituitarism.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Reduced carbohydrate intake for several days before the test.  INCLUDEPICTURE "http://www.testuniverse.com/images/cir-bullet.gif" \* MERGEFORMATINET Failure to follow dietary and exercise restrictions. QUESTIONS: What are the indications of OGTT ? What are the prerequisites of OGTT ? Draw a graph of a normal glucose tolerance. Glycated Hemoglobins Introduction: Glycohemoglobin (GHb, glycated hemoglobin, glycosylated hemoglobin) is a generic term for hemoglobin bound irreversibly (ketoamine form) to glucose. Often, the term is used to mean total glycated hemoglobin, and sometimes to mean hemoglobin A1c. Total glycated hemoglobin (Total GHb) refers to all the glycated hemoglobins, including glycated hemoglobin variants. Total glycated hemoglobin is usually determined by affinity chromatography or immunassays. Hemoglobin A1c (HbA1c) is the major subfraction of the glycated normal hemoglobin (HbA1). Determination of HbA1c is usually achieved by ion-exchange HPLC or gel electrophoresis. Objectives: It is to know the importance of glycated hemoglobin as a long term monitoring test which may be used to help controlling the treatment of diabetes mellitus. Types of Glycated hemoglobins: HbA1a1 = Hb + Fructose-1,6-bisphosphate (FBP) HbA1a2 = Hb + Glucose-6-phosphate HbA1b = Hb + Pyruvic acid HbA1c = Hb + Glucose (N-terminal of -chain) HbA1d = Hb + Glucose ( internal a.a. of /- chain) Using GHb : Monitoring blood glucose is a key component of successful diabetes management. With the availability of self-monitoring and HbA1C testing, laboratory testing for fasting glucose and 2-hour post-75g glucose load should no longer be used routinely to assess glucose control. Laboratory measurement of glucose, however, may be useful to verify the accuracy of home glucose monitoring equipment or when there has been a loss of diabetic control. HbA1C measurement provides a quantitative and reliable measure of glycemic status and control over an extended period of time, thereby complementing day-to-day monitoring. HbA1C levels are a better (and less expensive) measure of long-term glucose control than repeated fasting and p.c. glucose levels. Over the life of a red blood cell (which averages 120 days), a fraction of hemoglobin will become covalently bound to glucose and other sugar molecules. This reaction occurs non-enzymatically and at a rate which is proportional to the concentration of glucose in the blood. HbA1C is the largest single component of these glycated hemoglobins. N.B. Blood Glucose level reflects the previous few hours glycemic state, glycated Albumin reflects 10 14 days glycemic state, while HbA1c reflects the longest (2-3 months) glycemic state. Methods: There are currently four main techniques for determining glycated hemoglobins: Cation-exchange chromatography - separates hemoglobins using HPLC based on net charge as a result of glycation; Gel electrophoresis; Affinity chromatography - separates total glycated hemoglobins by binding to solid-phase dihydroxyborate; Immunoassay - based on binding to specific antibodies. Experiment # 3: Estimation of HbA1c by using affinity chromatography column Principle: In a chromatography column, the hemoglobins in a hemolysed sample is bound by different affinity to dihydroxyborate. Elution of HbA1c is carried out by phosphate buffer, while the other hemoglobins separate (elute) after by sodium chloride solution. Procedure: Calculation: % HbA1c = A1 X 100 /A1 + ( 4.75 X A2) Reference ranges: Degree of glucose controlTotal GHbHb A1cNormal (non-diabetic)< 7%< 6%Near normoglycemic7 to 8%6 to 7%Diabetes Control and Compliance Trial (DCCT) therapeutic goalLess than 7%In good control8 to 9%7 to 8%Actions suggested9 to 11%8 to 9%Not in control> 11 %> 9% The determination of a glycated hemoglobin level may assist in the initial diagnosis of diabetes, or it may be used to indicate the degree of long-term diabetic control in diabetic patients. The significance of a low glycated hemoglobin level has not been established. Annual HbA1c < 1.1 times the upper limit of normal (8.8%), suggesting less likely occurring complications. Annual HbA1c > 1.7 times the upper limit of normal (13.5%), suggesting more likely occurring complications. Correlation with Mean Blood Glucose Levels A single fasting blood glucose measurement only gives an indication of the patient's immediate past (last 1 to 2 hours) condition, and may not represent the true status of blood glucose regulation. In contrast, the level of glycated hemoglobin is directly related to the average glucose concentration over the life-span of the hemoglobin in the circulation. Various formulae have been proposed to demonstrate the correlation between the mean blood glucose (MBG) and Hemoglobin A1c (HbA1c). MBG mg/dl = (33.3 X HbA1c) - 86 Or, MBG mg/dl = 10 ( HbA1c +4 ) Discussion: Causes of elevated HbA1c: Uncontrolled D.M. ! HbF ! Triglycerides Lead toxicity ! iron anemia Splenectomy CRF Hemodialysis Causes of decreased HbA1c: Causes of ! RBCs life span ( hemolytic or hemorrhagic) Hemodilution (e.g. pregnancy) Questions: Give the objectives of glycated hemoglobin estimation. Write down different methods for the determination of glycated hemoglobin. What is the principle for the determination of glycated hemoglobin by chromatography ? Lipid Profile Introduction: Some beneficial aspects of lipids include the following: energy course, function and structural components of cell membranes, and precursor compound to many important substances such as vitamin D and steroid (sex) hormones. With evidence of a link between elevated lipids and atherosclerosis (also known as arteriosclerosis or atherothrombosis), there is increase interest from both the medical and lay community in the battery of tests commonly ordered as a lipid profile. Preparation for having blood collected for lipid testing should include a 12-14 hour overnight fast. Objectives: - The contribution of hypercholesterolemia to coronary heart disease (CHD) risk, including the importance of elevations in total cholesterol, LDL cholesterol, HDL cholesterol, ratio of total to HDL cholesterol. - The classification of dyslipidemias, including who to screen, and how often - The available diagnostic studies and their use, particularly determinations of HDL, LDL and total cholesterol, as well as the need to test for other cardiovascular risk factors . Experiment # 4:Glycerol-Phosphate Oxidase method for Triglycerides PRINCIPLE OF THE METHOD Sample triglycerides incubated with lipoproteinlipase (LPL), liberate glycerol and free fatty acids. Glycerol is converted to glycerol-3-phosphate (G3P) and adenosine-5-diphosphate (ADP) by glycerol kinase and ATP. Glycerol-3-phosphate (G3P) is then converted by glycerol phosphate dehydrogenase (GPO) to dihydroxyacetone phosphate (DAP) and hydrogen peroxide (H2O2). In the last reaction, hydrogen peroxide (H2O2) reacts with 4-aminophenazone (4-AP) and p-chlorophenol in presence of peroxidase (POD) to give a red colored dye: Principle: Triglycerides + H2O lipase Glycerol + FFA Glycerol + ATP glycerol kinase Glycerol-3-phosphate + ADP Glycerol-3-phosphate + O2 Glycerol-Phosphate Oxidase DHAP + H2O2  H2O2 + 4- Aminoantipyrine + Chlorophenol peroxidase Quinoneimine The intensity of the color formed is proportional to the triglycerides concentration in the sample. CLINICAL SIGNIFICANCE Triglycerides are fats that provide energy for the cell. Like cholesterol, they are delivered to the bodys cells by lipoproteins in the blood. A diet with a lot of saturated fats or carbohydrates will raise the triglyceride levels. The increases in serum triglycerides are relatively non-specific. For example liver dysfunction resulting from hepatitis, extra hepatic biliary obstruction or cirrhosis, diabetes mellitus is associated with the increase Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. PREPARATION Working reagent (WR): Dissolve () the contents of one vial R 2 Enzymes into one bottle of R 1 Buffer. Working reagent (WR): Dissolve () the contents of one vial R 2 Enzymes in 10 mL of R 1 Buffer. Cap and mix gently to dissolve contents. WR stability: 6 weeks at 2-8C or 1 week at room temperature (15-25C). SAMPLES Serum or heparinized or EDTA plasma1. Stability of the sample: 5 days at 2-8C . PROCEDURE 1. Assay conditions: Wavelength: . . . . . . . . . . . . . .. . . . . 505 nm (490-550) Cuvette: . . . . . . . . . . . . . . . . . . . . . . . . 1 cm light path Temperature . . . . . . . . . . . . . . . . . . . . 37C / 15-25C 2. Adjust the instrument to zero with distilled water. 3. Pipette into a cuvette: BlankStandardSample WR (mL) 1.0 1.0 1.0 Standard (L) -- 10 -- Sample (L) -- -- 10  4. Mix and incubate for 5 min. at 37C or 10 min. at room temperature. 5. Read the absorbance (A) of the samples and Standard, against the Blank. The colour is stable for at least 30 minutes. CALCULATIONS A Sample x 200 (Standard conc.) = mg/dL triglycerides in the sample A Standard Conversion factor: mg/dL x 0.0113= mmol/L. Reference ranges: Normal Fasting blood triglycerides = 60 160 mg/dl It is considered normal as long as it is below 200 mg/dl Discussion: -Types of hyperlipidaemias QUESTIONS: Give the different methods for the determination of triglycerides. Write a short note on hypertriglyceridemia. Give the upper cut off value of triglyceride for a diagnosis of hypertriglyceridemia. DETERMINATION OF CHOLESTEROL: INTRODUCTION: Cholesterol is a waxy substances used in every cell membrane you have and as a base for several hormones. The recommended daily allowance for dietary cholesterol intake is 300 milligrams. Most cells have some capacity to synthesize cholesterol. The largest percentage of synthesized cholesterol is made in the liver. Cholesterol lowering medications prescribed by physicians inhibit the synthesis of cholesterol by the liver, thereby reducing the level in the blood stream. OBJECTIVES: The estimation of cholesterol along with other parameters of lipid profile is necessary for the classification and diagnosis of lipemias PRINCIPLE OF THE METHOD The cholesterol present in the sample originates a coloured complex, according to the following reaction: The intensity of the color formed is proportional to the cholesterol concentration in the sample Principle (Experiment #5): Cholesterol esters + H2O Cholesterol esterase Cholesterol + FA Cholesterol + O2 Cholesterol Oxidase Cholesterol-3-one + H2O2 H2O2 + 4-AAP + Phenol Peroxidase Quinonimine CLINICAL SIGNIFICANCE Cholesterol is a fat-like substance that is found in all body cells. The liver makes all of the cholesterol the body needs to form cell membranes and to make certain hormones. The determination of serum cholesterol is one of the important tools in the diagnosis an classification of lipemia. High blood cholesterol is one of the major risk factors for heart disease5,6. Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. PREPARATION Working reagent (WR): Dissolve () the contents of one vial R 2 Enzymes in one bottle of R 1 Buffer. Cap and mix gently to dissolve contents. (WR) is stable: 4 months at 2-8C or 40 days at 15-25C. Avoid direct sunlight. SAMPLES Serum or plasma1,2: Stability of the sample for 7 days at 2-8C or freezing at 20C will keep samples stable for a few months. PROCEDURE 1. Assay conditions: Wavelength: . . . . . . . . . . . . . .. . . 505 nm (500-550) Cuvette: . . . . . . . . . . . . . . . . . . . . .. 1 cm light path Temperature . . . . . . . . . . . . . . . .. . . . .37C /15-25C 2. Adjust the instrument to zero with distilled water. 3. Pipette into a cuvette: BlankStandardSample WR (mL) 1.0 1.0 1.0 Standard (L) -- 10 -- Sample (L) -- -- 10  4. Mix and incubate for 5 min. at 37C or 10 min. at room temperature. 5. Read the absorbance (A) of the samples and Standard, against the Blank. The colour is stable for at least 60 minutes. CALCULATIONS A (Sample) x 200 (Standard conc.) = mg/dL cholesterol in the sample A (Standard) Conversion factor: mg/dL x 0.0258= mmol/L. *Normal range: Desirable blood cholesterol level < 200 mg/dl Suspect to vascular and CHD 200 240 mg/dl High risk group for CHD > 240 mg/dl Risk evaluation: Less than 200 mg/dL Normal 200-239 mg/dL Borderline 240 mg/dL and above High  LDL Cholesterol  PRINCIPLE OF THE METHOD Direct determination of serum LDLc (low-density lipoprotein cholesterol) levels without the need for any pre-treatment or centrifugation steps. The assay takes place in two steps. 1 Elimination of lipoprotein no-LDL Cholesterol esters + H2O Cholesterol esterase Cholesterol + FA Cholesterol + O2 Cholesterol Oxidase Cholesterol-3-one + H2O2 H2O2 catalase 2 H2O + O2 2 Measurement of LDLc Cholesterol esters + H2O Cholesterol esterase Cholesterol + FA  Cholesterol + O2 Cholesterol Oxidase Cholesterol-3-one + H2O2 H2O2 + 4-AAP + Phenol Peroxidase Quinonimine + 4 H2O2 The intensity of the color formed is proportional to the LDLc concentration in the sample. CLINICAL SIGNIFICANCE The LDLc particle is lipoproteins that transport cholesterol to the cells. Often called bad cholesterol because high levels are risk factor for coronary heart disease and are associated with obesity, diabetes and nephrosis 1,5,6. Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. PREPARATION - R 1 and R 2: Are ready to use. - HDLc/LDLc CAL: Dissolve the contents with 1 mL of distilled water. Cap vial and mix gently to dissolve contents. SAMPLES Serum : After sampling, the test should be performed without delay. Repeated freezing and thawing should be avoided. Stability of the sample: 7 days at 2-8C . PROCEDURE . Assay conditions: Wavelength: . . . . . . . . . . . . . .. . . 600 (590-700) nm Cuvette: . . . . . . . . . . . . . . . . . . . . .. . .1 cm. light path Temperature . . . . . . . . . . . . . . . . . . . . . . . . . . . .37C 2. Adjust the instrument to zero with distilled water. 3. Pipette into a cuvette: BlankStandardSampleR1(L)300300300Standard (L)------- 4------Sample (L)---------------4  4. Mix and incubate for 5 min. at 37C. 5. Add: R2 (L) 100100100 6. Mix and incubate for 5 min. at 37C. 7. Read the absorbance (A), against the Blank. CALCULATIONS (A) Sample x Standard.conc. = mg/dL of LDLc in the sample (A) Standard Conversion factor: mg/dL x 0.02586 . REFERENCE VALUES Levels of the risk Desirable < 100 mg/dL Medium 130-160 mg/dL High > 160 mg/dL HDL cholesterol PRINCIPLE OF THE METHOD The very low density (VLDL) and low density (LDL) lipoproteins from serum or plasma are precipitated by phosphotungstate in the presence of magnesium ions. After removed by centrifugation the clear supernatant containing high density lipoproteins (HDL) is used for the determination of HDL cholesterol CLINICAL SIGNIFICANCE HDL particles carry cholesterol from the cells back to the liver. HDL is known as good cholesterol because high levels are thought to lower the risk of heart disease. A low HDL cholesterol levels, is considered a greater heart disease risk. Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. Procedure :   PTA + B. sample RT incubation for 10 min Centrifugation for 10 min. at 4000 rpm    Supernatant cholesterol + Chol.Oxidase reagent -( HDL- Chol. Conc.  SAMPLES Serum or plasma1: Free of hemolysis. Removed from the blood clot as soon as possible. Stability : HDL Cholesterol is stable for 7 days at 2-8C . PROCEDURE Precipitation 1. Pipette into a centrifuge tube: R (L) 100 Sample (mL) 1.0  2. Mix well; allow to stand for 10 min at room temperature. 3. Centrifuge at 4000 r.p.m. for 20 min or 2 min at 12000 r.p.m.. 4. Collect the supernatant and test HDLc. Test Following the Cholesterol reagent instructions. CALCULATIONS - With Factor: A505 nm Sample x 320 = mg/Dl HDLc in the sample. A546 nm Sample x 475 = mg/Dl HDLc in the sample Calculation of LDL-cholesterol According to the Friedewald Formula: LDL cholesterol = Total cholesterol - Triglycerides -HDL cholesterol 5 Questions: Write a short note on Hyperlipidemia. Which one of the two HDL/LDL is more dangerous to health and give reason. Which diet can cause increase in HDL-Chol ? Write the equation for HDL-cholesterol calculated from TG, Total Chol.& LDL. Laboratory Renal Function Tests I- Urea Estimation & Blood Urea Nitrogen (BUN) Introduction: Kidney problems are very common in clinical medicine. Essentially all seriously sick patients will need their kidney function evaluated during the course of their illnesses. After history and physical exam are complete, the initial steps in checking patients' kidneys are performing the following tests: (1) urinalysis (2) serum creatinine (3) serum urea ("blood urea nitrogen", "BUN"). Next, you may check (4) ability to concentrate urine. Both creatinine and BUN are included on the common chemical profiles. You can check the ability to concentrate urine using a hygrometer, refractrometer, or dipstick. Objectives: Methods: 1- Chemical (direct) method:  Urea + Diacetyl monoxime(DAM) Diacetyl-Urea  Diacetyl-Urea + Fe3+ +acidic pH Yellow Diazine (measured at 540) 2-Enzymatic (indirect) method:  Urea + H2O Urease CO2+ NH3  Yellow Orange (at 540 nm)    Experiment # 6 (Modified Berthlots Reaction): PRINCIPLE OF THE METHOD Urea in the sample is hydrolized enzymatically into ammonia (NH4+) and carbon dioxide (CO2). Ammonia ions formed reacts with salicylate and hypochlorite (NaClO), in presence of the catalyst nitroprusside, to form a green indophenol: The intensity of the color formed is proportional to the urea concentration in the sample CLINICAL SIGNIFICANCE Urea is the final result of the metabolism of proteins; it is formed in the liver from its destruction. Elevated urea can appear in blood (uremia) in: diets with excess of proteins, renal diseases, heart failure, gastrointestinal hemorrhage, dehydration or renal obstruction1,6,7. Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. Principle:  Urea + H2O Urease CO2+ NH3  NH3 + Na-salicylate + Na-hypochlorite +Na-nitoprusside Indophenol PREPARATION - Working reagent (WR): Dissolve one tablet R 3 Enzymes in one bottle of R 1 Buffer. Cap and mix gently to dissolve contents. Stability: 4 weeks in the refrigerator (2-8C) or 7 days at room temperature (15-25C). - R 2 NaClO is ready to use : SAMPLES - Serum or heparinized plasma: Do not use ammonium salts or fluoride as anticoagulants. - Urine: Dilute sample 1/50 in distilled water. Mix. Multiply results by 50 (dilution factor). Preserve urine samples at pH < 4. Urea is stable at 2-8C for 5 days; PROCEDURE 1. Assay conditions: Wavelength: . . . . . . . . . . . . . .. . . . .. . . . . . 580 nm Cuvette: . . . . . . . . . . . . . . . . . . . . .. 1 cm light path Temperature. . . . . . . . . . . . . . . . . .. . . 37C / 15-25C 2. Adjust the instrument to zero with distilled water. 3. Pipette into a cuvette: BlankStandardSample WR (mL) 1.0 1.0 1.0 Standard (L) -- 10 -- Sample (L) -- -- 10  4. Mix and incubate 5 min at 37C or 10 min at room temperature (15-25C). 5. Pipette: Blank StandardSample R 2 (mL) 1.0 1.0 1.0  6. Mix and incubate 5 min at 37C or 10 min at room temperature (15-25C). 7. Read the absorbance (A) of the samples and calibrator, against the Blank. The colour is stable for at least 30 minutes at 15-25C. CALCULATIONS (A) Sample x 50 (Standard conc.) = mg/dL urea in the sample (A) Standard 10 mg/L urea BUN divided by 0.466 = 21 mg/L urea = 0.36 mmol/L urea. Conversion factor: mg/dL x 0.1665 = mmol/L. REFERENCE VALUES1 Serum : 15- 45 mg/dL (2.49-7.49 mmol/L) Urine : 20 - 35 gr/24 h. Blood Urea Nitrogen (BUN) 8 25 mg/dl Interpretation: Interpretation of the BUN is usually straightforward, though there are a few things to remember. #Increased BUN is, by definition, azotemia. It is due either to increased protein catabolism or impaired kidney function. *Increased protein catabolism results from: a really heavy protein meal (Kebda, El-Bek, etc.) severe stress (myocardial infarction, high fever, etc.) upper GI bleeding (blood being digested and absorbed) *Impaired kidney function may be "prerenal", "renal", or "postrenal". Prerenal azotemia results from underperfusion of the kidney: dehydration, hemorrhage, shock, congestive heart failure Renal azotemia has several familiar causes: acute tubular necrosis, chronic interstitial nephritis, glomerulonephritis, etc. Postrenal azotemia results from obstruction of urinary flow: prostate trouble, stones, surgical mishaps, tumors N.B. In acute renal failure, BUN increases around 20 mg/dL each day (*estimates vary; range of increase is 10-50 mg/dL daily). #Decreased BUN Lack of protein (celiac disease, some patients with nephrotic syndrome) Severe liver disease (end-stage cirrhosis, yellow atrophy, really bad hepatitis, halothane or acetaminophen toxicity, enzyme defects) Overhydration (iatrogenic, psychogenic water-drinking) Discussion: -Physiological & Biochemical Background: -Pathological & Disease Correlation: Questions: Write the different methods for estimation of blood urea? Calculate BUN on estimation of blood urea. - Mention causes of hyperazotemia. II- Plasma Creatinine Estimation Introduction: Creatinine is the end product of muscle metabolism. It is excreted through the kidneys and changes in creatinine are an early indicator of kidney disease as well as being seen in severe muscle damage or wasting diseases or with many medications such as antibiotics. this test can be performed on specimens drawn from patients in either the fasting or non fasting state. Methods: Direct Chemical methods: Jaffe method : See the principle and procedure (Experiment ) DNB method (used in dry chemistry:  Creatinine +Dinitrobenzoic acid +alkaline pH purplish rose Indirect Enzymatic methods: Deaminase method (One enzyme step method): Creatinine Deaminase methyl hydantoin + NH3 (detected by different techniques) Amidohydrolase method ( multi-enzymatic method): - Creatinine Creatinine. Amidohydrolase Creatine - Creatine Creatine kinase Creatine -p - Creatine-p +ATP Creatine +ADP - ADP + P-enol pyrovate (PEP) ATP +Pyruvate - Pyruvate + NADH+H+ LDH Lactate + NAD (with diminished absorbance at 340 nm) PRINCIPLE OF THE METHOD The assay is based on the reaction of creatinine with sodium picrate as described by Jaff. Creatinine reacts with alkaline picrate forming a red complex. The time interval chosen for measurements avoids interferences from other serum constituents. The intensity of the color formed is proportional to the creatinine concentration in the sample. Principle (Jaffe Method): Creatinine + Picric acid + alkaline pH 2,4,6 trinitrophenol (Janovskis complex) measured at 520 nm CLINICAL SIGNIFICANCE Creatinine is the result of the degradation of the creatine, component of muscles, it can be transformed into ATP, that is a source of high energy for the cells. The creatinine production depends on the modification of the muscular mass, and it varies little and the levels usually are very stable. Is excreted by the kidneys. With progressive renal insufficiency there is retention in blood of urea, creatinine and uric acid. Elevate creatinine level may be indicative of renal insufficiency1,4,5. Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. PREPARATION Working reagent (WR): Mix equal volumes of R 1 Picric Reagent and R 2 Alkaline reagent. The working reagent is stable for 10 days at 15-25C. Signs of reagent deterioration: - Presence of particles and turbidity. - Blank absorbance (A) at 492 nm 1.80. SAMPLES - Serum or heparinized plasma. Creatinine stability: 24 hours at 2-8C. - Urine: Dilute sample 1/50 with distilled water. Mix. Multiply results by 50 (dilution factor); Creatinine stability: 7 days at 2-8C. PROCEDURE 1. Assay conditions: Wavelength: . . . . . . . . . . . . . . . . . 492 nm (490-510) Cuvette: . . . . . . . . . . . . . . . . . . . . . . . . 1 cm. light path Temperature. . . . . . . . . . . . . . . . . . . . . 37C / 15-25C 2. Adjust the instrument to zero with distilled water. 3. Pipette into a cuvette: BlankStandardSample WR (mL) 1.0 1.0 1.0 Standard (L) -- 100 -- Sample (L) -- -- 100  4. Mix and start stopwatch. 5. Read the absorbance (A1) after 30 seconds and after 90 seconds (A2) of the sample addition. 6. Calculate: A= A2 A1. CALCULATIONS A Sample  A Blank x 2 (Standard conc.) = mg/dL of creatinine in the sample A Standard  ABlank Conversion factor: mg/dL x 88.4 = mol/L. l REFERENCE VALUES Serum or plasma: Male 0,7 - 1,4 mg/dL = (61.8  123.7) mol/L Female 0,6 - 1,1 mg/dL = (53.0 97.2 ) mol/L Urine: 15-25 mg/Kg/24 h Male 10 - 20 mg/Kg/24 h = 88 177 mol/Kg/24 h Female 8 18 mg/Kg/24 h = 71 177 mol/Kg/24 h  Interpretation: Causes of renal failure Discussion: Physiological & Biochemical Background: Other Renal Function Tests: Tutorial Creatinine clearance : is widely used to approximate glomerular filtration. You need a timed urine sample and a blood sample. The clearance of a substance is the volume of plasma "cleared" of that substance per unit time. Clearance = (conc. in urine) x (urine volume) (conc. in plasma) X time of urine collection (min.). In deciding how to "time" your collection, remember that you don't really need to collect urine for a full 24 hours. One group got more reliable results by a controlled collection over 4 hours, monitoring body position (kept them lying down) and hydration with body surface area measurement. Creatinine clearance is not a perfect measure of GFR, because some is not filtered and some is secreted into the proximal tubule. These fractions tend to cancel each other out in health, but when GFR drops below 30 mL/min, tubular secretion approaches or even exceeds the amount filtered at the glomerulus. *Also, lots and lots of red meat (protein and creatinine-rich) can lead to overestimates (maybe 30%) in GFR in renal failure patients. Reference range for creatinine clearance is 90-120 mL/min for young adults; values tend to fall by around 0.5 mL/year over age 20, worse for hypertensives . *Formulas to adjust "normal" for body surface area have been devised, etc. For kids, a height/creatinine ratio of 2.1 or less is normal. GFR for adults can be estimated by various formulas; try 1.12 x Creatinine Clearence - 20.6. Another formula to correct the clearance according to body surface area is {Corrected Cr.Cl. = Cr.Cl. X (1.7/ body surface area)} *Whether or not "corrections" are applied, creatinine clearance is a pretty good estimate of glomerular filtration rate except at very low values, when tubular secretion of creatinine become proportionately greater. DETERMINATION OF URIC ACID INTRODUCTION: Uric acid is apurine compound that circulates in plasma as sodium urate and is excreted by kidney. It is derived from the break down of nucleic acids that are ingested or come from the destruction of tissue cells; it is also synthesized in the body from simple compounds as shown in figure. OBJECTIVES: To know the uric acid level in the body To diagnose a case of Hyperuricemia (Gouts) METHODS: Chemical Method (Phosphotungestic acid Method?) Enzymatic Method PRINCIPLE {Enzymatic Colorimetric (Uricase Method)}: Uric acid is oxidized by uricase to allantoine and hydrogen peroxide (2H2O2), which under the influence of POD, 4aminophenazone (4-AP) and 2-4 Dichlorophenol sulfonate (DCPS) forms a red quinoneimine compound: Uric acid + 2H2O + O2 Uricase Allantoine + CO2 + 2H2O2 2H2O2 + 4-AP + DCPS POD Quinoneimine+ 4H2O The intensity of the red color formed is proportional to the uric acid concentration in the sample. CLINICAL SIGNIFICANCE Uric acid and its salts are end products of the purine metabolism. With progressive renal insufficiency, there is retention in blood of urea, creatinine and uric acid. Elevate uric acid level may be indicative of renal insufficiency and is commonly associated with gout Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. PREPARATION Working reagent (WR): Dissolve the contents of one vial R 2 Enzymes in one bottle R 1 Buffer. Cap and mix gently to dissolve contents. (WR) is stable after reconstitution 1 month at 2-8C or 10 days at room temperature. SAMPLES - Serum or plasma: Stability 3-5 days at 2-8C or 6 months at 20C. - Urine (24 h)1: Stability 4 days at 15-25C, pH >8. Dilute sample 1/50 in distilled water. Mix. Multiply results by 50 (dilution factor); If urine is cloudy; warm the specimen to 60C for 10 min to dissolve precipitated urates and uric acid. Do not refrigerate. PROCEDURE 1. Assay conditions: Wavelength: . . . . . . . . . . . . . . . . . . . .520 nm (490-550) Cuvette: . . . . . . . . . . . . . . . . . . . . .. . . . . 1 cm light path Temperature . . . . . . . . . . . . . . . . . . . . . . 37C / 15-25C 2. Adjust the instrument to zero with distilled water. 3. Pipette into a cuvette: BlankStandardSampleWR (ml)1.0 1.0 1.0Standard (L)------- 25--------Sample (L)---------------- 25 4. Mix and incubate for 5 min at 37C or 10 min at 15-25C. 5. Read the absorbance (A) of the samples and Standard, against the Blank. The colour is stable for at least 30 minutes. CALCULATIONS Serum or plasma (A) Samplex 6 (Standard conc.)= mg/dL uric acid in the sample (A) Standard Urine 24 h A) Samplex x 6 x vol. (dL) urine 24 h =mg/24 h uric acid Standard Conversion factor: mg/dL x 59.5= mol/L. REFERENCE VALUES: Serum or plasma: Women 2.5 - 6.8 mg/dL = 149 405 mol/L Men 3.6 - 7.7 mg/dL =214 458 mol/L Urine: 250 - 750 mg/24 h = 1.49 - 4.5 mmol/24 h CLINICAL SIGNIFICANCE: Hyperuricemia (Gout) DISCUSSION: Causes of elevated uric acidemia QUESTIONS: 1.Give the principle for the determination of serum uric acid by uricase method. 2. Write a short note on Uric acid metabolism. 3. Explain the hyperuricemia. PRERENAL VS. RENAL AZOTEMIA : A very common clinical problem is to distinguish prerenal azotemia (due to shock, dehydration, CHF -- also "hepatorenal syndrome") from renal azotemia (acute tubular necrosis, "renal shutdown".) Either could be the cause when a patient has been hypotensive and now is azotemic and oliguric. The management is different. One older technique is to calculate the BUN/creatinine ratio. This is normally between 10 and 20. Values over 20, suggest prerenal azotemia rather than acute tubular necrosis. High values are also seen postrenal azotemia and upper GI bleeding. In fact, a high BUN/creatinine ratio is a common finding, especially in the elderly, and a marker for ill-health . Another approach is to measure sodium on a urine specimen. In prerenal azotemia, urine sodium is low (the kidney responds to low blood flow by "trying to retain all the sodium it can.") In acute tubular necrosis, urine sodium is higher (the renal tubules are unable to concentrate or dilute the glomerular filtrate effectively.) Urinary sodium under 20 mEq/L suggests prerenal azotemia (or hepatorenal syndrome, etc.); urinary sodium over 40 mEq/L suggests acute tubular necrosis. *A further refinement, currently popular, is to measure the fractional excretion of filtered sodium, approximated by:  INCLUDEPICTURE "A:\\RENAL FUNCTION TESTS_files\\fena.gif" \* MERGEFORMATINET  Values less than 1% indicate prerenal azotemia; values over 2% indicate acute tubular necrosis. Several other factors can complicate the picture in such patients. Diuretics will increase the excretion of filtered sodium, while secondary hyperaldosteronism (as in cirrhosis) will decrease sodium excretion. In acute tubular necrosis due to myoglobinuria, sodium excretion is low (the tubules are plugged, not damaged.) *Tip: If you obtain urine by squeezing a diaper or the absorptive balls you placed into the diaper, your estimate of urine creatinine will be low because these things absorb creatinine . Urine Protein/creatinine ratio Urine protein/creatinine ratio (UP/UCr) is used to calculate urine protein loss into the urine without a need for 24 hour urine collection. Compared to conventional 24 hour- urinary protein value, UP/UCr is less time consuming and less accurate. Generally with proteinuria, UP/UCr is greater than 1.0. LESS FAMILIAR RENAL FUNCTION TESTS 1. Blood pH Changes in acid-base balance is observed frequently in renal failure especially when advanced. 2. Lipids Hyperlipidaemia can occur with renal disease, such as nephrotic syndrome. Increased hepatic lipoprotein synthesis and hypoalbuminaemia is proposed in the pathogenesis. 3. Plasma protein Generally the concentration of plasma protein is elevated due to dehydration but can be reduced in primary glomerular diseases such as glomerulonephritis and renal amyloidosis. 4. Amylase and lipase Elevated plasma lipase and amylase levels can be observed in dogs with renal disease, because these two enzymes are eliminated by the kidneys. 5. Total Red blood cell In chronic renal disease, non-regenerative anemia is commonly observed. It is mainly due to a reduced erythropoietin level secondary to the loss of renal parenchyma.Other causes of anemia in renal disease include haemorrhage, shorter the life span of erythrocytes and bone marrow depression. 6. N-acetyl-beta-D-glucosaminidase ("glucosaminidase", NAG) is a lysosomal enzyme (MW 140,000) found in serum and urine. Urinary NAG is a proposed marker for tubular disease, especially subtle industrial poisoning, acute pyelonephritis, early acute tubular necrosis, and early transplant rejection. (These functions are now largely taken over by beta-2 microglobulin). 7. Adenosine Deaminase Binding Protein is an enzyme from the brush borders of the proximal tubule. Like NAG, its presence in urine indicates tubular disease. 8. Alkaline phosphatase in urine comes from the proximal tubular brush border . 9. Beta-2 microglobulin (beta-2-m) is the short chain of the HLA class I proteins. In health, it is freely filtered by the glomerulus, and fully reabsorbed by the proximal tubule. Serum beta-2-m has been suggested as a measure of glomerular filtration rate, similar to creatinine. Obviously this isn't a good idea for patients with tissue necrosis, lymphomas, etc. Urine beta-2-m has found widespread acceptance as an research tool. It appears if levels in the serum and glomerular filtrate exceed what the proximal tubule can reabsorb (more than 4.5 mg/L) or if there is renal tubular disease. It is very sensitive as an indicator of the latter. 10. Tubular functions: Urinary amino acids and maximum concentrating ability are sensitive screens for tubular damage. Lithium clearance is a researcher's way of estimating delivery to the distal tubule. 11. Isotope scans exist to compare the function of the kidneys. These may prove a valuable supplement to the intravenous pyelogram. More recently, the 12. color Doppler sonogram, which is cheap and portable, has proved even more useful than these scans in transplant patients. Most recent of all, there's a Tc99 scanner that monitors glomerular filtration minute by minute, suitable for the intensive care . 13. Positron emission tomography is the latest way of measuring renal blood flow. SPECIFIC GRAVITY OF URINE While not a "blood test", checking urine specific gravity provides very important information about tubular function and hydration. People in our culture drink relatively little fluid. Thus "normal" people have fairly concentrated urine (SG greater than 1.010). Of course, the same is true of patients in prerenal azotemia (high urinary specific gravity, low or zero urinary sodium). Patients with tubular disease ("renal azotemia", i.e., acute tubular necrosis, really bad bilateral pyelonephritis or interstitia nephritis, or on diuretics, or with end-stage kidney) will have isosthenuria. Patients getting lots of fluid by IV, or with diabetes insipidus, or enthusiastic water-drinkers (asthmatics, crazies) will have low urine specific gravity. Serum and Urine Osmolality The term osmolality refers to the osmotic concentration of a fluid. The osmolality of serum, urine, or any other body fluid depends on the number of active ions or molecules in a solution. In laboratory reports, osmolality is expressed as "so many" milliosmoles per kilogram of water (mOsm/kg water). With a standard measurement of osmoles and of milliosmoles for clinical studies, the precise concentration of active solutes in the serum and urine can be calculated. Tests of both serum and urine osmolality can yield important information about a patient's ability to maintain a normal fluid balance status. Sodium, blood urea nitrogen, and blood glucose levels are major factors in determining serum osmolality. In severe dehydration serum osmolality will be increased, as there is less water in proportion to solutes in the serum or blood. Urine osmolality, like specific gravity, is a measurement of the concentration of urine. Urine osmolality reflects the total number of osmotically active particles in the urine, without regard to the size or weight of the particles. Substances such as glucose, proteins, or dyes increase the urinary specific gravity. Therefore, urine osmolality is a more accurate measurement of urine concentration than specific gravity, and urine osmolality can be compared with the serum osmolality to obtain an accurate picture of a patient's fluid balance. Reference values for osmolality: Serum osmolality: 282 - 295 mOsm/kg water; a serum osmolality of 285 mOsm correlates with a urine specific gravity of 1.010 Urine osmolality: extreme range of 50 - 1400 mOsm/kg water, but average is about 500 - 800 mOsm. After an overnight fast, the urine osmolality should be at least 3 times the serum osmolality Increased serum and urine osmolality (hyperosmolality) levels are seen in: Renal disease Congestive heart failure Addison's disease Dehydration Diabetes insipidus Hypercalcemia Diabetes mellitus/hyperglycemia Hypernatremia Alcohol ingestion Mannitol therapy Azotemia Decreased serum and urine osmolality (hypoosmolality) levels are seen in: Sodium loss due to diuretic use and a low salt diet Hyponatremia Adrenocortical insufficiency SIADH Excessive water replacement/overhydration/water intoxication Panic values for serum osmolality are values of less than 240 mOsm or greater than 321 mOsm. A serum of osmolality of 384 mOsm produces stupor. If the serum osmolality rises over 400 mOsm, the patient may have grand mal seizures. Values greater than 420 mOsm are fatal. When the serum osmolality is normal or increased, the kidneys are conserving water. As the serum osmolality rises, the urine osmolality should also rise. The higher the number of millosmoles in the urine, the more concentrated the urine; this is the expected physiological response to dehydration This table shows the relationship between serum and urine osmolality and the clinical significance of laboratory values. Serum OsmolalityUrine OsmolalityClinical Significance Normal values: 282-295mOsmNormal values: 500-800mOsm Normal or increasedIncreasedFluid volume deficitDecreasedDecreasedFluid volume excessNormal DecreasedIncreased fluid intake or diuretics Increased or normalDecreased (with no increase in fluid intake)Kidneys unable to concentrate urine or lack of ADH (diabetes insipidus)DecreasedIncreasedSIADH  Urine Concentration tests: An increase in plasma osmolarity stimulates ADH secretion by the posterior pituitary gland. ADH stimulates renal water resorption and increases urine SG. These tests are designed to identify concentrating defects in the kidney. They are indicated in animals that show polydipsia/polyuria (PD/PU) without azotaemia and dehydration and are contraindicated in dehydrated animals, pregnant animals or azotaemic animals with diluted urine. Liver Function Tests (LFT) Albumin estimation =========== Introduction: Albumin is made in the liver and is responsible for maintaining proper fluid balances. Too little albumin may result in fluids "leaking" out of the blood vessels into surrounding spaces such as the abdomen. Decreased amounts of albumin can occur when the liver is not making enough or if albumin is being lost through the kidneys. Increases in albumin do not occur naturally but can be seen in patients who had received albumin suspensions. Methods 1-Precipitation method 2-Electrophoresis 3-Globulin Tryptophan content method 4-Immunochemical methods. 5-Dye binding methods I) Precipitation method *Use serum only *Not applied for automation *Used now for separation & manufacturing albumin . ( ( *Precipitation is done by salting out of globulins &then albumin in the supernatant is measured using a protein estimation method. II) Electrophoresis =========== *Separation of Albumin from the major classes of protein in an electrical field & the staining %is obtained . Calculation of Albumin = % Albumin X Total Protein *Difficult method for Automation. *It is a quantitative method but tends to over estimate Albumin because albumin is the best binder of staining dyes &(the band density of alb. scanned by densitometer. III) Globulin Tryptophan content method ========== *In this method Tryptophan content of the globulin is fist estimated as following; Glycoxylic acid +tryptophan (Globulin)(Purple chromogen (measured at 540) Calculation of Albumin = T.Protein - Globulin IV) Immune chemical methods ============== A)-Electro -immune-diffusion (EID): Considered the Reference method ,Quantitative &Manual. *Migration of protein fractions in an electrical field through a medium contains specific antibodies to albumin. The height of the Rocket precipitin line is correlated to albumin conc. *Used for serum only. B)-Radial immune diffusion (RID):By measuring the diameter of precipitin ring between albumin &its antibodies incorporated in agarose gel. *Used for serum &CSF. Takes long time. C)-Turbidimetry: The reaction between albumin and its specific antibodies form complexes ,that will decrease the light transmission through the reaction phase more than free albumin (antigen). D)-Nephelometry:. E)-Radio immune assay (RIA). F)-Enzyme immune assay (ELISA) PRINCIPLE OF THE METHOD Albumin in the presence of bromcresol green at a slightly acid pH, produces a colour change of the indicator from yellow-green to green-blue. The intensity of the color formed is proportional to the albumin concentration in the sample . CLINICAL SIGNIFICANCE One of the most important serum proteins produced in the liver is albumin. This molecule has an extraordinarily wide rage of functions, including nutrition, maintenance of oncotic pressure and transport of Ca++, bilirubin, free fatty acid, drugs and steroids. Variation in albumin levels indicate liver diseases, malnutrition, skin lesions such as dermatitis and burns or dehydration. Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. PREPARATION Reagent and calibrator are ready to use Signs of reagent deterioration: - Presence of particles and turbidity. - Blank absorbance (A) at 630 nm 0.40. SAMPLES Serum or plasma, free of hemolysis: Stability 1 month at 2-8C or 1 week at 15-25C. PROCEDURE 1. Assay conditions: Wavelength: . . . . . . . . . . . . . .. . 630 nm (600-650) Cuvette: . . . . . . . . . . . . . . . . . . . . . . 1 cm light path Temperature . . . . . . . . . . . . . . . . . . . .. . . . 15-25C 2. Adjust the instrument to zero with distilled water. 3. Pipette into a cuvette: BlankStandardSample R (mL) 1.0 1.0 1.0 Standard (L) -- 5 -- Sample (L) -- -- 5  4. Mix and incubate for 10 min at room temperature (15-25C). 5. Read the absorbance (A) of the samples and Standard, against the Blank. The colour is stable 1 hour at room temperature. CALCULATIONS (A) Sample x 5 (Standard conc.) = g/dL albumin in the sample (A) Standard Conversion factor: g/dL x 144.9 = mol/L REFERENCE VALUES 3.5 to 5.0 g/dL. Total protein estimation Introduction: A Total Protein can be done on either a fasting or non fasting specimen. It is usually done as a general screening assay since it is composed of two major fractions (albumin and globulin). Elevations or decreases in a total protein must be investigated to find out which of the two components is causing the problem. Since many of the next level tests may be reported as percentages or ratios, it is necessary to have the total protein rerun at the time these tests are performed. Overall, a general reference range is 5.0 - 8.0 gram/dL.. Since this is a stable assay, the range of variation is quite small. Acceptable variation is 1.0 If both the albumin and globulin are elevated, one possibility is dehydration or a slow down of blood flow. If both are decreased, the most common culprit is liver function. Since both albumin and globulin can be assayed individually, they are sometimes reported as an "AGratio". (See albumin and globulin for specifics.) Patients with Waldenstrms macroglobulinemia may have total proteins above 8.5. They should consider having tests performed on urine specimens as this will lessen the clotting problem found in the specimen but still provide adequate answers to the physician. 1-Ultraviolet absorption method 2-Specific gravity methods for T.P. a)Phillips or b)Lowry &Hunter 3-Refractrometry. 4-Kjeldahl nitrogen detection method a)Titration or b) kinetic 5-CuSO4 (Cu-Pr complex) Methods a)Lowry or b) Biuret Normal (Reference)Ranges: - Ammonia (Plasma on Heparin)= 15-51 ug/dl - T.P Premature babies = begin from 3.6 g/dl Newborns = 4.6 -5.7 g/dl 7months -1yr. = 5.1 -7.3 g/dl 1-2yrs. = 5.7 -7.5 g/dl  Adults = 6.0 - 8.0 g/dl - Exercise &Ambulatory 0.5 g/dl to T.P (by extravasation of proteins) Ultraviolet Absorption:  270 290 nm 200 -225 nm *Used for Solutions rather than serum. *Using Quartz Cuvette (with no scratches) On using serum , Dilute 1:1000 with NaCl 0.15 mol/L. This method depends on Tryptophan &Tyrosine content of the protein. *Interference by free tyrosine,tryptophan, bil.&U.A. 2-Specific gravity method for Total proteins: a)Phillips et al.: *drops of serum are allowed to fall into "Universal"containers filled with CuSO4 soln. each of known sp.gr. (Stock soln.=159/L Sp.gr=1.1),then serial dilutions are made to get solns. of sp.gr between 1.015 1.035 At certain specific gravity a drop will not move neither up or down(=Sp.gr.of interest) Total protein(g/dl) = 365(Sp.gr.of Int. % 1.007 ) *Can estimate T.P between 3.3 %10.3 g/dl b)Column method (Lowry&Hunter): *Using only single gradient column of mixed organic liquids with CuSO4 jacket (maintaining constant temp.). *It requires only one drop,which will be hanged at certain gradient . *Like in Phillips method T.P can be calculated. 3-Refractometry method: *This method is based on the refraction of incident light by total dissolved solids. *A large drop of serum or urine is allowed to spread between slide &thin film and refracted rays make sharp line dividing the dark & light fields. *Can estimate T.P between 3.5 %11 g/dl 4-Kjeldahl Method: *The reference method *using protein free filtrate. *Depend on estimation of protein nitrogen. Protein  H2SO4+Catalyst +Na-Molybdate NH4+  Alkaline PH NH3 HCl(standard Sol.) NADPH +2oxoglutarate  ( either) (Titration) Neutral PH NADP + glutamate (Nisselerization) (Monitor abs.change at 340 nm) Concentration of total protein= detected nitrogen X100/16 = detected nitrogen X 6.25 *factor 6.25 is the result of 100/16 as each 100 g prt.(16 g Nitrogen. * Corrected pr.conc. = (pr.N2-NPN) X 6.25  5-Alkaline CUSO4 soln.Methods: Sample  NaOH + CuSO4. Copper 6-peptide bond protein complex  Folin(Fenol)+ K&NaTartarate(=color stabilizer) Cio-Calteau(PTA+Ph-Molbdic a.) Molybdinum blue + Violet color of Cu-Pr.Complex Tungesten blue(at 650- 750nm) (at 546nm)  LOWRYs Method BIURETs Method Sensitivity: 100 times > Biurets good for Pr. 2-12 g  Specificity: Less specific specific   No. of reagents: 2 Reagents One reagent  Drug Interference Dependence on Tryptophan&Tyrosine (salicylates,sulfa&tetracyclines) e.g Alb.=0.2 % Tryptophan by wt. Glob.=2% Tryptophan by wt. PRINCIPLE OF THE METHOD Proteins give an intensive violet-blue complex with copper salts in an alkaline medium. Iodide is included as an antioxidant. The intensity of the color formed is proportional to the total protein concentration in the sample CLINICAL SIGNIFICANCE The proteins are macromolecular organic compounds, widely distributed in the organism. They act like structural and transport elements. The proteins of the serum are divide in two fractions, albumin and globulins The determination of total proteins is useful in the detection of: - High protein levels caused by hemoconcentration like in the dehydrations or increase in the concentration of specific proteins. - Low protein level caused by hemodilution by an impared synthesis or loss (as by hemorrhage) or excessive protein catabolism. Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data PREPARATION The reagents are ready to use Signs of reagent deterioration: - Presence of particles and turbidity. - Blank absorbance (A) at 540 nm 0.22. SAMPLES Serum or heparinized plasma: Stability of the sample: 1 month at refrigerator (2-8C). PROCEDURE 1. Assay conditions: Wavelength: . . . . . . . . . . . . . . . . . . . . . . . 540 (530-550) nm Cuvette: . . . . . . . . . . . . . . . . . . . . .. . . . . . . . 1 cm. light path Temperature . . . . . . . . . . . . . . . . . . . . . . . . . .37C / 15-25C 2. Adjust the instrument to zero with distilled water. 3. Pipette into a cuvette: BlankStandardSampleR (mL)1.0 1.01.0Standard (L)------ 25-------Sample(L)--------------- 25 4. Mix and incubate 5 min at 37C or 10 min at room temperature. 5. Read the absorbance (A) of the samples and Standard, against the Blank. The colour is stable for at least 30 minutes. CALCULATIONS (A) Samplex 7 (Standard conc.)= g/dL of total protein in the sample (A) Standard REFERENCE VALUES Adults: 6.6 8.3 g/dL Newborn: 5.2 9.1 g/dL Bilirubin estimation Introduction: Bilirubin is the end product of red cell lysis and recycling of hemoglobin which is performed in the liver. The test quantifies two different forms of bilirubin, one is the final product while the other is an intermediate form. The build up of bilirubin in the blood stream is called jaundice and is a general sign of liver disease. Many medications, gall bladder disease as well as viruses such as infectious mononucleosis and hepatitis will have jaundice. Many infants are born with less than fully mature livers. As a consequence, for the first several days, they may show "neonatal jaundice" which is a build up of bilirubin in the blood stream. This should go away as the liver matures. Bilirubin determinations are used to study liver function and red cell metabolism CLINICAL SIGNIFICANCE Bilirubin is a breakdown product of hemoglobin. It is transported from the spleen to the liver and excreted into bile. Hyperbilirubinemia results from the increase of bilirubin concentrations in plasma. Causes of hyperbilirubinemia: Total bilirubin (T): Increase hemolysis, genetic errors, neonatal jaundice, ineffective erythrpoiesis, and drugs. Direct bilirubin (D): Hepatic cholestasis, genetic errors, hepatocellular damage1,5,6. Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. Methods for Bilirubin estimation =============== Direct Spectrophotometry: *Restricted to newborn(< 28 days) up to 3 months, because their serum contains no Carotenes. *Measuring absorbency of Bilirubin in serum at 2 wave lengths 450 & 540 nm The difference in the absorbance represents bilirubin absorbance (A450 - A540 ) *That is because Hemoglobin reads the same at both W.L while bilirubin reads at 450 nm. Direct Skin Bilirubinometer: *Restricted also to newborns up to 3 months. *Needs calibration using:-Methyl Orange solution. Or -Filter Multilayered color glass. A450 - A 540 = Absorbance of bilirubin Spectral shift change method: *Spectral shift through adding hydrophobic cationic polymer. *Used by KODAK ECTACAM only. 4-HPLC(High Purity Liquid Chromatography): Using Normal Silica Chromatography . The Reference method. 5-Colometric methods (Experiment # 8): *The most commonly used methods. Depend on reaction of bilirubin& Diazotized Sulfanilic acid (DSA) MELLOY &EVELYN M. JENDRASSIL-GROF M.*Accelerator: Methanol or UreaCaffeine &Na.Benzoate*PH : NeutralAlkaline(PH=12)*W.L : 660560 nm*Color : Red purplered Coloumetric Reaction: *Bil.Glucuronides + DSA (Azobilirubin +H2O+Co2+Hcl (Direct Bilirubin) *Bil.Glucuronides +DSA +Accelerator (Azobilirubin +H2O+Co2+Hcl(Total Bilirubin) 6-Bilirubin Oxidase Method : *Specific for Bilirubin only. *Bil. +Bil. Oxidase (Biliverdin (measured at 405 nm) PRINCIPLE OF THE METHOD Bilirubin is converted to colored azobilirubin by diazotized sulfanilic acid and measured photometrically. Of the two fractions presents in serum, bilirubin-glucuromide and free bilirubin loosely bound to albumin, only the former reacts directly in aqueous solution (bilirubin direct), while free bilirubin requires solubilization with dimethylsulfoxide (DMSO) to react (bilirubin indirect). In the determination of indirect bilirubin the direct is also determined, the results correspond to total bilirubin. The intensity of the color formed is proportional to the bilirrubin concentration in the sample PREPARATION All the reagents are ready to use Signs of reagent deterioration: - Presence of particles and turbidity. - Color development in R 2. Specimen Precautions: =================== Serum or Plasma Avoid Hemolysis Avoid light exposure Storage for 3 days in dark & refrigerator (for months if freezed at  70 C) Urine sample either Random or 24 hrs. not stored for >24 hrs. PROCEDURE 1. Assay conditions: Wavelength: . . . . . . . . . . . . . & . . . . 555 nm (530-580) Cuvette: . . . . . . . . . . . . . . . ... . . & & . . .1 cm light path Temperature . . . . . . . . . . . . . . . . . . . . . . . . . . . 15-25C 2. Adjust the instrument to zero with distilled water. 3. Pipette into a cuvette: Blank. Total BBlank Direct B. R 1 (D) (mL) -- -- 1.5 1.5 R 2 (T) (mL) 1.5 1.5 -- -- R 3 (L ) -- 50 -- 50 Sample 100 100 100 100  4. Mix and incubate exactly for 5 minutes at 15-25C. 5. Read the absorbance (A). CALCULATIONS With Factor: ((A) Sample - (A) Sample Blank) x Factor* = mg/dL bilirubin in the sample : Theoretical factor: Bilirubin (T) = 19,1 ; Bilirubin (D) = 14 Conversion factor: mg/dL x 17.1 = mol/L. REFERENCE VALUES Bilirubin Total Up to 1.10 mg/dL=18.81 mol/L Bilirubin Direct Up to 0.25 mg/dL=4.27 mol/L Questions: Write causes of jaundice What are the commonest methods of estimating serum bilirubin in neonates? Mention the different causes of elevated direct and indirect bilirubins. Catalytic (Enzymatic) activities of Liver (ELFT) 1-Gamma Glutamyl Transferase (GGT) Introduction: This enzyme used to metabolize materials in the kidney, liver, gall bladder, and pancreas. It is an exceptionally sensitive indicator of stress in these sites. As a consequence, variations in results may be quite common. Alcohol consumption (even a little) and many medications are the chief causes of these swings. This test is used to follow kidney, liver or pancreatic function PRINCIPLE OF THE METHOD (Kinetic test (Szasz) Gamma-glutamyl transferase (-GT) catalyses the transfer of -glutamyl group from -glutamyl-p-nitroanilide to acceptor glycylglycine, according to the following reaction:  --L-Glutamyl-3-carboxy-4-nitroanilide + Glycylglycine -GT -L-Glutamyl-glycylglycine + 2-Nitro-5-aminobenzoic acid The rate of 2-nitro-5-aminobenzoic acid formation, measured photometrically, is proportional to the catalytic concentration of -GT present in the sample CLINICAL SIGNIFICANCE Gamma-glutamyl transferase (-GT) is a cellular enzyme with wide tissue distribution in the body, primarily in the kidney, pancreas, liver and prostate. Measurements of gamma-glutamyl transferase (-GT) activity are used in the diagnosis and treatment of hepatobiliary diseases such biliary obstruction, cirrhosis or liver tumours Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. PREPARATION Working reagent (WR): Dissolve one tablet of R 2 Substrate in one vial of R 1 Buffer. Cap and mix gently to dissolve contents. Stability: 21 days at 2-8C or 5 days at room temperature (15-25C). Signs of reagent deterioration: - Presence of particles and turbidity. - Blank absorbance (A) at 405 nm e" 1.20. SAMPLES Serum. "GT is stable for at least 3 days at 2-8C, 8 hours at 15-25C and 1 month at  20C. PROCEDURE 1. Assay conditions: Wavelength: . . . . . . . . . . . . . . . . . . . . . . . . . . . . 405 nm Cuvette: . . . . . . . . . . . . . . . . . . . . .. . . . . . . 1 cm light path Constant temperature . . . . . . . . . . . . . . .25C /30C / 37C 2. Adjust the instrument to zero with distilled water or air. 3. Pipette into a cuvette: WR (mL) 1.0 Sample (L) 100  4. Mix, wait for 1 minute. 5. Read initial absorbance (A) of the sample, start the stopwatch and read absorbances at 1 minute intervals thereafter for 3 minutes. 6. Calculate the difference between absorbances and the average absorbance differences per minute ("A/min). CALCULATIONS Mean A= (A)/min = (A1+A2+A3) / 3 Enzyme activity (U/L) =  A X Factor "A/min x 1190 = U/L of -GT  Units: One international unit (IU) is the amount of enzyme that transforms 1 mol of substrate per minute, in standard conditions. The concentration is expressed in units per litre of sample (U/L). REFERENCE VALUES 25C30C37C Women 4-18 U/L 5-25 U/L 7-32 U/L Men 6-28 U/L 8-38 U/L 11-50 U/L  2- Alanine Transaminase (ALT) PRINCIPLE OF THE METHOD Alanine aminotranferase (ALT) o Glutamate pyruvate transaminase (GPT) catalyses the reversible transfer of an amino group from alanine to -ketoglutarate forming glutamate and piruvate. The piruvate produced is reduced to lactate by lactate dehydrogenase (LDH) and NADH:  -ketoglutarate + L-Alanine ALT (GPT) L-Glutamate + Pyruvate  Pyruvate + NADH+H+ Lactate dehydrogenase (LDH) L-Lactate + NAD The rate of decrease in concentration of NADH, measured photometrically, is proportional to the catalytic concentration of ALT present in the sample CLINICAL SIGNIFICANCE The ALT is a cellular enzyme, found in highest concentration in liver and kidney. High levels are observed in hepatic disease like hepatitis, diseases of muscles and traumatisms, its better application is in the diagnosis of the diseases of the liver. When they are used in conjunction with AST aid in the diagnosis of infarcts in the myocardium, since the value of the ALT stays within the normal limits in the presence of elevated levels of AST Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. PREPARATION Working reagent (WR): Dissolve one tablet of R2 Substrate in one vial of R1. Cap and mix gently to dissolve contents. Stability: 21 days at 2-8C or 72 hours at room temperature (15-25C). Signs of reagent deterioration: - Presence of particles and turbidity. - Blank absorbance (A) at 340 nm < 1.00. SAMPLES Serum or plasma: Stability 7 days at 2-8C.. PROCEDURE 1. Assay conditions: Wavelength: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 340 nm Cuvette: . . . . . . . . . . . . . . . . . . . . .. . . . . . . . 1 cm light path Constant temperature . . . . . . . . .. . . . . .25C / 30C / 37C 2. Adjust the instrument to zero with distilled water or air. 3. Pipette into a cuvette: WR (mL) 1.0 Sample (L) 100  4. Mix, incubate for 1 minute. 5. Read initial absorbance (A) of the sample, start the stopwatch and read absorbances at 1-minute intervals thereafter for 3 minutes. 6. Calculate the difference between absorbances and the average absorbance differences per minute ("A/min). CALCULATIONS A (mean difference of readings) = (A1 +A2+A3) / 3 ALT enzyme activity (U/L) = A X Factor (F1) "A/min x 1750 = U/L of ALT  Units: One international unit (IU) is the amount of enzyme that transforms 1 mol of substrate per minute, in standard conditions. The concentration is expressed in units per litre of sample (U/L). REFERENCE VALUES 25C 30C 37C Men up to 22 U/L 29 U/L 40 U/L Women up to 18 U/L 22 U/L 32 U/L Normal newborns have been reported to show a reference range of up to double the adult, attributed to the neonates hepatocytes. These values decline to adult levels by approximately 3 months of age. 3- Aspartate Transaminase (AST) Introduction: Aspartate Transaminase (AST) is also known by its older name, SGOT, this enzyme is needed in the utilization of energy sources. It is found in high concentrations in muscle (cardiac and others), liver, and other organs. This test usually is ordered to follow cardiac and muscle disease . This test can be performed on specimens from patients who are either in a fasting or non fasting. Adult reference ranges vary widely with different instruments. PRINCIPLE OF THE METHOD Aspartate aminotransferase (AST) formerly called glutamate oxaloacetate (GOT) catalyses the reversible transfer of an amino group from aspartate to -ketoglutarate forming glutamate and oxalacetate. The oxalacetate produced is reduced to malate by malate dehydrogenase (MDH) and NADH:  -ketoglutarate + L-Aspartate AST (GOT) L-Glutamate + Oxaloacetate  Oxaloacetate + NADH+H+ Malate dehydrogenase (MDH) Malate+ NAD The rate of decrease in concentration of NADH, measured photometrically, is proportional to the catalytic concentration of AST present in the sample. CLINICAL SIGNIFICANCE The AST is a cellular enzyme, is found in highest concentration in heart muscle, the cells of the liver, the cells of the skeletal muscle and in smaller amounts in other weaves. Although an elevated level of AST in the serum is not specific of the hepatic disease, is used mainly to diagnostic and to verify the course of this disease with other enzymes like ALT and ALP. Also it is used to control the patients after myocardial infarction, in skeletal muscle disease and other Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. PREPARATION Working reagent (WR): Dissolve one tablet of R.2 Substrate with one vial of R1 Buffer. Cap and mix gently to dissolve contents. Stability: 21 days at 2-8C or 72 hours at room temperature (15-25C). Signs of reagent deterioration: - Presence of particles and turbidity. - Blank absorbance (A) at 340 nm < 1.00. SAMPLES Serum or plasma: Stability 7 days at 2-8C.. PROCEDURE 1. Assay conditions: Wavelength: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 340 nm Cuvette: . . . . . . . . . . . . . . . . . . . . .. . . . . . . .1 cm. light path Constant temperature . . . . . . . . . . . . . . .25C /30C / 37C 2. Adjust the instrument to zero with distilled water or air. 3. Pipette into a cuvette: WR (mL) 1.0 Sample (L) 100  4. Mix, incubate for 1 minute. 5. Read initial absorbance (A) of the sample, start the stopwatch and read absorbances at 1 minute intervals thereafter for 3 minutes. 6. Calculate the difference between absorbances and the average absorbance differences per minute ("A/min). CALCULATIONS A (mean difference of readings)/min. = (A1 +A2+A3) / 3 AST enzyme activity (U/L) = A X Factor (F1) "A/min x 1750 = U/L of AST  Units: One international unit (IU) is the amount of enzyme that transforms 1 mol of substrate per minute, in standard conditions. The concentration is expressed in units per litre of sample (U/L). REFERENCE VALUES 25C 30C 37C Men up to 19 U/L 26 U/L 38 U/L Women up to 16 U/L 22 U/L 31 U/L Bone Profile Testes Calcium Determination Introduction: Calcium is required for cell function overall and for bone metabolism. Too little calcium gets you either a loss of tissue function or soft bones (osteoporosis) while too much gives you tetni ( cardiac arrest and/or lock jaw is from over clenching of muscles) or over brittle bones. Changes in calcium are used to assess bone function. Higher blood levels usually mean lower bone levels. Usually performed in conjunction with Phosphorous determinations. OBJECTIVES: -Ionized calcium constitutes 48 to 52 % of the total calcium, the un-ionized diffusible form constitutes 5 % approx. and about 43  47 % of the total plasma calcium is protein bound, primarily to albumin, but also to some extant to the -, - and -globulins. -To know the status body calcium (Tetany) METHODS: Chelation with o-Cresolphthalein Complexone(Colorimetric) Atomic absorption Spectrophotometry (AAS) Flame photometer ISE PRINCIPLE OF THE METHOD The measurement of calcium in the sample is based on formation of color complex between calcium and o-cresolphtalein in alkaline medium: Ca++ + o-Cresolphtalein OH Colored complex O-Cresolphthalein Complex one gives violet color in alkaline medium. The intensity of the colour formed is proportional to the calcium concentration in the sample CLINICAL SIGNIFICANCE Calcium is the most abundant and one of the most important minerals in the human body. Approximately 99% of body calcium is found in bones. A decrease in albumin level causes a decrease in serum calcium. Low levels of calcium are found in hypoparathyroidism, pseudohypoparathyroidism, vitamin D deficiency, malnutrition and intestinal malabsortion. Among causes of hypercalcemia are cancers, large intake of vitamin D, enhaced renal retention, osteoporosis, sarcosidosis, thyrotoxicosis, hyperparathyroidism. Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. PREPARATION All the reagents are ready to use. To prepare monoreagent, mix according to this proportion: 50 vol. of R1 and 1 vol. of R2. SAMPLES - Serum or plasma: Separated from cells as rapidly as possible. Blood anticoagulants with oxalate or EDTA are not acceptable since these chemicals will strongly chelate calcium. - Urine: Collect 24 hour urine specimen in calcium free containers. The collecting bottles should contain 10 ml of diluted Nitric acid (50% v/v). Record the volume. Dilute a sample 1/2 in distilled water. Mix. Multiply results by 2 (dilution factor). Stability of the samples: Calcium is stable 10 days at 2-8C. PROCEDURE 1. Assay conditions: Wavelength: . . . . . . . . . . . . . .. . . 570 nm (550-590) Cuvette: . . . . . . . . . . . . . . . . . . . . .. 1 cm. light path Temperature . . . . . . . . . . . . . . . . . . . 37C / 15-25C 2. Adjust the instrument to zero with distilled water. 3. Pipette into a cuvette: BlankStandardSampleR1 (mL) 2.0 2.0 2.0R2 (2 drop) 1 1 1Standard (L) ----- 20 -----Sample (L) ----- ------ 20 4. Mix and incubate for 5 min at 37C / 15-25C. 5. Read the absorbance (A) of the samples and calibrator, against the Blank. The color is stable for at least 40 minutes. CALCULATIONS Serum and plasma (A) Sample x 10 (Standard conc.) = mg/dL calcium (A) Standard Conversion factor: mg/dL x 0.25= mmol/L. REFERENCE VALUES Serum or plasma: Adults 8.5-10.5 mg /dL = 2.1-2.6 mmol/L Children 10 -12 mg/dL = 2.5 - 3 mmol/L Newborns 8 -13 mg/dL = 2 - 3.25 mmol/L RESULTS: CLINICAL SIGNIFICANCE: * HYPOCALCEMIA Vitamin D deficiency Hypoparathyroidism Alkalosis (Alkalemia) * HYPERCALCEMIA Hyperparathyroidism Malignancy of bone Thyrotoxicosis Vitamin D intoxication Idiopathic DISCUSSION: TETANY PRECAUTIONS: Avoid venous stasis (Increase protein & calcium) Do not use contaminated glass ware (Increase calcium) Lipemic Samples (Prepare blank 0.05 ml sample + 2.5 D.W) QUESTIONS: What is HYPOCALCEMIA? Write a short note on Tetany. Give the principle for the determination of serum calcium by colorimetric method. Enumerate different methods for the determination of serum calcium. Quantitative determination of phosphorus PRINCIPLE OF THE METHOD Inorganic phosphorus reacts with molybdic acid forming a phosphomolybdic complex. Its subsequent reduction in alkaline medium originates a blue molybdenum colour. The intensity of the color formed is proportional to the inorganic phosphorus concentration in the sample CLINICAL SIGNIFICANCE Phosphorus is an essential mineral for tissue bone formation and is required by every cell in the body for normal function. Approximately 85% of the body phosphorus is found in bone and in teeth. Low levels of phosphorus, can be caused by hypervitaminosis 0, primary hyperparathyroidism, renal tubular disorders, antacids or malabsortion. High levels of phosphorus can be caused by diet, bone metastases, liver disease, alcohol ingestion, diarrhea and vomiting Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. PREPARATION Working reagent (WR): Mix equal volumes of R 1 (Molybdic) and R 2 (Catalyzer) Stability: 24 h at 2-8C, protected from light. SAMPLES - Serum: Free of hemolysis. Serum should be removed from the clot as quickly as possible to avoid elevation of serum phosphorus from hydrolysis or leakage of phosphate present in erythrocytes. Stabilitr 7 days at 2-8C. - Urine (24 h): Collect the specimen into a bottle containing 10 mL of 10% v/v hydrochloric acid (HCI) to avoid phosphate precipitations. Adjust to pH 2. Dilute the sample 1/10 with distilled water. Mix. Multiply the result by 10 (dilution factor). Stability: 10 days at 2-BoC. PROCEDURE 1- Assay conditions: Wavelength: 710 nm (620-750) Cuvette: 1 cm. light path Temperature 37C 1 15-25C 2- Adjust the instrument to zero with distilled water. 3- Pipette into a cuvette: Blank Standard Sample WR (mL) 1.5 1.5 1.5 Standard (L) - 50 -- Sample (L) -- -- 50  4. Mix and incubate for 10 min at 37C or 30 min at room temperature (15-30C). 5- Read the absorbance (A) of the samples and calibrator, against the Blank. The colour is stable for at least 2 hours. CALCULATIONS Serum (A) Sample x 5 (Calibrator cone.) = mg/dL of phosphorus in the sample (A) Calibrator Conversion factor: mg/dL x 0.323 = mmol/L. REFERENCE VALUES Serum: Children : 4.0 - 7.0 mg/dL = (1.3 - 2.2 mmol/L) Adults : 2.5 - 5.0 mg/dL = (O.8 - 1.8 mmo/lL) Quantitative determination of alkaline phosphatase (ALP) PRINCIPLE OF THE METHOD Alkaline phosphatase (ALP) catalyses the hydrolysis of p-nitrophenyl phosphate at pH 10.4, liberating p-nitrophenol and phosphate, according to the following reaction: p-Nitrophenylphosphate + H20 p-Nitrophenol + Phosphate The rate of p-Nitrophenol formation, measured photometrically, is proportional to the catalytic concentration of alkaline phosphatase present in the sample CLINICAL SIGNIFICANCE Alkaline phosphatase is an enzyme present in almost all weaves of the organism, being particularly high in bone, liver, placenta, intestine and kidney. Both increases and decreases of plasma ALP are of importance clinically. Causes of increased plasma ALP: Paget's disease of bone, obstructive liver disease, hepatitis, hepatotoxicity caused by drugs or osteomalacia. Causes of decreased plasma ALP: Cretinism and vitamin C deficiency1,5,6. Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. PREPARATION working reagent (WR): Dissolve one tablet of R 2 Substrate in one vial of R 1 Buffer. SAMPLES Serum or heparinzed. plasma _Use unhemolyzed .serum, separated from the clot as soon as possible. Stability: 3 days at 2-8C. PROCEDURE 1-Assay conditions: Wavelength: . .. . .405 nm Cuvette: . . . . . . . . . . . . . . . . . . . . .. . .. . 1 cm light path Constant temperature 25C 30C 37C 2-Adjust the instrument to zero with distilled water or air. 3-Pipette into a cuvette: WR (mL)1.2(L)Sample20 4. Mix, incubate for 1 minute. 5-Read initial absorbance (A) of the sample, start the stopwatch and read absorbances at 1 minute intervals thereafter for 3 minutes. 6-Calculate the difference between absorbances and the average absorbance differences per minute (A/min). CALCULATIONS (A/min) x 3300 = U/L de ALP Units: One international unit (IU) is the amount of enzyme that transforms 1 mol of substrate per minute, in standard conditions. The concentration is expressed in units per litre of sample (U/L). REFERENCE VALUES1 25C 30C 37C Children (1-14 years) < 400 U/L < 480 U/L < 645 U/L Adults 60 - 170 U/L 73 - 207 U/L 98 - 279 U/L Factors affecting ALP activities in a normal population include exercise, periods of repaid growth in children and pregnancy. Cardiac profile Testes Quantitative determination of creatin kinase (CK) CLINICAL SIGNIFICANCE Creatine kinase is a cellular enzyme with wide tissue distribution in the body. Its physiological role is associated with adenosine triphosphate (ATP) generation for contractile or transport systems. Elevated CK values are observed in diseases of skeletal muscle and after myocardial infarction Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. PRINCIPLE OF THE METHOD Creatine kinase (CK) catalyses the reversible transfer of a phosphate group from phosphocreatine to ADP. This reaction is coupled to those catalysed by hexokinase (HK) and glucose-6-phosphate dehydrogenase (G6P-DH): Phosphocreatine + ADP CK Creatine + ATP ATP + Glucose HK ADP + Glucose-6-phosphate G6P + NADP + G6P-DH 6-Phosphogluconate + NADPH + H + The rate of NADPH formation, measured photometrically, is proportional to the catalytic concentration of CK present in the sample PREPARATION Working reagent (WR): Dissolve 1 tablet of R 2 Substrate with one vial of R 1. Cap vial and mix gently to dissolve contents. Stability: 5 days at 2-8C or 24 hours at room temperature (15-25C). STORAGE AND STABILITY All the components of the kit are stable until the expiration date on the label when stored tightly closed at 2-8C, protected from light and contaminations prevented during their use. Do not use the tablets if appears broken. Do not use reagents over the expiration date. Signs of reagent deterioration: - Presence of particles and turbidity. - Blank absorbance (A) at 340 nm e" 1.60. SAMPLES Serum or plasma: Stability 7 days at 2-8C, protected from light. The creatin kinase activity decreases 10% after 1 day at 2-5C or after 1 hour at 15-25C. PROCEDURE 1. Assay conditions: Wavelength: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 340 nm Cuvette: . . . . . . . . . . . . . . . . . . . . .. . . . . . . .1 cm light path Constant temperature . . . . . . . . .. . . . . .25C / 30C / 37C 2. Adjust the instrument to zero with distilled water or air. 3. Pipette into a cuvette: 25 - 30C37C WR (mL) 1.0 1.0 Sample (L) 40 20  4. Mix, incubate for 2 minutes. 5. Read initial absorbance (A) of the sample, start the stopwatch and read absorbances at 1 minute intervals thereafter for 3 minutes. 6. Calculate the difference between absorbances and the average absorbance differences per minute ("A/min). CALCULATIONS "A / min x 4127 = U/L CK25- 30C"A / min x 8095 = U/L CK 37C Units: One international unit (IU) is the amount of enzyme that transforms 1 mol of substrate per minute, in standard conditions. The concentration is expressed in units per litre of sample (U/L). REFERENCE VALUES 25C 30C 37C Men, up to 80 U/L 130 U/L 195 U/L Women, up to 70 U/L 110 U/L 170 U/L Quantitative determination of creatine kinase MB (CK-MB) PRINCIPLE OF THE METHOD An antibody to the anti CK-M inhibits completely CK-MM and subunit (M) of the CK-MB. The activity of the non-inhibited CK-B subunit is then assayed by the following series of reactions: Phosphocreatine + ADP CK Creatine + ATP ATP + Glucose HK ADP + Glucose-6-phosphate G6P + NADP + G6P-DH 6-Phosphogluconate + NADPH + H + The rate of NADPH formation, measured photometrically, is proportional to the catalytic concentration of CK-B present in the sample CLINICAL SIGNIFICANCE CK-MB is an enzyme formed by the association of two subunits from muscle (M) and nerve cells (B). CK-MB is usually present in serum at low concentration; it is increases after an acute infarct of myocardium and later descends at normal levels. Also is increased, rarely, in skeletal muscle damage. Clinical diagnosis should not be made on a single test result; it should integrate clinical and other laboratory data. PREPARATION - Working reagent (WR) Dissolve one tablet of R 2 in one vial of R 1. Cap vial and mix gently to dissolve contents. Stability: 8 days at 2-8C or 24 hours at 15-25C. Signs of reagent deterioration: - Presence of particles and turbidity. - Blank absorbance (A) at 340 nme" 1.60. SAMPLES Serum or plasma: Stability 7 days at 2-8C, protected from light. CK-MB activity decreases a 10% after 24 hours at 4C or 1 hour at 25C. PROCEDURE 1. Assay conditions: Wavelength: . . . . . . . . . . . . . . . . . . . . . . . . . . . 340 nm Cuvette: . . . . . . . . . . . . . . . . . . . . .. . . . . 1 cm light path Constant temperature . . . . . . . . .. . . . . .25C / 30C / 37C 2. Adjust the instrument to zero with distilled water or air. 3. Pipette into a cuvette: WR (mL) 1.0 Sample (L) 40  4. Mix. Incubate for 10 minute. 5. Read initial absorbance (A) of the sample, start the stopwatch and read again after 5 minutes (A2). 6. Calculate the difference between absorbances : A= A2  A1. CALCULATIONS A x 825 = U/L de CK-B A x 1651 = U/L de CK-MB  Units: One international unit (IU) is the amount of enzyme that transforms 1 mol of substrate per minute, in standard conditions. The concentration is expressed in units per litre of sample (U/L). Percentage of CK-MB activity in sample: CK-MB Activity % CK-MB Activity = x 100 CK total Activity REFERENCE VALUES Heart infarct probability is high at the following conditions: 25C 30C 37C CK-MB > 10 U/L > 15 U/L > 24 U/L CK-MB activity is between 6 and 25% of total CK activity. Amylase - blood Amylase is an  HYPERLINK "http://www.nlm.nih.gov/medlineplus/ency/article/002353.htm" enzyme that helps digest carbohydrates. It is produced in the pancreas and the glands that make saliva. When the pancreas is diseased or inflamed, amylase releases into the blood. A test can be done to measure the level of this enzyme in your blood. Amylase may also be measured with a urine test. No special preparation is needed. However, you should avoid alcohol before the test. The health care provider may ask you to stop taking drugs that may affect the test. NEVER stop taking any medications without first talking to your doctor. Drugs that can increase amylase measurements include: Asparaginase Aspirin Birth control pills Cholinergic medications Ethacrynic acid Methyldopa Opiates (codeine, meperidine, morphine) Thiazide diuretics What Abnormal Results Mean Increased blood amylase levels may occur due to:  HYPERLINK "http://www.nlm.nih.gov/medlineplus/ency/article/000287.htm" Acute pancreatitis  HYPERLINK "http://www.nlm.nih.gov/medlineplus/ency/article/000236.htm" Cancer of the pancreas, ovaries, or lungs  HYPERLINK "http://www.nlm.nih.gov/medlineplus/ency/article/000264.htm" Cholecystitis Gallbladder attack caused by disease Gastroenteritis (severe) Infection of the salivary glands (such as  HYPERLINK "http://www.nlm.nih.gov/medlineplus/ency/article/001557.htm" mumps) or a blockage  HYPERLINK "http://www.nlm.nih.gov/medlineplus/ency/article/000260.htm" Intestinal blockage  HYPERLINK "http://www.nlm.nih.gov/medlineplus/ency/article/001216.htm" Macroamylasemia Pancreatic or  HYPERLINK "http://www.nlm.nih.gov/medlineplus/ency/article/000263.htm" bile duct blockage  HYPERLINK "http://www.nlm.nih.gov/medlineplus/ency/article/000206.htm" Perforated ulcer  HYPERLINK "http://www.nlm.nih.gov/medlineplus/ency/article/000895.htm" Tubal pregnancy (may have burst open) Decreased amylase levels may occur due to: Cancer of the pancreas Damage to the pancreas Kidney disease  HYPERLINK "http://www.nlm.nih.gov/medlineplus/ency/article/000898.htm" Toxemia of pregnancy Appendix (1) Collective Knowledge of Most Common Lab.Tests Blood Tests Glucose: Glucose is the primary blood sugar test and indicates blood sugar level at the time blood was drawn. High values are seen in diabetics. In addition to pancreatic functions, Glucose may be altered by diet and medication. Normal fasting value is 70-110. Fructosamine: Indicates blood sugar levels over the past one to three weeks. HGB A1C (Glycohemoglobin): Indicates blood sugar activity for the past three months. BUN: BUN stands for Blood Urea Nitrogen and is a waste product which should be removed from the blood by the kidneys. This test measures kidney function. Normal range is 6-20. Creatinine: Creatinine is a waste product which should be removed from the blood by the kidneys. This test measures kidney function. Normal range is 0.5-1.2. ASAT/ALT: Material found in the liver cells and muscle (heart) cells. Damage to these cells will increase values. Normal range is 10-60. LDH: LDH is a material found in blood cells and liver cells. Breakdown of the blood cells as in heart disease or liver damage may increase values. Normal range is 91-180. Alkaline Phosphorus: A material found in the blood related to liver and bone. Normal range for adult males is 20-125; normal range for adult females is 42-124. SGOT, SGPT: Two measures of liver function; occasionally affected by muscle injury. GGTP: The earliest liver function to become abnormal. Total Bilirubin: The level of pigment in the blood. Elevations can be associated with liver disease or breakdown or red blood cells. Slight increases are sometimes seen without significance. Some people normally have isolated elevations of bilirubin called Gilbert's disease. Normal range is 1.0-1.2. Total Protein: This is a combination of albumin and globulin, which are proteins. Abnormal values occur in liver disease and poor nutrition. Normal range is 6.7-8.0. Globulin: Globulin helps to combat infection on a normal level. It is the total protein value minus albumin value. Normal range is 2.3-4.0. A/G Ratio: Albumin value divided by the globulin value. Normal range is 0.8-2.4. Calcium: The most abundant mineral found in the human body. Abnormalities are found in loss of bone, kidney disease and lack of Vitamin D. Normal range is 8.5-10.5. Phosphorous: Related to bone activity and usually follows exact opposite of calcium. Normal range is 2.5-4.6. Uric Acid: A material which, if in excess, can deposit stones in the kidney or in the joints and cause gout. Normal range for males is 4.0-7.0; normal range for females is 2.0-6.0. Cholesterol: A blood fat related in part to eating animal fats such as eggs, cheese, cream, liver, pork, beef, etc. Increased values may indicate a tendency to have hardening of the arteries. Values of 180 or less are associated with least risk of heart disease; in addition to diet and exercise. Lipoproteins: Proteins combined with lipids that serve as carriers of cholesterol. LDL ("Bad" Cholesterol); HDL ("Good" Cholesterol). The higher the value, the less likely that cholesterol deposits are in the blood stream and the less likely the chance of coronary heart disease. Cholesterol/HDL ratio measures the coronary risk factors. Triglycerides: A blood fat related to calories and starch (sweets) in the diet. High levels can impair circulation and lead to hardening of the arteries. Alcohol also will increase the value. Fast overnight test for accurate test results. Normal range for males is 40-160; normal range for feales is 35-135. Magnesium: An element absorbed in the intestine. Abnormal levels are found in pancreatitis, alcoholism and Addison's disease. Normal range is 1.8-2.4. Socium: A body salt, also termed electrolyte. Kidney disease and some diseases of the adrenal gland and dehydration can cause abnormal results. Normal range is 135-145. Potassium: A body salt or electrolyte found mostly inside of cells. "Water pills" may lower potassium and increase kidney damage. Normal range is 3.6-5.0. Chloride: A body salt/electrolyte, it usually follows the same pattern as sodium. Normal range is 101-111. Co2: Buffer system which assists in the transport of carbon dioxide from the tissue to the lungs. Normal range is 21-31. HIV antibody: Presence of antibody is associated with having been infected by the virus known to cause AIDS (Acquired Immune Deficiency Syndrome). PSA: Abnormal levels in the serum are associated with clinical abnormalities of the prostate, including prostate cancer. Because PSA is found in normal, malignant and benign prostatic tissue, clinical discrimination is based upon its serum level. Complete Blood Count WBC (White Blood Cells): White blood count is the number of white blood cells. It helps combat infection. Normal range is 4.8-10.8. RBC (Red Blood Cells): Red blood count is the number of red blood cells. It relates to anemia and oxygen transport. Normal range for males is 4.7-6.1; normal range for females is 4.2-5.4. HGB/HCT: Hemoglobin is an iron-bearing protein which is the red coloring matter found in blood. Normal range for males is 14-18; normal range for females is 12-16. MCH/MCV/MCHC: Mathematical relationship between red blood count size, red blood count number and hemoglobin concentration. Platelets: Platelets deal with hemostasis and blood coagulation. Normal range is 130-400. Urine Tests WBC (White Blood Cells): Indicates possible infection of urinary tract, bladder or kidney. RBC (Red Blood Cells): Possible kidney stone, kidney infection or tumor. Casts: Possible kidney infection or disease. Glucose: Sugar in the urine, possibility of glucose intolerance or low renal threshold. Protein: Possible kidney infection or disease. Appendix (2) Common Blood ProfilesReference values for the more commonly employed laboratory tests are given in the following table. The reference values are in the units currently often used and in the International System (SI) of Units.TestCurrent unitsFactorSI unitsDiabetic ScreenGlucose, fasting65-110 mg/dl0.0553.57-6.05 mmol/LGlucose , random71-180mg/dl0.0553.9-10.0 mmol/LGlycosylated hemoglobin ( Hba1c )5.5 - 8.5%Heart disease risk factors (fasting lipids )Total Cholesterol<200 mg/dl0.0259<5.2 mmol/LHDL cholesterol>35 mg/dl0.0259>0.9 mmol/LLDL cholesterol<150 mg/dl0.0259<3.9 mmol/LTriglyceride<205 mg/dl0.0113<2.3 mmol/LTotal cholesterol/HDL ratio<5.81<5.8Liver function testsTotal Bilirubin0.25-1.5 mg/dl17.14.3-25.6 m mol/LDirect Bilirubin0-0.5 mg/dl17.10 - 8 m mol/LIndirect Bilirubin0-0.9 mg/dl17.10-14 m mol/LTotal Protein6.5-8.5 gm/dl1065-85 gm/LAlbumin3.5-4.8 gm/dl0.1540.54 - 0.74mmol/LGlobulin2.0-3.9 g/dl1020-39 g/LAlbumin/Globulin ratio1-2.511-2.5g -Glutamy transpeptidase (GGT) -Male11-50 IU/L1.67 X 10-818-84 X 10-8 Katal/Lg -Glutamy transpeptidase (GGT) -Female7-35 IU/L12-58 X 10-8 Katal/LAlkaline Phosphatase45-125 IU/L(up to 1000 IU/L in young children)1.67 X 10-80.75-2.1 X 10-8 Katal/LAlanine aminotransferase (SGPT / ALT)5-35 IU/L1.67 X 10-88.4 -58 X 10-8 Katal/LAspartate aminotransferase (SGOT/ AST)5-40 IU/L1.67 X 10-88.4 -67 X 10-8 Katal/LRenal/Kidney Function TestsUrea (BUN)8-25 mg/dl0.3572.9-8.9 mmol/LCreatinine0.6-1.7 mg/dl88.453-150 m mol/LUric acid3.5-8.0 mg/dl0.0590.21-0.47 mmol/LPotassium3.3-4.9 mmol/L13.3-4.9 mmol/LSodium135-145 mmol/L1135-145 mmol/LTotal Calcium8.9-10.3 mg/dl0.252.23-2.57 mmol/LFree Calcium4.5-5.0 mg/dl0.251.12-1.25 mmol/LPhosphate2.5-4.5 mg/dl0.3230.8-1.5 mmol/LOther Common Serum Chemistries/Enzymatic ActivitiesTestCurrent unitsFactorSI unitsAmmonia (plasma)11-35 m mol/L111-35 m mol/LBlood gases (arterial, whole blood) - pH7.35-7.4517.35-7.45Blood gases (arterial, whole blood) - PO280-105 mmHg0.13310.6-14.0 kPaBlood gases (arterial, whole blood) - PCO235 - 45 mmHg0.1334.7-6.0 kPaBlood gases (arterial, whole blood) -Carbon dioxide content22-31 mmol/L122-31 mmol/L-Carotene50-300 m g/dl0.01860.9-5.6 m mol/LCeruplasmin0.23-0.58 gm/L6.71.5-3.9 m mol/LChloride95-105 mEq/L195-105 mmol/LCopper - Male70-140 m g/dl0.15711.0-22 m mol/LCopper - Female85-155 m g/dl0.15713.3-24.3 m mol/LComplement (total, hemolytic)118-226CH50U/mlC381-175 mg/dl0.010.8-1.75gm/LC412-34 mg/dl0.010.12-0.34 gm/LCreatinine Clearence60-120 ml/minFerritin - Children13-145 ng/ml2.2529-326 pmol/LFerritin -Male, adult25-240 ng/ml56-540 pmol/LFerritin - Female, adult12-130 ng/ml27-292 pmol/LFibrinogen150-360 mg/dl0.011.5-3.6 gm/LFolate - Plasma1.7-12.6 ng/ml2.273.9-29 nmol/LFolate - Red cell153-602 ng/ml347-1367 nmol/LHaptoglobin100-300 mg/dl0.011.10-3.00 gm/LImmunoglobulin - IgA39-358 mg/dl0.010.  9q  ./>bgxyȖyjjjhU!56>*OJQJ\]h%hU!5>*OJQJ\h%hU!5OJQJ\hU!5>*OJQJ\hU!>*CJOJQJaJh%5>*CJOJQJ\aJhU!OJQJo(hU!5OJQJ\h"OJQJhU!CJOJQJaJhU!OJQJhU!5>*CJOJQJ\aJ$    9:;OfgGkd$$Ifl0 % 64 la$If $If  9r $If$a$ gh{`Gkd$$Ifl0 % 64 la$If  9r $IfGkdb$$Ifl0 % 64 la   $ X Y `Gkd$$Ifl0 % 64 la$If  9r $IfGkd&$$Ifl0 % 64 laY Z m `GkdL$$Ifl0 % 64 la$If  9r $IfGkd$$Ifl0 % 64 la ! " 6 [ \ `Gkd$$Ifl0 % 64 la$If  9r $IfGkd$$Ifl0 % 64 la\ ] q `Gkd$$Ifl0 % 64 la$If  9r $IfGkdr$$Ifl0 % 64 la  `[YYYW$a$Gkd$$Ifl0 % 64 la$If  9r $IfGkd6$$Ifl0 % 64 la ./=>Xab=$a$gd%$a$2=>X[ln 1IOST $:;MN\]繪xxxoohU!H*OJQJ"hU!H*OJQJehrhU!>*OJQJhU!6OJQJ]hU!6>*OJQJ]hU!56>*OJQJ\]hU!5OJQJ\hU!H*OJQJ"jhU!OJQJUmHnHuhWOJQJhU!OJQJhU!OJQJehr+a:^_nopqrqH^H]^buw AWrvLMaghοܭοΒ|qhh`h#OJQJhU!>*OJQJhU!6OJQJ]hU!5OJQJ\ jhU!OJQJ#h%hU!56>*OJQJ\]hU!H*OJQJ"jhU!OJQJUmHnHuh%hU!5>*OJQJ\h%hU!5OJQJ\hU!6>*OJQJ]hU!OJQJhU!56>*OJQJ\]#qj  I['gd  & Fxx]^gd  & Fxx]^gd $a$` & FH^HH^Hhijk Ib2<F[\]ku~qf]RqRIh H*OJQJ jbh OJQJh H*OJQJ jah OJQJ"jh OJQJUmHnHuh 5>*OJQJ\h OJQJh h OJQJh h 5OJQJ\hU!CJOJQJaJhU!H*OJQJ"jhU!OJQJUmHnHuhU!6>*OJQJ]hU!6OJQJ]hU!OJQJhU!H*OJQJ $%'g5Bk#ǽǰǒǂǽǂtc!h h B*OJQJ^Jphh7FiB*OJQJ^Jphh7Fih 5OJQJ\^Jh7Fih >*OJQJ^Jh h 5OJQJ\^Jh 5OJQJ\^Jh OJQJ^Jh h OJQJ^J"jh OJQJUmHnHuh H*OJQJh H*OJQJh OJQJ"U}T /  & FOgdvrgdvr^ $^a$gd  & FNgd gd7Figd #124T @!A!!䲟xxdSESESEShvrB*OJQJ^Jph!hvrhvrB*OJQJ^Jph'hvrhvr5B*OJQJ\^JphhU!OJQJhU!OJQJehrh hU!CJOJQJaJ%h hU!5>*CJOJQJ\aJ%h h 5>*CJOJQJ\aJ'h h 5B*OJQJ\^Jphh 5OJQJ\!h h B*OJQJ^Jphh7Fi5OJQJ\ !!!!!!!! $Ifgd+K & FPgdvrgdvr!!! " """%"&"."/"?"@"""### #!#*#0#Y#e#r#s#t###$ྰxhWOhU!OJQJ!h)5B*OJQJ\^Jphhvr>*B*OJQJ^Jph$hvrhvr>*B*OJQJ^Jph'hvrhvr5B*OJQJ\^Jph!hvr5B*OJQJ\^JphhvrB*OJQJ^Jph!hvrhvrB*OJQJ^Jph hvrhvrCJOJQJ^JaJhvrhvrCJOJQJaJ hvrhvrCJOJQJ^JaJ!!!!" "`WWWW $Ifgd+Kkd$$IfTl\d{  V064 laZ " """!"%"`WWWW $Ifgd+Kkd$$IfTl\d{  V064 laZ%"&"3"7";"?"`WWWW $Ifgd+Kkdf$$IfTl\d{  V064 laZ?"@"A"""# #f#t#`[S[K[[[ & FRgdvr & FQgdvrgdvrkd$$IfTl\d{  V064 laZt###$#$$$H$$$$$+%U%q%%%%&&=&i&j&&&&p^pgd# Wxx]^W 9r ^gdvr$ $$$*$,$F$$$%%%%%%s&&&&''((()d)j)***]+i+o++,;,,,,,--=->-b-c-------00=1hU!OJQJZhU!>*CJOJQJaJhvr>*CJOJQJaJhU!5OJQJ\hU!>*OJQJZo(h#>*OJQJhU!>*OJQJh#hU!5OJQJ\hU!5>*OJQJ\hU!OJQJhU!H*OJQJ5&&&&''%'='T'U''''''''.(l((( ^^8^8p^p@ ^@ ^ & F x^gdU!^ & F x^gdU!(((f)j))**!*"*#*J*K*\*]*********^` ^` ^h^h ^  ^  & F p^p 9r ***** +++.+>+[+\+i+l+++,,,,,,,,->-c- & F $a$ & F (^(c---------0000<1=1J1128292Q2R2w2x2.33 h^h & F $a$$a$^ & F =1J182R2t2x2y2222283933333A4B444445555556636465666666637475767777777c8Լ԰ԤԘԌԀjhU!OJQJUj#hU!OJQJUj hU!OJQJUj3 hU!OJQJUj hU!OJQJUjQ hU!OJQJUjhU!OJQJUjhU!OJQJUhU!5OJQJ\hU!OJQJhU!5>*OJQJ\234Z56636466489 :S:T:j:::;?;@;J;;@<B<<<<< $$Ifa$  h^hc8d88888U9V99999S:h:A;I;K;X;;<B<O<==>>>>??4?6?b?d???????@@6@7@E@F@V@W@g@h@u@v@@@@ȕhU!5>*OJQJ\hU!OJQJmHsH jhU!OJQJhU!OJQJehrhU!5OJQJ\jhU!OJQJUjhU!OJQJUhU!OJQJjhU!OJQJU6<<<<< = =>>>WQQQ$Ifkd$$Ifl\`'T  ` P 0'64 la  9r $If $$Ifa$ >>>>>>>bYYY $$Ifa$kd$$Ifl4\`'T  ` P 0'64 laf4$If>> ?*?>?@?h___Y$If $$Ifa$kd$$Ifl4\`'T  ` P 0'64 laf4@?B?R?V?l?n?h___Y$If $$Ifa$kdT$$Ifl4\`'T  ` P 0'64 laf4n?p?????h___Y$If $$Ifa$kd $$Ifl4\`'T  ` P 0'64 laf4??????h___Y$If $$Ifa$kd$$Ifl4\`'T  ` P 0'64 laf4??@(@@@T@a@p@@h]]WWW]W$If  9r $Ifkd$$Ifl4\`'T  ` P 0'64 laf4@@@@@@@@A][[[YYO 8]^8kd$$Ifl4B\`'T  `  P 0'64 laf4 $$Ifa$@@@@@AAAAAAAABBBBB1B@BBBBCC4CNCXCgCDDuFFFFGG H H Hׇׇװׇׇ}qqejhU!OJQJUjhU!OJQJUhU!0JOJQJhU!OJQJehrhU!>*OJQJhU!0J>*B* OJQJphhU!0J>*B*OJQJphhU!B*OJQJphhU!5OJQJ\hU!OJQJhU!0JB*OJQJph$hU!0J5>*B*OJQJ\ph'AAAAAAAAAAekdh$$Ifl\#    064 la$If AAAAAAkeeee$Ifkd $$Ifl\#    064 laAAAAABkeeee$Ifkd$$Ifl\#    064 laBBBBBCDDuFFGki_ii_i_i_ 8]^8kdW$$Ifl\#    064 la HHHHzH{H|H}HHHHHHIIIIIInIoIpIqI|I}IIIIIIIAJBJCJDJ_J`JJJJJJJ#K$K%K&K3K4KKKj'hU!OJQJUjhU!OJQJUjEhU!OJQJUjԶhU!OJQJUjchU!OJQJUjhU!OJQJUhU!5OJQJ\hU!5>*OJQJ\jchU!OJQJUhU!OJQJjhU!OJQJU2GHHHH~HHHHHH{RRUV'X(X3X4XWX|XXXXX$a$gdvr & F & F h^h ]^$a$KKKKKKKKK LLeLfLgLhLtLuLLLLLLL5M6M7M8MEMFMMMMMMMNNN NNNkNlNmNnNxNyNNNNNj hU!OJQJUjhU!OJQJUj>hU!OJQJUjhU!OJQJUj\hU!OJQJUjhU!OJQJUjzhU!OJQJUj hU!OJQJUhU!OJQJjhU!OJQJUjhU!OJQJU2NNNO?O^O_OOOOOOOJPKPLPMPbPcPPPPPPP'Q(Q)Q*Q;QhU!OJQJUjhU!OJQJUj\hU!OJQJUjhU!OJQJUjzhU!OJQJUj hU!OJQJUjhU!OJQJUjhU!OJQJUjhU!OJQJUhU!OJQJ4UWVWWWWWWWWW(X3XXXXXX_[k[\J\X\Z\\\B]D]]]]]^^ ^ ^^6^4_8_``߸ߐߐ߇߇߇{߇{{ߐ߇khU!OJQJehrhU!OJQJmHsHhU!H*OJQJhU!5>*OJQJ\hU!CJOJQJaJhU!5>*CJOJQJ\aJhvr5>*CJOJQJ\aJhU!5>*OJQJj hU!OJQJUhU!OJQJjhU!OJQJUjhU!OJQJU'XXXXYZ_[k[\N\\]D]]^6^`[cd#dsddd & F dd[$\$#$d%d&d'dNOPQ $a$gdvr``aaaccd#deefgggg/g0g6gHgagbgkglgrghhh&ikkhmm\oroppprrtuu,uֵ֪֪֎rh0Gh0G5OJQJ\^Jh0G5>*OJQJ\hU!5>*CJOJQJ\aJhU!5H*OJQJ\hU!5OJQJ\hU!5H*OJQJ\hU!5>*OJQJ\hU!H*OJQJhU!OJQJhU!OJQJehr"hU!H*OJQJehr+deeeeeff0g6gHgbglgsg$Ifdd[$\$ & F dd[$\$ sgtggggrlll$Ifkd$$IfF#II06    34ab gggggrlll$IfkdK$$IfF#II06    34ab gggghrlll$Ifkd$$IfF#II06    34ab hhhh'hrlll$Ifkd$$IfF#II06    34ab 'h(h:hChKhrlll$Ifkdy$$IfF#II06    34ab KhLh[hbhhhrlll$Ifkd3$$IfF#II06    34ab hhihwiiNjyjkl$mrpppnppJ#$d%d&d'dNOPQkd$$IfF#II06    34ab $mhmmmmmn n*OJQJ\hU!H*OJQJhU!H*OJQJh`OJQJhNqOJQJ"jhU!OJQJUmHnHuhU!OJQJhU!5>*OJQJ\h0Gh0GOJQJ^Jh0Gh0G5OJQJ\^Jh0G5OJQJ\^J)xy"y$y&y'yyz{|{}{{{{O|P|y|z||||||||ϿϿuuugVE!h_R'5B*OJQJ\^Jph!h`5B*OJQJ\^Jphh`B*OJQJ^Jphhc+B*OJQJ^Jph'h0Gh0G5B*OJQJ\^Jph!h0Gh0GB*OJQJ^Jphh_R'OJQJ^Jh0Gh0GOJQJ^Jh0Gh0G5OJQJ\^Jh`5OJQJ\^Jh^5OJQJ\^Jh`OJQJ^Jh0Gh^OJQJ^J||}!}+},}}}}}i~~~~~~~~~~~~~~ϻugYuYuG#jh[hhd>*UmHnHuh_R'CJOJQJ^JaJh_R'CJOJQJ^JaJh0Gh0GOJQJ h_R'h0GCJOJQJ^JaJh0Gh:&OJQJ h_R'h:&CJOJQJ^JaJh`B*OJQJ^Jph'h0Gh0G5B*OJQJ\^Jph!h`5B*OJQJ\^Jph!h0Gh0GB*OJQJ^Jphh_R'B*OJQJ^Jphy~~~~~~~Xkd$$IfTl\ 7 V04 la $IfgdU!~~~~~~aXXXX $IfgdU!kdd$$IfTl)\ 7 V04 la ~~~~~~aXXXX $IfgdU!kd!$$IfTlf\ 7 V04 la ~~~$7a\WW\\RPgd3+gd_R'gd0Gkd$$IfTl\ 7 V04 la  #$%7̀ـ΁ρЁAƼѫwh]w]]w]hU!>*OJQJ\hU!5>*CJOJQJaJhU!5>*OJQJhU!OJQJ\hU!OJQJhU!5>*OJQJ\h[h5>*OJQJ\!h3+hU!B*OJQJ^Jphh0Gh0G5\ h[h5\h` h0Gh0G h[hh0Gh[h h[hh[h h[h>*h[hh[h>*h[hh`>* 7k̀΀ـH΁ρAB&'Bgdc+ $`a$gdHz$a$H^H & F HX^H`XAB[%&'BCDZ[e|Åڅۅ 0FPde{ĸwghHzhc+5OJQJ\^Jhc+5OJQJ\^JhU!H*OJQJhc+OJQJhU!H*OJQJ"jhU!OJQJUmHnHuhU!OJQJhU!5>*OJQJ\hU!5>*OJQJhc+OJQJ^JhHzhHzOJQJ^JhHzhHz5OJQJ\^Jhc+OJQJ\&BCd|fRĊ )1 $IfgdU! & F^`gd^gd3+gd^gdc+h^h{fgsQRZ[ډۉ܉:;12Jdzn]N= h_R'h^CJOJQJ^JaJh_R'hCJOJQJaJ h_R'hCJOJQJ^JaJ)h_R'h^B*CJOJQJ^JaJphh^B*OJQJ^Jph!h^h^B*OJQJ^Jph!h^5B*OJQJ\^Jph'h^h^5B*OJQJ\^Jphh^hc+OJQJ\h^hc+OJQJh^hc+5OJQJ\ hc+5\hHzhc+OJQJ^J12;@EJ`WWWW $IfgdU!kd$$IfTl\w ?8 V0K64 la JKZ^bf`WWWW $IfgdU!kdi$$IfTl\w ?8 V0K64 la JKSUVfgopERS]_Ҍӌgv񳟳rjR/h^h^5B*CJOJQJ\^JaJphhU!OJQJh^h^5>*OJQJ\h^B*OJQJ^Jphh^>*B*OJQJ^Jph'h^h^5B*OJQJ\^Jph!h^h^B*OJQJ^Jphh_R'CJOJQJ^JaJ h_R'h^CJOJQJ^JaJh_R'CJOJQJ^JaJh_R'h^CJOJQJaJfgtx|`WWWW $IfgdU!kd7$$IfTl\w ?8 V0K64 la ʋDESҌ`[KK[[[[ & F^`gd^gd^kd$$IfTl\w ?8 V0K64 la ҌԌ@gyz{[kd$$IfTl0  V 6wG64 la$wG&#$/IfgdVgd^h^h vy{Ѝэ֍ˎ͎̎Ύώƶyk`XP`k`H=hbh zOJQJh zOJQJh8r_OJQJhbOJQJhbhbOJQJhbhb5OJQJ\hbhb5>*OJQJ\hb5>*OJQJ\"jh_POJQJUmHnHuh^5>*CJOJQJ\aJhU!5>*CJOJQJ\aJhhVCJaJ hhVCJOJQJ^JaJhU!OJQJ)hh^B*CJOJQJ^JaJphʍЍэҍ50$a$[kd$$IfTl0  V 6wG64 la$wG&#$/IfgdV[kdH$$IfTl0  V 6wG64 laҍӍԍՍ֍PQtvېܐ9 $IfgdZ>CgdZ>Ch^hgd8r_h^hgd z$a$ ">QRabяُ $%Fbtuvwאِؐېܐ"jh8r_OJQJUmHnHuh z5OJQJ\h8r_H*OJQJh8r_OJQJh8r_H*OJQJ"jh zOJQJUmHnHuh zH*OJQJh zH*OJQJh_POJQJhbhbOJQJh zOJQJ6ܐݐސߐ.56789: (=>?N渭wwwwwk`h_P5OJQJ\hZ>C5>*OJQJ\h8r_h8r_OJQJh8r_h8r_5OJQJ\hbhb5>*OJQJ\hbhb5OJQJ\hbhbOJQJh8r_5OJQJ\h_PH*OJQJh_POJQJh8r_H*OJQJh8r_H*OJQJh8r_OJQJ"jh8r_OJQJUmHnHu Z[\]gh|}LM•ŕƕɕʕ͕Εѕӕݕޕ ߹hEh$X7OJQJhEhSQOJQJh%phEh%pOJQJhEhZ>COJQJh+KOJQJh_POJQJhZ>ChZ>COJQJhZ>COJQJhZ>C5OJQJ\hZ>ChZ>C5OJQJ\:ƕʕΕҕ_VVVV $IfgdZ>Ckd2$$Ifl\DP X 8 t044 laytEҕӕ_VVVV $IfgdZ>Ckd$$Ifl\DP X 8 t044 laytE _VVVV $IfgdZ>Ckd$$Ifl\DP X 8 t044 laytEKW[_c_ZQHHH $IfgdZ>C $Ifgd$X7gdZ>Ckdu$$Ifl\DP X 8 t044 laytEIJKRUdeʖ˖̖Ж֖ٖؖږ*9;=MNwk`RJh6{OJQJh6{h6{5OJQJ\h6{h6{OJQJh6{5>*OJQJ\hR\hZ>COJQJhR\OJQJhR\hR\>*OJQJhR\>*OJQJhR\5OJQJ\hZ>ChZ>C5OJQJ\h_POJQJhZ>ChZ>COJQJh$X7hEh$X7OJQJh$X7OJQJh$X7hZ>COJQJh$X7h$X7OJQJhZ>COJQJcdRiԚ՚֚^YTTNNNNh^hgdpagd_Pkd6$$Ifl\8 mH t0644 laytEN`awx !"OPRhԚ֚9:;HIϼ혣r]RR]RhU!5OJQJ\(jhU!5OJQJU\mHnHu"jhU!OJQJUmHnHuhU!5>*OJQJ\hU!OJQJhpahpaOJQJhpahpa5OJQJ\hpa5OJQJ\%hpahpa5>*CJOJQJ\aJ"hpahpa5CJOJQJ\aJhpa5>*OJQJ\hpaOJQJh6{h6{OJQJ :IJKěƛțɛʛ.0$w&#$/Ifgd_P & Fx^x`gd_R'gd_R' h]^h]h^hIKL[^yěśƛǛʛ̛./019:;͜ϜМyjy[O[O[h_R'B*OJQJphh_R'h_R'B*OJQJphh_R'5B*OJQJ\ph#h_R'h_R'5B*OJQJ\phh_R'5B*\ph jhU!OJQJhpa5OJQJ\(jhU!5OJQJU\mHnHu"jhpaOJQJUmHnHuhpaH*OJQJhU!H*OJQJhU!OJQJhpaOJQJhU!5OJQJ\Мٜۜ123%45ghCEReϘω}}ωq`qO hv,(hv,(>*B*OJQJph hv,(h_R'>*B*OJQJphhv,(B*OJQJphhHTB*OJQJphhHT5B*OJQJ\ph!h_R'h_R'B*OJQJ^Jphh_R'B*OJQJphh_R'h_R'CJaJh_R'h_R'CJOJQJaJh_R'h_R'B*OJQJphh_R'5B*OJQJ\ph#h_R'h_R'5B*OJQJ\ph+0|jj$w&#$/Ifgd_Pkd$$IfTl0 V 6w064 la0134qߝ&|wwgggwwwww & F^`gd_R'gd_R'kd$$IfTl0 V 6w064 la e˟>j àĠŠ#$$a$ & F h]^hgdv,(gd_R'eʟpqŠӠ#$2hsxҢ5IenxzˣͣΣ(߼Ӭӑ߈߈߈߈߈߈߈ӑvv"jhU!OJQJUmHnHuhU!>*OJQJhU!5OJQJ\hU!5>*CJOJQJ\aJh^5>*CJOJQJ\aJhU!5>*OJQJhv,(5>*OJQJ\hU!5>*OJQJ\hU!OJQJh_R'B*CJaJphhv,(B*CJaJph.$2ͣj Bgd x^`xh^hgdV^h^h^(*j¤ BYZ[פtf[fh5OJQJ\hh5OJQJ\hhU!5>*OJQJ\+jhU!5>*OJQJU\mHnHuhU!H*OJQJ^JhU!5H*OJQJ\hVOJQJhU!H*OJQJ+jhU!5H*OJQJU\mHnHuhU!5OJQJ\hU!5>*OJQJ\hU!OJQJhU!H*OJQJ#[DEIJSUV_`gxϨҨߨŹodXddF#hh5B*OJQJ\phhhU!H*OJQJhhU!OJQJ(jhhU!OJQJUmHnHuhU!H*OJQJhH*OJQJhU!H*OJQJ"jhU!OJQJUmHnHuhU!OJQJhU!5>*OJQJ\hh5>*OJQJ\hh5OJQJ\h5OJQJ\hOJQJhhOJQJIUߨLΪ678 $IfgdT & F#^`gd & F"^`gd & F!^`gd & F ^`gd x^`xgdʩͩLNXY7PstʿrjrjrU)hhB*CJOJQJ^JaJphhCJaJhhCJOJQJaJhhYCJOJQJaJhB*OJQJph!hhB*OJQJ^Jph#hh5B*OJQJ\phhhU!OJQJhhU!5OJQJ\hhOJQJ^JhhOJQJhhB*OJQJph8>GOPY^chWkdJ$$IfTl\Pg  V064 laF $IfgdThix|`WWWW $IfgdTkd$$IfTl\Pg  V064 laF`WWWW $IfgdTkd$$IfTl\Pg  V064 laF`[KK[BB $IfgdT & F$^`gdgdkdl$$IfTl\Pg  V064 laF./MSZ[îͮήϮ߮ʸ{ococcTB#h h5B*OJQJ\phh 5B*OJQJ\phh B*OJQJphhYB*OJQJphhYhB*OJQJph hYhY>*B*OJQJphhY>*B*OJQJphhhB*OJQJph#hh5B*OJQJ\ph!hhB*OJQJ^JphhhYCJOJQJaJ)hhB*CJOJQJ^JaJph #(-Wkd"$$IfTl\o V064 la $IfgdT-./{ή`[KK[[[[ & F%8^8`gdgdkd$$IfTl\o V064 la߮ #$%P`¯Я=Z &Tes˱ٱHZh8FHW%Q[Jky OqrsҾҾүүҾҡҾҾҡҾҡҡҾҾҊҾүүx"jhU!OJQJUmHnHuhU!CJOJQJaJhU!5OJQJ\hU!56OJQJ\]hU!56>*OJQJ\]hU!5>*OJQJ\h OJQJhU!OJQJh h OJQJh hOJQJh hB*OJQJph/OP`¯=jְ T˱H8HPQ]^^  ^` & Fdd[$\$ & F ^`gd gd "JkyOr׷I|d^^ & F & Fd^ & Fd & Fd$a$H^H & Fs׷"#0|ܸ޸ 12N^_ѹ߹ RkûƻhOJQJ^JhhOJQJ^Jhh5OJQJ\^JhhU!OJQJhU!5OJQJ\hU!H*OJQJ"jhU!OJQJUmHnHuhU!>*OJQJhU!5>*OJQJ\hSOJQJhU!OJQJ3 ^߹Rƻmnڿ ,V & F(^`gdS & F'x^x`gdS & F&^`gdSgdS^gdgdgd(^(ƻǻnpXY ²}}raM*OJQJ\h5OJQJ\ )V]@A'?@XYacduv~,9Ҿ୞~pb~b~O$hpoh+>*B*OJQJ^Jphh+CJOJQJ^JaJh+CJOJQJ^JaJh+hSCJOJQJaJ h+hSCJOJQJ^JaJh+h+CJOJQJaJ h+h+CJOJQJ^JaJ'hShS5B*OJQJ\^Jphh+B*OJQJ^Jph!hShSB*OJQJ^JphhSB*OJQJ^Jph &'(.7? $IfgdT & F*^`gdSgdS & F)gd+ ?@INSX`WWWW $IfgdTkd$$IfTl\ n V064 la XYhlqu`WWWW $IfgdTkdD$$IfTl\ n V064 la uv`WWWW $IfgdTkd$$IfTl\ n V064 la +,:2`[KKK[[Fgd+ & F+^`gdSgdSkd$$IfTl\ n V064 la &(8: .028ɻ}}lXJBhU!OJQJhpoB*OJQJ^Jph'hShS5B*OJQJ\^Jph!hpo5B*OJQJ\^Jphh+B*OJQJ^Jphh+B*OJQJ^Jph!hShSB*OJQJ^Jph!hSh+B*OJQJ^JphhpoB*OJQJ^Jph!h+h+B*OJQJ^Jph$hpoh+>*B*OJQJ^Jph$hpoh+>*B*OJQJ^Jph28`&^Rkd$$IfTl0 W#8 V64 la ?kdf$$IfTl # V64 la $IfgdTgdV 8:^`&'@Ast*:;yzлyfS%h+Kh+K5>*CJ OJQJ\aJ %h+KhU!5>*CJ OJQJ\aJ "h+Kh+K5CJOJQJ\aJh+K5>*CJOJQJ\aJh.B5>*CJOJQJ\aJh.BOJQJhpoOJQJhU!OJQJhVhpoOJQJ^J!hVhpoB*OJQJ^Jph'hVhpo5B*OJQJ\^JphhVhpoOJQJ&'@AGse?kd$$IfTl # V64 la $IfgdTRkd.$$IfTl0 W#8 V64 la st|RMHHFgdpogdpoRkde$$IfTl0 W#8 V64 la $IfgdTRkd$$IfTl0 W#8 V64 la  *;c3X?gdV$a$gdV @^`@8^8 H]^HH^H$@&a$^ 0^`0gd+KcdVYcƻ㯠xmx[PHPHPHhnOJQJhhOJQJ"jhnOJQJUmHnHuhn>*OJQJ\hn5>*OJQJhVOJQJ\hV5OJQJhV5>*OJQJhV5>*CJOJQJaJhV5>*OJQJ\hU!5OJQJ\(jhU!5OJQJU\mHnHuhU!OJQJhU!5>*OJQJ\hU!5>*CJOJQJ\aJ,XYbc$% $7$8$H$IfgdE 7$8$H$gd=gdn^gdV & FgdV$a$gdVgdV !g#%23P (\]fgpqrȺwi^heT5OJQJ\h+Kh+K5OJQJ\h+K5OJQJ\heTOJQJheTheTOJQJheTheT5OJQJ\hnhV5OJQJhnhnOJQJhnhn5OJQJ\hhV5OJQJhn5OJQJ\hh5OJQJ\hnOJQJhhOJQJ$ab  )*.01no JVڿh=>*OJQJh=5OJQJ\heTheT5OJQJ\h=OJQJh=hThEh=OJQJhEhTOJQJhTOJQJheTheTOJQJheTOJQJ=Pkd$$Ifl\0 Uet t0644 laytE $7$8$H$IfgdE ^PPPP $7$8$H$IfgdEkd$$Ifl\0 Uet t0644 laytE  */^PPPP $7$8$H$IfgdEkd\$$Ifl\0 Uet t0644 laytE/0J^UUPPPGP`gdVgdV 7$8$H$gd kd $$Ifl\0 Uet t0644 laytEVclno!5־wkwkwk`whU!5OJQJ\hU!5>*OJQJ\hU!OJQJh+KhU!5\h+KhV5\hVOJQJ\h&hV5OJQJh&h&OJQJhV5>*OJQJhV5OJQJh&heTheTOJQJheTheT5OJQJ\heTh OJQJh >*OJQJh OJQJ ?Jy{\c`^gd+K^gdVgdV`gdVHsGsa w & Fdd[$\$]^ @^`@`$a$^sVa w)O:*õÚéééééééé~~ééss~éhU!5OJQJ\hU!>*OJQJ$hU!5>*B* OJQJ\^JphhU!56>*OJQJ\]hU!5>*OJQJ\hU!5>*OJQJ\^JhU!OJQJhU!B*OJQJ^JphjhU!OJQJU^JhU!OJQJ^JjhU!OJQJU^J-)oZ[vghT & Fdd[$\$$a$^^*no 'ZvghT]^k !12HIJthU!>*CJOJQJaJh4;OJQJ&hU!56>*B*OJQJ\]phj hU!OJQJUhU!B*OJQJphhU!0JOJQJhU!>*OJQJhU!>*CJOJQJaJhU!CJOJQJaJhU!5>*OJQJ\hU!5OJQJ\hU!OJQJ* -<Oak\k!2I $$Ifa$ & Fdd[$\$ & Fdd[$\$IJZfv~uuuuu $$Ifa$kd$$IflF p#4  k 06    4 la~uuu $$Ifa$kd$$IflF p#4  k 06    4 la~uuu $$Ifa$kd@$$IflF p#4  k 06    4 la~uuu $$Ifa$kd$$IflF p#4  k 06    4 la.[~uuu $$Ifa$kd$$IflF p#4  k 06    4 la~uuu $$Ifa$kdA $$IflF p#4  k 06    4 la~||kaXVN$a$gd4; < gd4; @^`@dd[$\$]^kd $$IflF p#4  k 06    4 la()*BCSo-@$ L^`La$ L^`L$a$*BA @ > @ ^ p       1 [ e h i k     * d e i ԴԨԴԝԍԂԂԂԂԂhU!6>*OJQJ jhU!OJQJmHnHu jhU!OJQJhU!CJOJQJaJhU!56>*OJQJ jhU!OJQJhU!5OJQJhU!OJQJhU!5>*OJQJhU!5CJOJQJaJhU!CJOJQJaJ3Ac   5@   . =  Q g h $ a$  & F  ]^` L^`L$ L^`La$h          - / 0 7 N GU\r9 & F-gd. & F,gd.gd. L^`L L]`L i j         0 H  4 7 M GHT|~OQ[Ѷxxxc)h.h.B*CJOJQJ^JaJphh.B*OJQJ^Jphh.h.OJQJ!h.h.B*OJQJ^Jph'h.h.5B*OJQJ\^Jph!h.5B*OJQJ\^Jphh.OJQJ^Jh.h.OJQJ^Jh.h.5OJQJ\^JhU!OJQJhU!5OJQJ&9qJkd3 $$IfTl\:C&  V064 la $IfgdZgd. & F.gd.  -.346GHov~ྰxpepeh.h.OJQJh TOJQJ h.h3BCJOJQJ^JaJ$h3Bh3B>*B*OJQJ^Jph'h.h.5B*OJQJ\^Jphh3BB*OJQJ^Jph!h.h.B*OJQJ^Jph h.h.CJOJQJ^JaJh.h.CJOJQJaJ h.h.CJOJQJ^JaJ"Wkd $$IfTl\:C&  V064 la $IfgdZ `WWWW $IfgdZkd $$IfTl\:C&  V064 la3 6H`[SS[[[[[ & F/gd.gd.kdU $$IfTl\:C&  V064 la H?q7b$X $9]9a$gd T $]a$gd T$a$gd Tgd T &dPgd T$&dPa$gd TOP7$%-.2^_qs    a"d"z"$$8$^$%% %0%2%n%ݱեݱՊՂեh DOJQJh D6>*OJQJ]h T56>*OJQJ\]jh TOJQJUjh T5OJQJU\h T6>*OJQJ]h TOJQJo(h TOJQJh T5OJQJ\h T5>*OJQJ\h TCJOJQJaJ3+,-./V./01_sR $]a$gd T $ & Fa$gd T & Fgd T$a$gd Tgd T $9]9a$gd TRd    !1"a"b"z""b#$$^$$$%%0%4%%%%B&x&gd Dgd T$a$gd T $]a$gd Tn%%$&<&B&C&&&&&&&&&'' '''n''''(((/(G(`((((()))))))))̵̤̿̿̿̿̿̿̿̓̃̿rrfh T6>*OJQJ]!jh D5OJQJU\^J jh T5OJQJ\^J h T5OJQJ\^JmHsH!jh T5OJQJU\^Jh TOJQJ^Jh D5OJQJ\^Jh T5OJQJ\^Jjh TOJQJUh DOJQJh TOJQJh T5OJQJ\(x&&&&'l'm''':(((*)u))))))**e*g*$a$gd Tgd D $t]ta$gd T $]a$gd D $]a$gd T $]a$gd Tgd T))*H*]*e*f**********+b+g++,-----------..."...K.......*OJQJ]h D6>*OJQJ],g********b++a,b,,,>--------,.-... $]a$gd T $]a$gd T $]a$gd T$a$gd T..../E/F/G/e/////0~00,1A1C1^1`1d1e1f1}1~11_2`2b2x255 5ߺäxm^h K5B*OJQJ\phh Kh DOJQJh KOJQJh Kh8HOJQJh Kh8H5OJQJ\h K5OJQJ\h8H5CJ\aJhU!5OJQJ\h T>*OJQJh DOJQJh{~DOJQJjh TOJQJUh TOJQJjh{~DOJQJUjh DOJQJU 55355565V5W5Y55555556 66u6v666o777777777ųxxxg\gKgKgK!hEhj!B*OJQJ^JphhEh KOJQJ!hEh KB*OJQJ^Jphh KB*OJQJphh K5B*OJQJ\ph!h Kh KB*OJQJ^Jphh Kh KB*OJQJph#h Kh K5B*OJQJ\phh Kh K5OJQJ\h K5OJQJ\h Kh8HB*OJQJph#h Kh8H5B*OJQJ\ph56+67R7n7o7p7v777 $Ifgd K & F2gd K & F1gd Kgd K 777777^UUUU $Ifgd Kkd $$Ifl\ I*2e t0644 laytE77777777777777777777777r8s8888889999.9F9㰢sg`\hZ h Kh KhZB*OJQJphhZ>*B*OJQJphh Kh KB*OJQJph#h Kh K5B*OJQJ\phhZB*OJQJ^Jph!h Kh KB*OJQJ^Jph!hEhj!B*OJQJ^Jph!hEh KB*OJQJ^JphhEh KOJQJ!hEh KB*OJQJ^Jph#777777^UUUU $Ifgd Kkd$$Ifl\ I*2e t0644 laytE777777^UUUU $Ifgd Kkd$$Ifl\ I*2e t0644 laytE777(888899^YQQYYYY & F3gd Kgd KkdW$$Ifl\ I*2e t0644 laytE9Z9[999>>?&?'?A?B????@@@@@@AfAA7`7^`h^h 71^7`1 & F$a$gda{gd)F999999::<<<<<>>>?'?????????@@@AAAABB;B?BzB~BBBCC DDDùҐҐҐҐҐq jhU!5OJQJ\hU!>*OJQJhU!OJQJhU!5OJQJ\h{>h5RCJaJh5Rh5ROJQJha{OJQJh5Rh5R5\ ha{5\h5Rha{hU!5>*OJQJ\h)5>*OJQJ\h)hU!5CJ\aJhU!h),AAAAAABBBB>B?BdBzB{B|BBBCCCC%C&C9C $$Ifa$ & F & F7`79C:CZCpC $$Ifa$$Ifnkd$$Ifl09 064 lapCqCCC $$Ifa$$Ifnkd$$Ifl09 064 laCCCC $$Ifa$$Ifnkd)$$Ifl09 064 laCCCC $$Ifa$$Ifnkd$$Ifl09 064 laCCCC6DDD0E1E2EOEPEnEEE]^nkd7$$Ifl09 064 laD'D)D4DDDDDDDDDDEEE0E1ELEPEEEEEEHHHH+HMHNHOHoHHHപziZziZha{hZ5>*OJQJ\!ha{h5RB*OJQJ^Jph'ha{h5R5B*OJQJ\^Jph!ha{5B*OJQJ\^Jphh5R h5Rh5Rh5Rh5R5\ha{ jhU!OJQJ jhU!5OJQJ\hU!56>*OJQJ\]hU!OJQJhU!5OJQJ\hU!5>*OJQJ\#EH,HpHHHHHHIIDJJJJKXLLLL & F6^`gd5R & F5gda{$a$gd5R & Fgd5Rgd5R & F4^`gd5Rgda{gd5Rgd(XHJJKK L LLLLLLLMMMM.M/M6MLMMMNMOMoMyMMMMMMͿͿͪyjyjy\yjNyjͿha{CJOJQJ^JaJha{CJOJQJ^JaJha{h5RCJOJQJaJ ha{h5RCJOJQJ^JaJha{ha{CJOJQJaJ ha{ha{CJOJQJ^JaJ)ha{h5RB*CJOJQJ^JaJphha{B*OJQJ^Jph!ha{h5RB*OJQJ^Jph'ha{h5R5B*OJQJ\^Jphha{h5R5OJQJ\LLLLLLLLDkd$$IfTlrA l3| V064 la $Ifgd7LLLLLLMMDkd$$IfTlrA l3| V064 la $Ifgd7M MMMMM"M&MDkdF$$IfTlrA l3| V064 la $Ifgd7&M*M.M/M8M=MBMGMDkd $$IfTlrA l3| V064 la $Ifgd7GMLMMMNMMMD?// & F7^`gd5Rgd5Rkd$$IfTlPrA l3| V064 la $Ifgd7MMMM NwNNNOYOOOOOPQQQZSSdTUU$a$gd/$a$gd/$a$gd/gdTX$a$ & Fgd7gda{gd5RMM N!NJNKNLN_NmNnNoNvNwNxNNNNNNNNNNNNNNNNNNNNNOھگzznbZhU!OJQJhU!5>*OJQJ\hZ5>*OJQJ\h75>*OJQJ\h7h7OJQJ h{>h7h75B*\phha{5B*\phha{hZ5>*OJQJ\ha{B*OJQJ^Jphha{B*OJQJ^Jph!ha{h5RB*OJQJ^Jph'ha{h5R5B*OJQJ\^Jph"OOOOOOPQQQQRZS\SnSSSSUUUXļ~h\~P\~A~h+K5B*OJQJ\phhMh B*OJQJphh/B*OJQJph+jh/B*OJQJUmHnHphuh/h/B*OJQJphhTXOJQJhTX>*OJQJhTXB*OJQJph#h/h/5B*OJQJ\phhU!OJQJhU!5>*OJQJ\hv|{5>*OJQJ\%hv|{hU!5>*CJOJQJ\aJh&5>*CJOJQJ\aJUV1XXXXY:YYYYTZhZ&[>[j[\R\\ $h^ha$gdFA $a$gdMh gdFA $ & F8^`a$gdFA $a$gdFA gdFA $a$gdFA $a$gdFA $a$gd/XXXXXYYYTZVZfZ&[([<[\\\]]P^R^l^n^p^r^^^^^_J_R_`_p`q````Ƶܵܵtf_ h h h h 5OJQJ\hFA hNB*OJQJphh OJQJmHsHh OJQJh 5OJQJ\%h hFA B*CJOJQJaJph!hFA hFA B*OJQJ^Jphhv|{B*OJQJ^JphhFA OJQJhFA hFA OJQJhFA hFA 5OJQJ\hTX5OJQJ\%\\\\\]]]]Lykd$$IfTl0V3 V064 la $$Ifa$gd $IfgdgdFA $h^h`a$gdFA $h^h`a$gdFA ]]]3]]P^R^n^p^^ __nnnfaaagd $a$gdFA $ & F:^`a$gdFA gdFA ykd@$$IfTl0V3 V064 la _H_J_p```````yme`TTTT $$Ifa$gdgd $a$gd  $ a$gdNokd$$IfTlV  V 6064 la(($&#$/IfgdN ```````TTTT $$Ifa$gdkd$$IfTl\ D  V064 la.```````TTTT $$Ifa$gdkd>$$IfTl\ D  V064 la.`````aa.a`[YQQYLgdTX$a$gd^CPgd kd$$IfTl\ D  V064 la.```````aaa-a"d$d@dBd˼tbS>6'hTXhAuOJQJmHsHhAuOJQJ(jhTXhAuOJQJUmHnHuhTXhTXB*OJQJph#hTXhTX5B*OJQJ\phhv|{5B*OJQJ\phhTXhU!OJQJhU!5>*CJOJQJ\aJhU!5CJOJQJ\aJh^CP5CJOJQJ\aJhTX5CJOJQJ\aJhU!5>*OJQJ\)h h B*CJOJQJ^JaJph%h h B*CJOJQJaJph.avc"dddee|ffgUhhhhhViiiiij$ & F;^`a$gdl:$a$gdl:gdl:$a$gdl:gdl:$a$gdTX$a$gdl:gdAu$a$gdTXBddddde0ePeeeeee{f|f}fffhhhhhh+i,ivjcUJBJBhl:OJQJhl:hl:OJQJhl:hl:5OJQJ\ hl:hl:hTXB*OJQJphhTXhTXB*OJQJphhl:hTXEHH*OJQJhTXhTX5\hl:hl:EHH*OJQJhl:EHH*OJQJhl:hTXOJQJhl:hAuOJQJhAuOJQJ(jhTXhAuOJQJUmHnHuhTXhAuH*OJQJhTXhAuOJQJ,iiijjjJjKjUjkkkkmmmmmTnnnnnn>p?pOpPpkppp|ppppppppָ}rg_____h=OJQJh=5OJQJ\hOG5OJQJ\hl:hOGB*OJQJphhOGhl:OJQJ hl:hOGhl:hOGOJQJhl:hOGOJQJmHsH%hnhl:B*CJOJQJaJphh+K5OJQJ\!hl:hl:B*OJQJ^Jphhl:hl:5OJQJ\hl:hl:OJQJ%jjjJjVjljjkTkkkkkk $$Ifa$gd $Ifgd$h^h`a$gdl:$h^h`a$gdl: $h^ha$gdl:$a$gdMh $a$gdl:gdl:gdl: kkkk}q $$Ifa$gd $Ifgdykd$$IfTl07! V064 lankkkklmmmTnnnnnf]T`gdOG^gdOG$a$gdl:$ & F=^`a$gdl:gdl:ykdF$$IfTl07! V064 lan nnn>pPpppqqyqiaUUa $q^qa$gdl:$a$gdl:$a$gdl:$a$gdOGokd$$IfTl  V 6P064 la(($P&#$/IfgdOGppppppp qqqqqqq&rRrSrUrVrWr`rrttv϶}r`Qhl:hl:B*OJQJph#hl:hl:5B*OJQJ\phhl:hU!OJQJhl:hU!5>*OJQJ\hv|{hU!5>*OJQJ\hv|{5>*OJQJ\hv|{hv|{5>*OJQJ\hv|{hv|{5OJQJ\h&5OJQJ\h^CP5OJQJ\h^CPh^CPOJQJh^CPOJQJhl:hl:OJQJh=OJQJqqqqqqqqqqqqqqqqqqqqqqqqqqq \h]hgd^CPgd^CP $h]ha$gdv|{qqqq'r(rtrurrsttvww>xxxyczzF{T{k{{$a$gdl:gdn$a$gdl:gdl:$a$ \h]hgd^CPvvw wTwfwtwwwww x#x*x2x>xxxxF{G{S{{| |@||||||||/~ɽɽɮtiɂtiti^tih+K5OJQJ\hl:hl:OJQJhl:hl:5OJQJ\hn5OJQJ\#hl:hl:5B*OJQJ\phhn5B*OJQJ\phhl:hl:B*OJQJphhl:hnH*OJQJhl:hnOJQJhl:hnOJQJmHsHhnOJQJ(jhl:hnOJQJUmHnHu!{{|A|i||||||<}}}~/~0~gdl:$h^h`a$gdl:$h^h`a$gdl: $h^ha$gdl:$a$gd+K$a$gdl:gdl:$ & F>^`a$gdl:$a$gdl:$a$gdngdn/~0~R~S~̀΀ԁ ҂ӂ 1:AGNXlnu|зЃ{{{{{{{{{pbhl:hU!5OJQJ\hl:hU!OJQJhdnOJQJhA)5OJQJ\hn5OJQJ\hl:hnB*OJQJphhl:hnOJQJmHsHhl:hnOJQJhl:hl:5OJQJ\hl:hl:OJQJ%hnhl:B*CJOJQJaJph!hl:hl:B*OJQJ^Jph%0~9~>~?~L~Q~qykd$$IfTl0 V064 la& $$Ifa$gd $IfgdQ~R~S~s~~̀΀jԁnnnf]T`gdn^gdn$a$gdl:$ & F@^`a$gdl:gdl:ykd6$$IfTl0 V064 la& ԁ҂'`yqiaUUaS $q^qa$gdl:$a$gdl:$a$gdl:$a$gdnokd$$IfTl  V 6 %064 la(($ %&#$/Ifgdn у҃tȇʇ܇އ)Seiw;< $7$8$H$IfgdE 7$8$H$gdngdHj & F``$a$$a$gd+K]҃ȇއij  Ͽj\QCQ;Q;h!&OJQJh!&hv|{6OJQJ]h!&hv|{OJQJh!&hv|{5OJQJ\(jh AA5OJQJU\mHnHuh!&hU!OJQJ\h!&hU!5OJQJh!&hU!5>*OJQJh!&hU!OJQJh!&hU!5>*OJQJ\hU!5>*CJOJQJ\aJhv|{5>*CJOJQJ\aJh+K5>*CJOJQJ\aJhA)5>*CJOJQJ\aJ&*-6FG`aωvwxz ɍgh ]^ȼ摆{憝sss{sshnOJQJhn5OJQJ\h!&5OJQJ\h!&hU!5OJQJh!&hv|{5OJQJ\hHjOJQJhHjOJQJ\h!&hHjOJQJ\h!&OJQJh AAOJQJh!&hv|{6OJQJ]h!&hv|{OJQJh!&hv|{CJ OJQJaJ -9;\^beil}Ȑʐ̐АѐOP}~͑')*;<LM˩h!&h!&OJQJh!&h!&5OJQJ\hU>*OJQJhU5OJQJ\h!&hv|{5OJQJ\hUOJQJhnhEh 9 OJQJhEhnOJQJh!&hv|{OJQJhnOJQJ8<BKRS\bipPkd~$$Ifl\Tj cDe t0644 laytE $7$8$H$IfgdEpq}^PPPP $7$8$H$IfgdEkdB $$Ifl\Tj cDe t0644 laytE^PPPP $7$8$H$IfgdEkd!$$Ifl\Tj cDe t0644 laytEʐϐ^PPPP $7$8$H$IfgdEkd!$$Ifl\Tj cDe t0644 laytEϐА^UPNINNNgd!&gdU 7$8$H$gdUkd"$$Ifl\Tj cDe t0644 laytEMTcsw’ʒՒ={ "#ĔŔǔӔȼȱȼȼȨȟhU!OJQJhU!OJQJ\hU!5>*OJQJhU!5OJQJhw5OJQJh6g5>*OJQJh!&hU!OJQJ\h!&hU!5OJQJh!&hU!5>*OJQJh!&5>*OJQJhUOJQJh!&h!&OJQJ,,-=Re{|}ēۓ"#T & F & F`p^p & F ^`ĔŔƔǔҔӔY* dhx^gdQ| dh^gdQ|$dh]^a$gdQ| dh|^gdQ|+dh]^+gd k & F & Fܕߕ*sΙ ̚4͵ufZfufZfufNfuZfZfZfh <OJQJ^J_H h kOJQJ^J_H hQ|hQ|OJQJ^J_H "hQ|hQ|5OJQJ\^J_H *h+KhQ|5CJOJQJ\^J_H aJ.h+KhQ|5CJOJQJRHx\^J_H aJ.h+KhQ|5CJOJQJRHm\^J_H aJ4h <h k56CJOJQJRHm\]^J_H aJ.h^CP56CJOJQJRHm\]^J_H aJs̚ !A|o  K dhgdQ| dh]gdMh dh^gdQ|  dh^ gdQ| sdh^sgdQ|$ndh]^na$gdQ|xdhx]x^gdQ|!dh]^!gdQ|H dh]H ^gdQ| dh^gdQ| 48 qs|М,089?@ݷݗݫݫ݈{{jY{Y{Mݫh kOJQJ^J_H  hQ|h <OJQJRHy^J_H  hQ|h <OJQJRH^J_H hQ|h <OJQJ_H hQ|h <OJQJ^J_H &hQ|hQ|6OJQJRHP]^J_H h >SOJQJ^J_H "hQ|hQ|5OJQJ\^J_H &hQ|hQ|6OJQJRHW]^J_H hQ|hQ|OJQJ^J_H &hQ|hQ|6OJQJRHZ]^J_H A^|Мќ؜e$&dh$K B&#$/If^&a$gd <$dh$K B&#$/If^a$gd <$vdh$K B&#$/If]va$gd <$dh$K B&#$/Ifa$gd <Tdh]^T`gdQ|  K dhgdQ|  U dhgdQ|lP4$dh$K B&#$/If^a$gd <$!dh$K B&#$/If^!a$gd <>dh$K B&#$/If^>gd <ykdR#$$IfT\W C V 6K BaiP4$vdh$K B&#$/If]va$gd <>dh$K B&#$/If^>gd <ykd$$$IfT\W C V 6K Ba$&dh$K B&#$/If^&a$gd <,M4>dh$K B&#$/If^>gd <ykd$$$IfT\W C V 6K Ba$&dh$K B&#$/If^&a$gd <$dh$K B&#$/If^a$gd <,04891ykdt%$$IfT\W C V 6K Ba$&dh$K B&#$/If^&a$gd <$dh$K B&#$/If^a$gd <$vdh$K B&#$/If]va$gd <9:  }ž&o` {qq dhgdQ| P q dhgdO dh^gdQ| dh^gdQ|dh]^gdQ|>Cdh]>^`CgdQ|5!dh]5^!gdQ|*Ydh]*^Y`gdQ|* dh&]*^ gdQ| dhigdQ| ֝םޝߝ  !.2HJkž̞ޞߞ)*xi]]]RhQ|hQ|OJQJhOOJQJ^J_H h k5OJQJ\^J_H &hQ|hQ|6OJQJRHW]^J_H h+KhQ|OJQJ^J_H  hQ|hQ|OJQJRHi^J_H ,jhQ|hQ|OJQJU^JmHnHu"hQ|hQ|5OJQJ\^J_H h kOJQJ^J_H hQ|hQ|>*OJQJ^J_H hQ|hQ|OJQJ^J_H &)*=y;ΡԣS^s dh]gd9W  dh] ^ gd9WH dh]H ^gd=  dh^ gd9W$  dh] ^ a$gd9W dh]^ gd9W[d<][^gd^CPdhgdQ|  q dhgdO *4<=Zvy;<VWYZf|n`OC4h9Wh9WOJQJ^J_H hP hOJQJ^J_H  h9Wh9WOJQJRH^J_H hMh OJQJRH^J_H h9Wh9WH*OJQJ^J&jhP hOJQJU^JmHnHuh9Wh9WOJQJ^Jh9Wh9W5OJQJ\^J&h+KhMh 5CJOJQJ\^JaJ&h+Kh9W5CJOJQJ\^JaJ h^CP5CJOJQJ\^JaJhQ|5CJOJQJaJhQ|hQ|5OJQJ5gˣԣS^` EGamnor|}LP$@`d|վվȬȢ}p}ffU h9Wh9WOJQJRH;^J_H hROOJQJ^JhEh FOJQJ^JhEh9WOJQJhEh9WOJQJ^Jh Fh9WOJQJ^Jh FOJQJ^J"h9Wh9W6OJQJ]^J_H h=OJQJ^Jh9Wh9WOJQJ^Jh9Wh9W5OJQJ\^Jh9Wh9WOJQJ^J_H hMh OJQJ^J_H !^sEaim$dh$If]a$gdEdh$If]gdE P dh]gd9W P dh]gd9W K&  dh]gd9W dh]gd=mny|lY$dh$If]a$gdE  Ldh$If]gdE}kd8&$$Ifl0$  t0644 laytE|}~L$@xhZN<fdh|]f^gdRO kdh]kgdRO kdh]kgdRO Pdh]gd9W dh]gd9W{kd&$$Ifl0$  t0644 laytE@|ި*lZ{{{$a$gd=lD gd^CPgd fdh]fgdRO  fdh]fgdRO  fdh]fgd9Wkdhi]k^gd9Wfdh]f^gd9WfZdh]f^Zgd9W 56IMNO]^4GYZӪԪժҽzhYhh=lD5CJOJQJ\aJ"h=lDh=lD5CJOJQJ\aJ"h=lDh5CJOJQJ\aJ"h=lDh5CJOJQJ\aJh=lDOJQJh=lDhOJQJh^CPOJQJhhhOJQJhROOJQJ^Jh9Wh9WOJQJ^J!h9Wh9W5H*OJQJ\^Jh9Wh9W5OJQJ\^Jժĭޭ"ACƮ°o\L\hB#B*EHH*OJQJph$hhB*EHH*OJQJphh=lDB*EHH*OJQJphh=lDB*OJQJph+jh=lDB*OJQJUmHnHphuhhB*OJQJph#hh5B*OJQJ\phhe5B*OJQJ\phhh=lDB*OJQJph"h=lDh=lD5CJOJQJ\aJh=lDh=lD5OJQJ\DƮԮ&UnȰɰTV$ & FE^`a$gd$a$gdgdgd$a$gd!`gd=lD$a$gdgd=lDƮǮӮɰTVf9:vw68:·ķҷ۸(.ð܌{܌ooheB*OJQJph!hh5EHH*OJQJ\hhB*OJQJph)hehB*CJOJQJ^JaJph%hehB*CJOJQJaJph!hhB*OJQJ^JphheOJQJhhOJQJhh5OJQJ\he5OJQJ\+VhEܴ79:;EK $$Ifa$gdgd$h^h`a$gd$h^h`a$gd $h^ha$gd$a$gde$a$gdgdKLUZ_sj^^ $$Ifa$gd $Ifgdkdl'$$IfTlF YR- V06    4 la[ _`mqusj^^ $$Ifa$gd $Ifgdkd2($$IfTlF YR- V06    4 la[ uvw@:lsn[[[nSJ $Ifgd$a$gd$ & FH^`a$gdgdkd($$IfTlF YR- V06    4 la[ l}ykd)$$IfTlj0 l,"x V064 la` $Ifgd·ķ7nopqryqyiy$a$gde$a$gd$a$gdgdykdf*$$IfTl0 l,"x V064 la` .TU_fmpstڹƺֺٻxjbSSShheB*OJQJphheOJQJhh5OJQJ\ hehCJOJQJ^JaJ&heh5CJOJQJ\^JaJ h^CP5CJOJQJ\^JaJh^CP5OJQJ\^Jhe5OJQJ\^J!hhB*OJQJ^JphhhOJQJheB*OJQJphhhB*OJQJphrstֺfTug$z &#$/Ifgd & FI^`gdgdF gde!`gdegdegdgdֺغ&'(2Dcefͻ,ھګڞwm\H'hh5B*OJQJ\^Jph!hhB*OJQJ^JphhFOJQJ^Jhh5OJQJ\^Jhe5OJQJ\^JheOJQJ^JhhOJQJ^J$hheB*EHH*OJQJphheB*EHH*OJQJphheB*OJQJphhheB*OJQJph+jheB*OJQJUmHnHphu¾ؿ hthε⤙zezVh^CPhCJOJQJaJ)h^CPhB*CJOJQJ^JaJph h^CPhCJOJQJ^JaJh^CPCJOJQJ^JaJhhOJQJ hFhCJOJQJ^JaJhFB*OJQJ^JphhhFOJQJ'hh5B*OJQJ\^Jph!hhB*OJQJ^JphhFhOJQJ^Jjkd+$$IfTl0q V 6z 064 la$z &#$/Ifgdfh|wrrrwwii $IfgdgdFgdkd+$$IfTl0q V 6z 064 la ttttttttt dd@&[$\$gdEXgdykd^,$$IfTl0 : V064 laC 0Ersy!+5DUWblvͼͫͼ~ͼsksksksksksk^hEX5CJ0KH$\aJ0h^CPOJQJhhOJQJh^CPCJOJQJ^JaJ h^CPh^CPCJOJQJ^JaJh^CPB*OJQJ^Jph!h^CP5B*OJQJ\^Jph!hhB*OJQJ^Jph'hh5B*OJQJ\^Jph;jhh5B*OJQJU\^JmHnHphuDEKLp.z{!"89MNWX]^no&'679:IJ'(*+=h^CPB*OJQJ^Jph hEXo( h{hEX hEX0J#jhEXUhEXh{hEX5CJ0KH$\aJ0H@pa.IzMn$$ & FVdddA$[$\$gdEXgdEX & FSdd[$\$gdEX dd[$\$gdEXgdEXn(a)*+<=?@ABCPgdgdgdEX & FUdd[$\$gdEXgdEX & FTdd[$\$gdEX$$ & FVdddA$[$\$gdEX=ABCOP~26  T_ =G3?ɱxgxgxgxgxgxgxgxgxgxgxgxgxgxgxgxgx!hU!5B* OJQJ\^Jph~hU!5OJQJ\'hU!56B* OJQJ\]^Jphvj2hU!56>*B* CJOJQJ\]^JaJphvj/hU!56B* CJOJQJ\]^JaJphvjhU!5CJOJQJaJh^CP5CJOJQJaJhzYhCJaJ!hhB*OJQJ^Jph(P~2 T =3VEK$a$VbEOKOW[Ncd|HU()ARZst!hU!5B*OJQJ\^JphhU!OJQJhU!OJQJ^J!hU!5B*OJQJ\^JphhU!5CJOJQJ\aJ'hU!56B* OJQJ\]^JphvjhU!5OJQJ\!hU!5B* OJQJ\^Jph~7WNOdH)R $$Ifa$stekd-$$If#0634ab$Iftkd-$$If,#   0634abp tyLkdY.$$If\ O #0634ab $$Ifa$$If$Ifekd;/$$If#y0634abHIJKwyzfhVXrtdfDFOP  GIVXabcdhU!H*OJQJ^J!hU!5B*OJQJ\^JphhU!OJQJ^JhU!OJQJhU!B*OJQJ^JphMuofff $$Ifa$$Ifkd/$$If0 #  0634abp [ULLL $$Ifa$$Ifkd0$$If\ O #0634ab/9DFH[UULFL$If $$Ifa$$Ifkd1$$If\ O #0634abHIJ[U$Ifkdn2$$If\ O #0634abJKxy$IfekdJ3$$If#y0634abyzuofff $$Ifa$$Ifkd3$$If0 #  0634abp [ULLL $$Ifa$$Ifkd4$$If\ O #0634ab[ULLL $$Ifa$$Ifkd5$$If\ O #0634ab*@Nf[ULLL $$Ifa$$Ifkdq6$$If\ O #0634abfh[ULLL $$Ifa$$IfkdM7$$If\ O #0634ab[U$Ifkd)8$$If\ O #0634ab$Ifekd9$$If#0634ab *4Vuofff $$Ifa$$Ifkd9$$If0 #  0634abp VXz[ULLL $$Ifa$$Ifkdz:$$If\ O #0634ab[ULLL $$Ifa$$IfkdV;$$If\ O #0634ab:V\r[ULLL $$Ifa$$Ifkd2<$$If\ O #0634abrt[ULLL $$Ifa$$Ifkd=$$If\ O #0634ab[ULLL $$Ifa$$Ifkd=$$If\ O #0634abHTXd[ULLL $$Ifa$$Ifkd>$$If\ O #0634abdf[ULLL $$Ifa$$Ifkd?$$If\ O #0634ab.8:O[ULFL$If $$Ifa$$Ifkd~@$$If\ O #0634abOPe[ULLL $$Ifa$$IfkdZA$$If\ O #0634ab [ULLL $$Ifa$$Ifkd6B$$If\ O #0634ab  4>Ja[ULLL $$Ifa$$IfkdC$$If\ O #0634ababc[U$IfkdC$$If\ O #0634abcd$If$IfekdD$$If#0634abuofff $$Ifa$$IfkdjE$$If0 #  0634abp [ULLL $$Ifa$$Ifkd?F$$If\ O #0634ab ~$&LNPRbdxz"$68)*MNuvABtubdĥƥ<>U!hU!5B*OJQJ\^Jph!hU!5B*OJQJ\^JphhU!OJQJhU!OJQJ^JP 4P\~[ULLL $$Ifa$$IfkdG$$If\ O #0634ab~[ULLL $$Ifa$$IfkdG$$If\ O #0634ab$[ULLL $$Ifa$$IfkdH$$If\ O #0634ab$&B`j[ULLL $$Ifa$$IfkdI$$If\ O #0634ab[ULLL $$Ifa$$IfkdJ$$If\ O #0634ab".L[ULLL $$Ifa$$IfkdgK$$If\ O #0634abLNP[U$IfkdCL$$If\ O #0634abPRtkdM$$If,#   0634abp $$Ifa$ekdM$$If#0634ab&BFLF$Ifkd~N$$If\ O #0634ab $$Ifa$$IfFbdRL$Ifkd`O$$If\ O #0634ab $$Ifa$8P\x[ULLL $$Ifa$$IfkdM[ULLL $$Ifa$$IfkdX$$If\ O #0634abMNcqsu[ULLL $$Ifa$$IfkdY$$If\ O #0634abuv[ULLL $$Ifa$$IfkdZ$$If\ O #0634ab[ULLL $$Ifa$$Ifkdh[$$If\ O #0634ab[ULLL $$Ifa$$IfkdD\$$If\ O #0634ab!/4A[ULLL $$Ifa$$Ifkd ]$$If\ O #0634abABRaft[ULLL $$Ifa$$Ifkd]$$If\ O #0634abtu[ULLL $$Ifa$$Ifkd^$$If\ O #0634ab[ULLL $$Ifa$$Ifkd_$$If\ O #0634ab[ULLL $$Ifa$$Ifkd`$$If\ O #0634ab39-3.58 gm/LImmunoglobulin - IgM33-229 mg/dl0.010.33-2.29 gm/LImmunoglobulin - IgG679-1537 mg/dl0.016.79-15.37 gm/LIron - Male80-160 m g/dl0.17914.3-28.6 m mol/LIron - Female60-135 m g/dl10.7-24.2 m mol/LIron - Binding capacity250-350 m g/dl44.7-62.6 m mol/LIron - Transferrin saturation16-57%116-57%Lactate (plasma)0.3-1.3 mmol/L10.3-1.3 mmol/LMagnesium1.5-2.1 mEq/L0.50.7-1.1 mmol/LOsmolality270-290 mOsm/kg1270-290 mOsm/kgProtein electrophoresis - Alpha- 1- globulin0.1-0.5 gm/dl101-5 gm/LProtein electrophoresis - Alpha -2- globulin0.3-1.2 gm/dl103-12 gm/LProtein electrophoresis - Beta globulin0.7-1.7 gm/dl107-17 gm/LProtein electrophoresis - Gamma globulin0.7-1.7 gm/dl107-17 gm/LVitamin A30-95 m g/dl0.0351.05-3.32 m mol/LVitamin B12200-800 pg/ml0.739148-591 pmol/LOther common serum enzymatic activitiesTestCurrent unitsFactorSI unitsAldolase1.5-8.1 IU/L1.67 X 10-82.5-13.5 X 10-8 Katal/LAmylase25-115 IU/L1.67 X 10-842-192 X 10-8 Katal/LCreatine kinase - MaleUp to 185 IU/L1.67 X 10-8Up to 309X10-8 Katal/LCreatine kinase - FemaleUp to 150 IU/L1.67 X 10-8Up to 251X10-8 Katal/LLactic dehydrogenase90-250 IU/L1.67 X 10-8150-417 X 10-8 Katal/LLipase4-24 IU/dl1040-240 IU/L5' - Nucleotidase2-16 IU/L1.67 X 10-83-27 X 10-8 Katal/LPhosphatase, acidUp to 0.7 IU/L1.67 X 10-8Up to 1.2X10-8 Katal/LCommon Serum Hormone ValuesTestCurrent unitsFactorSI unitsACTH, fasting (8 AM)20-100 pg/ml0.224.4-22 pmol/LAldosterone10-160 ng/L2.7728-443 mmol/LCortisol (plasma, morning)8-25 m g/dl0.0270.22-0.57 m mol/LFSH - MaleUp to 20 IU/L1Up to 20 IU/LFSH Female - FollicularUp to 20 IU/L1Up to 20 IU/LFSH Female - LutealUp to 15 IU/L1Up to 15 IU/LFSH Female - Midcycle15-30 IU/L115-30 IU/LFSH Female - Postmenopausal>40 IU/L1>40 IU/LGastrin, fastingUp to 130 pg/ml1Up to 130 ng/LGrowth hormone, fasting<5 ng/ml1<5 m g/L17-Hydroxyprogesterone - Prepubertal3-90 ng/dl17-Hydroxyprogesterone - Male, adult27-199 ng/dl17-Hydroxyprogesterone - Female - Follicular15-70 ng/dl17-Hydroxyprogesterone - Female - Luteal35-290 ng/dlInsulin, fasting (72 hr)<10 mU/L1<10 mU/LLH - MaleUp to 25 IU/L1Up to 25 IU/LLH - Female -FollicularUp to 40 IU/L1Up to 40 IU/LLH - Female - LutealUp to 25 IU/L1Up to 25 IU/LLH - Female - Midcycle50-150 IU/L150-150 IU/LLH - Female - Postmenopausal>30 IU/L1>30 IU/LParathyroid hormone2-10 U/ml12-10 arb unitsProgesterone - MaleUp to 100 ng/dlProgesterone - Female -FollicularUp to 150 ng/dlProgesterone - Female - Luteal250-2800 ng/dlProgesterone - Female -1st trimester1300-5000 ng/dlProlactin - Male2-12- ng/ml12-12 ug/LProlactin - Female2-20 ng/ml12-20 ug/LRenin activity (plasma)0.9-3.3 ng/ml/hr0.2780.2-0.9 ng/L.sTestosterone, total - Male280-1000 ng/dl0.034610-35 nmol/LTestosterone, total - Female20 -120 ng/dl1-4 nmol/LTestosterone, free - Male52-280 pg/ml0.003460.18-1.0 nmol/LTestosterone, free - Female1.1-6.3 pg/ml4-22 X 10- nmol/LThyroxine, total ( T4 )5.0-11.0 ug/dl12.964-142 nmol/LThyroxine, free1.0-2.3 ng/dl12.913-30 pmol/LT3 resin uptake35-45%0.010.35-0.45 arb unitsTriiodothyronine (T3)100-216 ng/dl0.01541.54-3.23 nmol/LT4 index1.75-4.9511.75-4.95 arb unitsTSHUp to 10 m U/ml1Up to 10 mU/LVitamin D, 1,25 dihydroxy20-76 pg/mlVitamin D, 25 hydroxy10-55 ng/mCommon Urinary ChemistriesTestCurrent unitsFactorSI unitsD -aminolevulinic acid1.3-7.0 mg/day7.69.9-53 m mol/dayAmylase0.04-0.30 IU/min10.04-0.30 IU/minCalcium< 250mg/day0.025< 6.25 nmol/dayCatecholamines< 135 m g/day1Up to 135 m g/dayDopamine90-440 m g/dayEpinephrine< 13 m g/day5.5Up to 71 nmol/dayNorepinephrine11-86 m g/day5.965-507 nmol/dayCopper15-50 m g/day0.01570.2-0.78 m mol/dayCortisol, free20-90 m g/day2.7655- 248 nmol/dayCreatinine - Male1.0-2.0 gm/day0.00880.009-0.018 mmol/dayCreatinine - Female0.6-1.5 gm/day0.005-0.013 mmol/day5Hydroxyindoleacetic acid1.8-6 mg/day5.39.5-31.8 m mol/dayHydroxyproline, total25-77 mg/day7.63191-588 m mol/dayMetanephrine0.3-1.0 mg/dayOxalateUp to 40 mg/day7.93< 317 m mol/dayPorphyrin-Coproporphyrin15-125m g/day1.5323-191 nmol/dayPorphyrin-Uroporphyrin< 30 m g/day1.2Up to 36 nmol/dayProtein< 150 mg/day0.001Up to 0.150 gm/dayVanillylmandelic acid (VMA)0.5-7 mg/day5.052.5-35.3 m mol/dayCommon Hematologic StudiesTestCurrent unitsFactorSI unitsCoagulation studies - Bleeding time2.5-9.5 min60150-570 secCoagulation studies -Partial thromboplastin time25-41 sec125-41 secCoagulation studies - Prothrombin time10.8-13.0 sec110.8-13.0 secCoagulation studies - Thrombin time11.3-18.5 sec111.3-18.5 secHematocrit - Male40.7-50.3%0.010.4-0.503 arb unitsHematocrit - Female36.1-44.3%0.36-0.44 arb unitsHemoglobin - Male13.8-17.2 gm/dl0.628.56-10.7 mmol/LHemoglobin - Female12.1-15.1 gm/dl7.50-9.36 mmol/LErythrocyte / RBC count - Male4.5-5.7 X106/m l1064.5-5.7 X 10/LErythrocyte / RBC count - Female3.9- 5.0X106/m l3.9-5.0 X 10/LLeukocyte count3.8-9.8X 10/m l1063.8-9.8 X 109/LLeukocyte profile - Lymphocytes1.2-3.3X 10/m lLeukocyte profile - Mononuclear cells0.1-0.7X10/m lLeukocyte profile - Granulocytes1.8-6.6X 10/m lPlatelet count190 -405 X10/m l106190-405 X 109/LErythrocyte indices - Mean corpuscular hemoglobin26.7-33.7 pg/cell0.0621.66-2.09 fmol/cellErythrocyte indices - Mean corpuscular hemoglobin concentration32.7-35.5 gm/dl0.6220.3-22.0 mmol/LErythrocyte indices - Mean corpuscular volume80.0-97.6 cu m80.0-97.6 flErythrocyte indices - Red cell distribution width11.8-14.6%Erythrocyte Sedimentation rateUp to 30 mm/hr1Up to 30 mm/hrReticulocyte count0.2-2.0% Practical Sheet #( ) Practical Experiment: ........................................................... Objectives: .... Principle: F`j[ULLL $$Ifa$$Ifkdla$$If\ O #0634abҤܤ[ULLL $$Ifa$$IfkdHb$$If\ O #0634ab2>b[ULLL $$Ifa$$Ifkd$c$$If\ O #0634abbdĥ[ULLL $$Ifa$$Ifkdd$$If\ O #0634abĥƥ<[ULLL $$Ifa$$Ifkdd$$If\ O #0634ab<>z[ULLL $$Ifa$$Ifkde$$If\ O #0634abܦ[ULLL $$Ifa$$Ifkdf$$If\ O #0634ab08V[ULLL $$Ifa$$Ifkdpg$$If\ O #0634abVXBDԨ֨\^FHDF  DFSU^_լ׬8:DFOP{}ح٭tvhU!H*OJQJ^J!hU!5B*OJQJ\^Jph!hU!5B*OJQJ\^JphhU!OJQJhU!OJQJ^JLVXn[ULLL $$Ifa$$IfkdLh$$If\ O #0634ab*0B[ULLL $$Ifa$$Ifkd(i$$If\ O #0634abBDԨ[ULLL $$Ifa$$Ifkdj$$If\ O #0634abԨ֨&BH\[ULLL $$Ifa$$Ifkdj$$If\ O #0634ab\^̩ҩ[ULLL $$Ifa$$Ifkdk$$If\ O #0634ab"F[ULLL $$Ifa$$Ifkdl$$If\ O #0634abFH`|[ULLL $$Ifa$$Ifkdtm$$If\ O #0634ab[U$IfkdPn$$If\ O #0634abtkdo$$If,#   0634abp $$Ifa$ekd,o$$If#0634ab$2DFXrLF$Ifkdp$$If\ O #0634ab $$Ifa$$If̫RL$Ifkdmq$$If\ O #0634ab $$Ifa$,;G^[ULLL $$Ifa$$IfkdIr$$If\ O #0634ab^_x[ULLL $$Ifa$$Ifkd%s$$If\ O #0634ab̬ج[ULLL $$Ifa$$Ifkdt$$If\ O #0634ab[ULLL $$Ifa$$Ifkdt$$If\ O #0634ab%/;O[ULLL $$Ifa$$Ifkdu$$If\ O #0634abOPcr~[ULLL $$Ifa$$Ifkdv$$If\ O #0634ab[U$Ifkdqw$$If\ O #0634abtkdx$$If,#   0634abp $$Ifa$ekdMx$$If#0634abȭϭح٭LF$Ifkdy$$If\ O #0634ab $$Ifa$$If6NXtRL$Ifkdz$$If\ O #0634ab $$Ifa$tvĮЮ[ULLL $$Ifa$$Ifkdj{$$If\ O #0634abvHJz|ܰްBD:;xy  ABuvٳڳ  23ijִ״+,jk"#XYbcζ϶<=fg@B$!hU!5B*OJQJ\^JphhU!H*OJQJ^JhU!OJQJhU!OJQJ^JS (,H[ULLL $$Ifa$$IfkdF|$$If\ O #0634abHJz[ULLL $$Ifa$$Ifkd"}$$If\ O #0634ab[ULLL $$Ifa$$Ifkd}$$If\ O #0634abJ`dz[ULLL $$Ifa$$Ifkd~$$If\ O #0634abz|ưʰܰ[ULLL $$Ifa$$Ifkd$$If\ O #0634abܰް $B[ULLL $$Ifa$$Ifkd$$If\ O #0634abBDt[ULLL $$Ifa$$Ifkdt$$If\ O #0634ab[ULFF$If $$Ifa$$IfkdP$$If\ O #0634ab)68:[ULFF$If $$Ifa$$Ifkd,$$If\ O #0634ab:;htvx[ULFF$If $$Ifa$$Ifkd$$If\ O #0634abxy[ULFF$If $$Ifa$$Ifkd$$If\ O #0634abͲֲز[ULLL $$Ifa$$Ifkd$$If\ O #0634ab [ULLL $$Ifa$$Ifkd$$If\ O #0634ab  #13A[ULLL $$Ifa$$Ifkdx$$If\ O #0634abABWegu[ULLL $$Ifa$$IfkdT$$If\ O #0634abuv[ULLL $$Ifa$$Ifkd0$$If\ O #0634abųγгٳ[ULLL $$Ifa$$Ifkd $$If\ O #0634abٳڳ [ULLL $$Ifa$$Ifkd$$If\ O #0634ab  .02[ULLL $$Ifa$$Ifkdċ$$If\ O #0634ab23Uegi[ULLL $$Ifa$$Ifkd$$If\ O #0634abij[ULLL $$Ifa$$Ifkd|$$If\ O #0634ab´ҴԴִ[ULLL $$Ifa$$IfkdX$$If\ O #0634abִ״[ULLL $$Ifa$$Ifkd4$$If\ O #0634ab!+[ULLL $$Ifa$$Ifkd$$If\ O #0634ab+,DU[j[ULLL $$Ifa$$Ifkd$$If\ O #0634abjk[ULLL $$Ifa$$Ifkdȑ$$If\ O #0634abǵյ׵[ULLL $$Ifa$$Ifkd$$If\ O #0634ab "[ULLL $$Ifa$$Ifkd$$If\ O #0634ab"#?MOb[ULLL $$Ifa$$Ifkd\$$If\ O #0634abbc{[ULLL $$Ifa$$Ifkd8$$If\ O #0634abζ[ULLL $$Ifa$$Ifkd$$If\ O #0634abζ϶߶[ULLL $$Ifa$$Ifkd$$If\ O #0634ab$+<[ULLL $$Ifa$$Ifkd̗$$If\ O #0634ab<=FPRf[ULLL $$Ifa$$Ifkd$$If\ O #0634abfgk $@[ULLL $$Ifa$$Ifkd$$If\ O #0634ab@Bv[ULLL $$Ifa$$Ifkd`$$If\ O #0634abĸڸ޸[ULLL $$Ifa$$Ifkd<$$If\ O #0634ab[UUUU$Ifkd$$If\ O #0634ab$[R $$Ifa$kd$$If\ O #0634ab$&0LZl{{{ $$Ifa$$IftkdН$$If,#   0634abp $&ln>@24VX:<24FH¿68"$Z\\]TU46 *hU!H*OJQJ^J!hU!5B*OJQJ\^JphhU!OJQJ^J!hU!5B*OJQJ\^JphhU!OJQJLln¹[ULLL $$Ifa$$Ifkd$$If\ O #0634ab>[ULLL $$Ifa$$Ifkdq$$If\ O #0634ab>@Pht[ULLL $$Ifa$$IfkdM$$If\ O #0634abкԺ[ULLL $$Ifa$$Ifkd)$$If\ O #0634ab *.2[ULLL $$Ifa$$Ifkd$$If\ O #0634ab24Lfn[ULLL $$Ifa$$Ifkd$$If\ O #0634abλֻ[ULLL $$Ifa$$Ifkd$$If\ O #0634ab"0V[ULLL $$Ifa$$Ifkd$$If\ O #0634abVXv[ULLL $$Ifa$$Ifkdu$$If\ O #0634ab:[ULLL $$Ifa$$IfkdQ$$If\ O #0634ab:<d[ULFL$If $$Ifa$$Ifkd-$$If\ O #0634ab 2[ULLL $$Ifa$$Ifkd $$If\ O #0634ab24`z[ULLL $$Ifa$$Ifkd$$If\ O #0634abľ[ULLL $$Ifa$$Ifkd$$If\ O #0634ab&F[ULLL $$Ifa$$Ifkd$$If\ O #0634abFHz[ULLL $$Ifa$$Ifkdy$$If\ O #0634ab¿ 6[ULLL $$Ifa$$IfkdU$$If\ O #0634ab68Hbn[ULLL $$Ifa$$Ifkd1$$If\ O #0634ab[ULLL $$Ifa$$Ifkd $$If\ O #0634ab "[UUUU$Ifkd$$If\ O #0634ab"$Z[R $$Ifa$kdů$$If\ O #0634abZ\f{{{ $$Ifa$$Iftkd$$If,#   0634abp [ULLL $$Ifa$$Ifkd`$$If\ O #0634abCNQ\[ULLL $$Ifa$$IfkdB$$If\ O #0634ab\][ULLL $$Ifa$$Ifkd$$If\ O #0634ab[ULLL $$Ifa$$Ifkd$$If\ O #0634ab [ULLL $$Ifa$$Ifkdִ$$If\ O #0634ab3>@T[ULLL $$Ifa$$Ifkd$$If\ O #0634abTUgw|[ULLL $$Ifa$$Ifkd$$If\ O #0634ab[ULLL $$Ifa$$Ifkdj$$If\ O #0634ab 4[ULLL $$Ifa$$IfkdF$$If\ O #0634ab46x[ULFL$If $$Ifa$$Ifkd"$$If\ O #0634ab2[ULLL $$Ifa$$Ifkd$$If\ O #0634ab*,24123apy '=Q245➏~ hU!5B*CJ H*\aJ phhU!5B*CJ\aJphhU!hU!5;>*OJQJ\UhU!5>*OJQJ\^JhU!OJQJ^JhU!5OJQJ\^JhU!5>*OJQJhU!OJQJhU!OJQJ^JhU!H*OJQJ^J.24t[ULLL $$Ifa$$Ifkdں$$If\ O #0634ab [ULLL $$Ifa$$Ifkd$$If\ O #0634abXz~[ULLL $$Ifa$$Ifkd$$If\ O #0634ab[ULLL $$Ifa$$Ifkdn$$If\ O #0634abZ[ULLL $$Ifa$$IfkdJ$$If\ O #0634ab6V`[ULLL $$Ifa$$Ifkd&$$If\ O #0634ab[ULLL $$Ifa$$Ifkd$$If\ O #0634ab[ULFL$If $$Ifa$$Ifkd$$If\ O #0634ab[ULLL $$Ifa$$Ifkd$$If\ O #0634ab$-/1[ULLF$If $$Ifa$$Ifkd$$If\ O #0634ab123K[YQQQII$dha$$dha$kdr$$If\ O #0634abop{)1267VWst$dha$dh.................. Results: ............................ Comments & Questions .............................. ( HgI2 +KI) pH indicator dye (dry chemistry) NH3 Kinetic Multi-enzymatic method Ammonia detecting electrode Conductivity difference between non-ionized urea and ionized ammonia Berthlots 56hU!OJQJhU!5>*CJ\aJhU!hU!B*ph,1F. A!"#$%7 `$$If!vh56 5.#v6 #v.:V l655 4`$$If!vh56 5.#v6 #v.:V l655 4`$$If!vh56 5.#v6 #v.:V l655 4`$$If!vh56 5.#v6 #v.:V l655 4`$$If!vh56 5.#v6 #v.:V l655 4`$$If!vh56 5.#v6 #v.:V l655 4`$$If!vh56 5.#v6 #v.:V l655 4`$$If!vh56 5.#v6 #v.:V l655 4`$$If!vh56 5.#v6 #v.:V l655 4`$$If!vh56 5.#v6 #v.:V l655 4`$$If!vh56 5.#v6 #v.:V l655 4`$$If!vh56 5.#v6 #v.:V l655 4`$$If!vh56 5.#v6 #v.:V l655 4$$IfZ!vh5v55|5#vv#v#v|#v:V l V0654aZ$$IfZ!vh5v55|5#vv#v#v|#v:V l V0654aZ$$IfZ!vh5v55|5#vv#v#v|#v:V l V0654aZ$$IfZ!vh5v55|5#vv#v#v|#v:V l V0654aZDdh  S 6Acir-bullet"@@bީ^z@ _p--l* nީ^z@ _p--lPNG  IHDR -@.A1B4E6F8H;J>LANCPDQGTKWMYP[Q\U_XbYc\e^gbkemhpiqmupwqxt{v}z}܀܁܄݈݉ތߏᘜᙞ✠㠤㢦䥨䦪媭欰歱簳粵趹鸻麽꼾2s@bKGDH cmPPJCmp0712HsAIDATx^흉:qM@J aOni I&m%-B %@ÒHWڿfX#id?{=|=Si։Tt&R"#qZY擦t*-qOM'||ςJ]rg'|yN ݶd%%y~,׍3l9W>.ERc9\[c]{Q彜ɚ-{'vsKݼY /O0Sp2yya,Y]Ӹ>G8?nـ o^a-!Α> r)熕ٰ&#vq`tӱy4sfL8'pQ)x϶:F=!p(@.e]*~Ϲ,\ʂ)J3 u|۹ɹJK̤aΌIy5&*N+f}^:Ϙ B?@jf$KtB,fDi(LP02|Պn-vn@mX<^G 1hP|\c:yqA+\frvP!7 <Nm|`y9ba^yvwȆaug.v NAgk(+(R4:[*l䴇E`ŭE!71]sog_,g?[9FdI0[rT(pRiƸAܨ_ bZjsvRt_l Hv  hؗD<"j7;v d- HDilhv?W04@1.+K>:^g'N4VRt3׬8͟r| 8eѹKxfl0;8-hfl[r3g*CV0tR!Ij#|<-:zPpňO8.%c2>c2@+袋/%XmMRJ/Aag\v&PK}v2_y+hO<*fGN}NDwfi/2LylqhSy&HjQ qNg[ V0GlʰYBE ơvz"Bw`QϐH{Q>Wr:;&OƐxM#Bͅ@PbN$x1]v/8G&g J,מwTgd?KV]8>c2xl퀪+$@)ZYy6 a71t*39!9t6F z'=P5.9]

gyhbL;URIhPT:qÏ>9ItBt\{c<(\ڈJFxjӓ)ʤ?'ZŽU(e &ٙBT;WQ4Ttf\97&&}=a쀿rRDO%vZ|(4RQ3/ڛmrQ{:2΍ 6X]xxsWQ )h4(:y3Npz^Y;Fe'frFQDƮ8-'s:;N s 4>3*I&L4,sQ4.03>W#r>;TdqU8SeVCKG`y4D@y^':yY)X)JԹlM#Nur3g`(+eS}D7:Pɥ#Q"F`(Rg+JJPWʦenu"<++E@y^):YX)'uy\L>IY)X)JԹlF`(Rg <++E@y^):uy\L~g`(+eSy YD*4G@= mnCh$" B6g Yy˄ dY"///l>p~ɼQJ4"1qV@+uz^Y" w τ HUuLrtW<(]nnx+ LΕGA9tp<(_M70U_r<ݕVxP2\zL7PJLrtW<(]nnx+ LΕGA9tp<(_M70U_r<ݕVxP2\zL7PJLr<ݕ&J#oe6dU}=tW[%&GA9tsxP2@=*19˓&xP"g]?ݞm+r9xر鮈yxܧN ?&;1bQp+b W /]3%91P H0|Lg^PT\M0q5bz4TIr,HHx'PqxtW x>&eZAR9t>!|L 0B(#.8LESP;a_ 8xy1]Rʱ;]2yEZ"@ %"cpZ@L3GXdr<= 8EbJ*ɱHOMd <7:jt ;U"4>e AsЊs-`e(plOoZ@ϟSk 즉f!%z ϝdv;Z4XOl^%*bOqt <R˦x:<ۮA<z~plOrz\(= @aaYijZ6dhn6gWF* - <[:F+"QsOUeFy([_ 2ҫ Nc#9!ב';yd5Ǽd[uIPa 'lFTC?MY톖I.jT{d삗!8[[ #<4Х9x̳+q. PsNt Tt,h@s FMJdW7'oE|4@k5WY$mBkƭfz؀ [=ސ7*Z Dajx)a5$fŭۨ97FELLmAmFOc S@nEJ<4|Q"dr_my g1sb6*Fq6h@@mN Yr4ʳ'B!@; `/7MЅ5H=XG)h2ܾ(`ɿ|,XOӚ<_WoO zhHxHطwI yZBGU|a Yt?4(6?{CgWEsfďDwt nuFK5P=ʅFB 26$ou<'"QU_pk%O F@$&X>뾌-9l ] !3j>J=:nd|5U# WIT$;pc80f`wc@K$y{Qîf4 *lg6f@OAtZ5~O>`$-P"[l鍬ĸ1Ĺ R Q~3{*Ax<ѨƣX?B@Zc*7bpܳ@7eS7Tpn,7F t)s=~%Gpcy3`7WVVڐqx \ϭJ͙ 9Rߛ 8xmxr, 5YK:o.1"ϱLoSg?# ۯlV.8HqTmYBţ" wE)Pxt@ -b<_V7/3$(Hf2BLYf5- t-BB zꩄ_ٮc߸Վc'"firP>kkr)H q[5'gC X辱:jHrœ,VZG`h+/Yky z, dװzq\hp%S9/[,J'9l+S,Vvuy+мR95w6n[X 0p=⨗1@K*|+:s<#<8[GS uwe[Q^\gggD43#N>rg2ni7pWyvW-м"7 ay l7p=*%Oв*߀O tW ܅8Dza}9t*wa rŶ S*Hw*DϙH+9cZw8xuR]9n~}k$ E/B zjr<'4=l-Zd1e[9:kZyX&.Wl)Fn!oR0U yK_gh8x {\;73sƔ bG̓f 0@P<3Ϯ=p >̑gԛh7gΠ=ǣ(JQ WH ,Gn4+<>?(>x[a-W5>Tϗ-|;w,txXr4y 4Kup+w4u9ǝf kwMه|k0~_W$5y0Ζ]y@Oz$(iHy/=O dL 'Bg]<3U_"Ď#f +܆QO}n0Y@7䞍h{.ϟm|L7@OѦ@{s~%Hokf$=ݕFσs{O#(pxϼg tcg&~~9 d\?߼m[ː&E5kl1(;:٘c Ez\i$lp~7!_}J#K9y`#v͙\Lunפp;/ߙl3I@+eк0pva9j— REcgx^ j}gXrvn/@wGh*6ԵOa+/(b&|޿oBBoBoFGﳫ|R aWkghֈ$߂f?xa #d6ij,4=Mb+(ȳFyK3nO).ųm#py>9Zyt }йA_9*o?zl;3m _ks?m X{" ڤm;{uW<F2<_ ,^8sےB2Ͽ3yx՚'X)r\r>͞}q*#g9MMvlUtQjLYtgX t~0|hb<' Z)SxYFk }-?2h OI*9]Cx&/L oEr;̑_ԈS<\L1帛J/ܣdy܋ h9nc^7g7pٮJp]=嶪}Kpg!%kyDx{A̳_`m ~:ϼ9>f/ ./y^̚Kdr<.$Ss1#U3`CA6O Nw'(2eĬi@Cgi-/@τQҼo08 npAH):h?$ܹWJ<7sϰ.SSX5dz?סL7&)~rUYc8)aUop0|RM pXb ɱ_TJln7h6j f<+}H[v}3\/}'OQ6#H6jSY{<pRa B8 lO:^/uϽʏͼ.J>7vX~ʽNh,q#,Mӝma{}L&Ǿ3 K 1>D>,Ѣ*Vv³y ]WߏBovl7s9K\ؖn"ٜf Y/2CF+z53 K:8 lgϰ8Zb21[>9!)<ӌ/Ym7F.Li.i۶a;vc1?HDk2%͸ Gp[<3}ی]&vWŀ95լl@ɢ<[m+g/Q{Ӣk9.#;m~V:~5 ) ~}&bK27s ~]BNR.gMjyO8>._$W -YxӺ'6 ;8S n09o8B_$P WR48eԒ1 @O&3m۾s\xbUaE*yބXfgSrjZ'}ב)ܜ *vz1s d0곿af&c+Hρ.~HD>7Z7pUP}窳hA29Ckn Ix<'y> 4o=UZe5Fb^D@yvߞl v*/}Mu- bO^H@Ounݶc(a .Z;V0C_êAYrDS1,Fg2vs`x>3xF 'G[ӣ>9ϴ9,Q1WW_1mu)hAbNxfYF5dlg @^0ef.-l ~~u)W u*?l3oJ "'~99{Na&Ǥ[c--BMFI9YR!e@g {s?:zQ=K,yHA7* QJsGg\Cl#a ,g|&o~WP\hkԥz+^& |[jɤp+FJ@;ϼc<>Odh1j(+N3ÓU`~iݻs^g6sM @ʂѬ%U'<ȤOV|&<0y£&v-?mHS& p&y>>M?b tsxD8T:*gK4=xnYWc'o~Ξ~*y/)~^X,4~׈ޱθie ,dO,p+Fɣ)&z=} q1oY챖CbM1}uNpny&c ޝwQQ=7Mt9$:wYh8(?mBYnR7 w,4%5i], 䘇E b0 xF;4=w۬_#j%8sƅw[P)^3(t?Z\ȅ%LŮ)dl}Ɵ[{1 ȥ_*K8Ws9MH lֺДxTLC&U]w P qH b dqJ̤St@ο3 a, ~VZϷx}T% t27uX1b  %&z[[zZgGM/8D{~JmDn9.Mޤ 0QDlrȺ{5ޒLC -BAAWS8C­A)4")Dp#ϮyF˫tx噉mQL@qUDWq򌿮ota@4as^C(0huΔq3~0c sfi.^-4-%^ixv Or to9ǓMHSUCU<5Q\O&`P#/@ߤp+NX@Yꉖ.,!.^ գ\0^h\_#%3s(waaN۔ьgA##/q8L94G4t/gCQY$aBC1QOmW~9_[(0JV̍977r&Rپ?)*)hgyi>#&2jxNֺeT ﳃw'4ת s^D>/߸ol? o!OyOMH?`*4edr0/:l晄Q bn a@p&"3,TA)ϣ adHynVNv&23zx6`5 CT7|N!'>&aEL$79!0aS&a­u'9|O[<. x^yr7y5'_&oddr|Eav66|(oVbg%8r !(:x'NGUF`nu"QF,^@VNAyN$3{VFsgSЏmkUj*m Qos'{Rm~FKf(.?aRi"ˤJeD@yfIE^&ˤJeD@yfIE^&ˤJeD@yfIE^&s;W8)ϫt|3%#< 6-ߨc-B"[3@#nbK.<Ut^{PMx&YqkS9SB9~W\!GL56a#Ï`pW 'r|7TV9WDm&·/a9BDFtF<3ttPS0O~__l3?lB~ <;܆x8F_==nO&7Sh^z8|H H;~__2d܄@fb-ϳIר@U,Z-SP1p` 8t7y̆"*/ʐd8 v>y :`|#ϏBI uƩ#K?'5b,2DB&yҿʑiN*@<rHQ1 Y!e %$^љ Cz6E϶  h=ULKHF2ĹARb P# $6Xr#-!>XA΁~g<%yT:.fmq(wVjiyAbdP( ɊP -@.A1B4E6F8H;J>LANCPDQGTKWMYP[Q\U_XbYc\e^gbkemhpiqmupwqxt{v}+z}܀܁܄݈݉ތߏᘜᙞ✠㠤㢦䥨䦪媭欰歱簳粵趹鸻麽꼾$obKGDH cmPPJCmp0712HsKIDATx^흉-Q', (n dq @$@EQ鮪^3w93ukj̽w <'sF2m2x~ll߾d`\#o_{)3?f7*89ͤYun͸VJ1fQF<u+>T N^V=cK=FI2Y-V0_qN^[Qzsxyųyij$㙙 eDyTnt& ,Oa9$Hd+H,Z|,,U}~g\ʖHe#to~8=ԻLmcb\fF6Y8_952sC2#T 8!_2iqKb7>>kJ*)#4=Ӣ< Ľ(lu<Ӊ3W)iN>&ugwZI@7ZNt.L -$}mS)޵lej<#6í~^16Xyq%; sy3Y&>3<d"4ωesœW @7tfCp/;/C"Y7AeS)Ao,$♒DP lI(EUKxa3\&3'Vó¡c=}(-bQ"gD}V,Hݛ>{0#v_ E <*uھ&5{%)C JUsO>SU7fs~X񠂨3G-C$^tg/vaeTjAH"yϒOy# 3cGFgOt2O3ȍhsm͎'EJN2|n<`58BsƵc§A{,=)˽QLș4FI % rÇ)0@܇M0e7՘]VtxYh<Ñ8K|M̴L{EQo³_YbMFĤ Oe9/f) Q-PhDj׶h!8hYΒ]Pœ)|wNUۇ7?}(ZawPfr)p~|'fh?|ow&dT>Y*o{֓ IoD*ƍʦE6I dN33<8.Q;yq $o8);e\Ⱦ(;s´8( "|  +9 $r+,43xQ8^ҤW

Ou3xȳ%lݗ]/g ~iv8px~8x<ق l ;^v|ߖaky!}bF/Or81]_SN7O=:~ ,{֊u":xP?ռ`ؾ{p&- <+AU%&<ųyROY>fv)s$;{ dɖAN#ɓ:޼ St\>X߾ƘG;H3#Ŗ.g )9tpp zwVbϜ7se9n%M;:JzbkO3r&V3qX?g=0?ϧL08@p/(m$W4Z.-x]sP!=_pd_̞kp+xvs)A:]7y(;gHnk"p! Xb Y:v,<97E28*9Y*#OCyfE/!a,xUSyvg}|5oRrw~7̮xOn;9ci x?#HQIfʧxfyUW)[~>τQVSu\8<󋓃*?Љr7ɱ=xg(g.hy{DJF<ϑ<;x8]IOdVKL#SH{;=sM{x4:'+97I? fgb<])86攝^̢c;%b$$RP]܁U0%M{6?p8$EK1Tg0ꊈ3X|$Mz~Jmo?|$=. ;##|;a#(X!CJEG#l=q'm)IXbU}B 8x>공No70!T Yug%[C^xnxgz8@iA w &Wjϳ y0nC^xn8U /w\o<Ｑj.UxSxIiHիU?d#3>Cl^Hg_n(cW𚀗[tLU%z~ oZፈbFpOc` zDnV"~gw<]E#K?5zgR>R!+<#EX)?!m~X$1gVljCvO? wis~'odgWοnJg"#s4-9 d+RwaAշsޮ3#c pUCz$OdVM>X7op?zPPj#?vy& .^FȳGNs=ı fzy*9]$yOPI"M2i* Za:uKI>鑌s}dr,è(nZ<##y~RY `$#E, 0veIEqxm}yc f{Qy;۰INH9K%\$.j-bTi]a,r_PY7xxo6~x'xYPӸx犕ajSʃ^zfv+cm}ëdfbttSa٪۠I ryOD/?gB=ާ=|cXN7hФo  {,ym p`4Q~Z@(:Y+_B?Q7T=,ދzc3>`r;Cx)< ;_W7Tɱ/px!1&lX,/)l;*kWqB~Sk o0Ra= t| qzómt`fZesOlt')q*m߰hZj :Vf?*otFWmZd`{\TY;KὀBM RƭG!yrNa-Dž?u;0 6]Z,f!dƭXo157崲V1ݸu@Uu@pzUwϺvc72g n9^s&o[}à1a4S?e>Ԧ4SjA5~:~GwӃt{\O͙5DLTŭPotg Ct0H[ؕ]sE&& V UA%Zbе+tgؐkh7j7 &WZNC*5L0'o &BSDj K1Sxf ج`.~;rg;A|ó[aNy@ӡ8g~;lwV_dTqX'n: +%)ۍ=_Yv-@!:ky#Yu6qO&o[}1`s!lg-A1ls Jx29w)'$pf{U|oL ڬH @y>j *q7Aq(Wniy|q{x>sm=M5؉umki5WR ]it9@y\B@_ X*fahnhzsp4 ]IA,T18n5j 5BpMX~d' ^Pn zߣǁ΄g&=.k5ųF].!$gn~E< 8sa|c!1?mv`x66 Cbz8ڬފ0ض!jM3+o]BbFHf܈H=j=uS =Ux6ef/L[ffܒ5[S1MhMјc#( Vosx :>Ћ VPlomO/ zmanX޷R!Tpq] J؋ rU!u9kVx՛Q4B58Yײ^X trP*Uk;Rg8ށ5h5Кh[szM@+x5p ;|>]Ou+"{1 F&] Y-fR:@+$$?P+>1G33g'_7n;`<۳mQqr]ij=%~WQvy;$Q N_ngbcpet~HYǘV㨲ZB x|'5)t ԋUtpnA9@A,% GH"3OQr -BG'Qgo&DUu] @"@+ ppm5A85gWl =-ֹSIcg /жo8_BbKP3vٶٵ!"1\I 8<>~jTɰAjmZ!!hVu<}Z`܉Eݯp{|(q)"'ͤ7M:A9[R,Ǚxah u@+m 9BU|"1lo,ξ ?n<VnƕbTUth&qodt<+x y]=)0TK" VR% OK{5L=CgUuyއ<@GKѤYV|]Qa7̦ƨ8 JuaUDUvp{7: .\WD5CKmXt~ls2AvB 1g9J-ᰨ[Qb|;.޽P ]7Pj*$ܷPTijOr= S[%<^ў%&U45Z>:Tgj8tq;DLY|*Ȟ۰ѡd/,0K/njhy?Xqap~zCz GƸ7NYGdg~^y=$$3aw9kȾ dlCݭRǧv@ij>YTg0cޡ_<ٞta* V_X>O`qvtrG9 &Lֻ óyg؆5`B ]>y&kxFVM@O락 [;gT>q T~&`55o)7BSOO$X:ҌKg~B >`F蓹͹o=u` y@&jGXHVUi(ϺQJUT ʯRGdڍ)MNՁsQ)1$[g\**ayvq /J.1][v:ь&c*p]Y(]u\T^=7Z.̢sMq5]_]@f[s Է%}<w耴Bu[am v>j@Z&_g*p@bBr.:b ClM}xKoFjRcOx.v.,8R3K|~À Ϊ81ev{ @7m!'4<Lb=`\U,wW yceqfnjtb)x#5A@/lNy}=9;NBMjjIƳ.H=h=Xb E䂿"{?Yٔbݜ@ УCGSڹ$Ϻؕ cO,y~c<[ujXy9ϟEU]!tFy.>t_BEXJk@+7x?yV_Vf? R ϻASv,=ǨB2sIq":ܤ-˲hg[7:3=m/`sg97 τ~^"G &lM@U϶⾸ԽN8gg9N̳8̑@[7J*:3G?!AǢϖZ>O}`Oj7L>n t߀#:9iap坎+ghx}|==2c]ڮ۵q̮ Ayn\:BӾ1_6jyl}@dLgv'ioQPxC#s3fn<@xtp×4};k[#>񼳼o~}FuQH@tsRMq2<\qzPr 3s:7LWeï=R̄vJ7<@ d-c<놬-JSy~c<[TkGn<ȳ+B Om7LF"] -ǝyBNq+4)@ c,ecnZ7\n!Yg 7nt;tFv<+I3 ]V+ٛݴMMgG&WluOا4~ |!փMlO#ނw,)qbx)nE13ϻi*0Uh1o䕽&~Ë琜f„Q72n:;Yd;AwZ̟#`rVyEBӎ?x~YeG} K7dk/zi Wy7k w6FU-2c4Gсǹ' +@'Z1ZϐUPO?~R_/Tj:xͮ?Je<ڞ즛qTg <& z"[4'Xh7Sĭ#@NQg[\-ݼ'>MgHZ N*N7gߺ RH :ɳ`ɧuCVLxL(apr ~+j0cBK>ye-ް !._sW_~ZnTN9ǘT$$"ӧFuC+Ant\r3Rʳұn,%tVJ k@ϵxML@{zFW@kF%j.W&o%f^[Yx$;gQ;@wT]5HEt*ᦳr Urͳ {zXu$p[Qj<•bv\zD^BU $ړ.@y.OQ&!'tZD[m` G%}uY <{AI }꒜4TBT7az>=/3K|Tk_XlB]viR @l8[y{KڇeDڲOoY7Le&I7-`&'ԡOEy}I¤r:"B+SLD)%s 5,ij4H:tq G" aMUAVqar}J0ߙtx b|ګ4As4YS͘k /x&5N2KNjP0M]..5~ .7m:Cf u^gg k#X ( YcSJˁV JW9u:EH@jM/s 7 B|s#sֿH[dχ.ji@CHԍdhBATuQ\9[gwJϮvEsLgT(VD@|EܻHϻҦUh}?ڍųhLJB$r%~~wf+ټƆd +1{rH-~4hݬ_P$oIwi9t.Jb99`nr*".b- uVK%U,ɩx.\]5MU cM9+e^NrPVP]t ئ$ֹ;pZ߀>>D ?zK(#L?qE[+{YEB$3݇<uqJ"A9G 1qK`LrFuA}(2NEvE_YwVY]Qݘ*}oMOYN[O7lp} iI3y萼<5%Ra8%#h<%o5L9p>&x6d=8h3I9?t]=`x7F~?W!h F%$2໎Wd>Uubk^Euƿm?~3vcl@3z_%9Q[33D>8JJbٔc]q- wTSX<빸xwme lI7Jܠfk~w)\.&cҝzZŖ@ƿm/g`+Nrd-snHz5AoK;.BB@=ʻryot2TvȆ&od؊<ܠfk~w)\.;[J} BiR쿔gyme lI>O?k6}oܠfk~wyFȶ&_nMn^,]*|ӁU%G۳H//E`s󻬿6jϯ%\oWOnna.R|\tH)*FR⹴od~FijY*Pq+<,]3œy6RqKMeun9T9j8g*dz-ó w0Dj!{,:LG\3B+)];qIe6Ww`S9o0)< sp4dzWNa0mcKW¼_vkfDU^IǴ; ͢ G`dd8L}><-9c 6AΡi,i}2uЕdJ})}9*LKdz/?l{ưb_ٙJNF0š U:9ڡ飃2ј}< "ed=Yϥ*x-ey@JxV_~Ia'Yg:-,7h\W""ռ.ŁL.sњYy^:۶_l}k~<^.Cu]AU%șiu_|ϖGlEN{MYbF<y+31XXq5e/3YՉ")pvE9,_Ã]V >mC8-mۥ/;{`;I$~i/ R ,V{L< dɳ[tl^oEx>/ 'x65:]<ۂn*6v5Ԋ64LxQiq,<8g52p|>3jVg^|E5.f!pg8i!VG LK`:\g\,"@Śeݨ%~Σ:1\cςTv̋6ܾ ̋*ٕ /;Vd.`z1ngW|qv %\iFMQs,T+D2uP!Xb}e@ Yl .x_^ݸI,!/ց+9RA'Fuy~jx.e3QwZ夸08rJ_0&=<1SCq)/rlH5UR1]4;4RE޲]H9SJt}d͏sxV}UkVV;tð{;}I6H?SfF(t"93tcb{; G!G:72ɳ{aU#SOUx&( щPlO"f1:㫌皟ayW$ @3K,X{We=j+N9H^C;G0SLLɼk\C|"ӂsd3ɵ[&,x!yk"r|>5I_GQ}%k5ŀm'*z: ZAiewIHgU/&mA\fV~p:mܧK$zaS%(_J|a3IENDB`$$If!vh54 5 5k #v4 #v #vk :V l0654 5 5k 4$$If!vh54 5 5k #v4 #v #vk :V l0654 5 5k 4$$If!vh54 5 5k #v4 #v #vk :V l0654 5 5k 4$$If!vh54 5 5k #v4 #v #vk :V l0654 5 5k 4$$If!vh54 5 5k #v4 #v #vk :V l0654 5 5k 4$$If!vh54 5 5k #v4 #v #vk :V l0654 5 5k 4$$If!vh54 5 5k #v4 #v #vk :V l0654 5 5k 4Ddo#<P  3 P`h3"((-$$If!vh5v55|5#vv#v#v|#v:V l V0654a$$If!vh5v55|5#vv#v#v|#v:V l V0654a$$If!vh5v55|5#vv#v#v|#v:V l V0654a$$If!vh5v55|5#vv#v#v|#v:V l V0654a$$If!vh5525e5#v#v2#ve#v:V l t065525e5aytE$$If!vh5525e5#v#v2#ve#v:V l t065525e5aytE$$If!vh5525e5#v#v2#ve#v:V l t065525e5aytE$$If!vh5525e5#v#v2#ve#v:V l t065525e5aytE$$If!vh55#v:V l0654$$If!vh55#v:V l0654$$If!vh55#v:V l0654$$If!vh55#v:V l0654$$If!vh55#v:V l0654$$If!vh55W555I#v#vW#v#v#vI:V l V0654a$$If!vh55W555I#v#vW#v#v#vI:V l V0654a$$If!vh55W555I#v#vW#v#v#vI:V l V0654a$$If!vh55W555I#v#vW#v#v#vI:V l V0654a$$If!vh55W555I#v#vW#v#v#vI:V lP V0654a$$If!vh55X#v#vX:V l V06,5/ 4a$$If!vh55X#v#vX:V l V06,5/ 4a$$If!vh5 #v :V l V 606,54$$If.!vh55I5I5#v#vI#v:V l V0654a.$$If.!vh55I5I5#v#vI#v:V l V0654a.$$If.!vh55I5I5#v#vI#v:V l V0654a.$$Ifn!vh55X#v#vX:V l V065/ 4an$$Ifn!vh55X#v#vX:V l V065/ 4an$$If!vh5u #vu :V l V 6P06,54$$If&!vh55X#v#vX:V l V065/ 4a&$$If&!vh55X#v#vX:V l V065/ 4a&$$If!vh5 #v :V l V 6 %06,54$$If!vh555e5#v#v#ve#v:V l t06555e5aytE$$If!vh555e5#v#v#ve#v:V l t06555e5aytE$$If!vh555e5#v#v#ve#v:V l t06555e5aytE$$If!vh555e5#v#v#ve#v:V l t06555e5aytE$$If!vh555e5#v#v#ve#v:V l t06555e5aytE$$If!vh5555#v#v#v#v:V  V 6K B,5555/ 4$$If!vh5555#v#v#v#v:V  V 6K B,5555/ 4$$If!vh5555#v#v#v#v:V  V 6K B,5555/ 4$$If!vh5555#v#v#v#v:V  V 6K B,5555/  / 4$$If!vh55#v#v:V l t0655aytE$$If!vh55#v#v:V l t0655aytE$$If[ !vh55R5-#v#vR#v-:V l V0655R5-/ 4a[ $$If[ !vh55R5-#v#vR#v-:V l V0655R5-/ 4a[ $$If[ !vh55R5-#v#vR#v-:V l V0655R5-/ 4a[ $$If` !vh5x5#vx#v:V lj V06,5x54a` $$If` !vh5x5#vx#v:V l V06,5x54a` $$If!vh55#v#v:V l V 6z 0654$$If!vh55#v#v:V l V 6z 0654$$IfC!vh5 5: #v #v: :V l V065 5: 4aC$$If!vh5##v#:V ,   06,5/ 34p $$If!vh5##v#:V 065/ 34$$If!vh5 555 #v #v#v#v :V 06,5555/ 34$$If!vh5##v#:V 065y/ 34$$If!vh5 5*#v #v*:V   06,55/ 34p $$If!vh5 555 #v #v#v#v :V 06,,5555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5##v#:V 065y/ 34$$If!vh5 5*#v #v*:V   06,55/ 34p $$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5##v#:V 06,5/ 34$$If!vh5 5*#v #v*:V   06,55/ 34p $$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5##v#:V 06,5/ 34$$If!vh5 5*#v #v*:V   06,55/ 34p $$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5##v#:V 06,5/ 34$$If!vh5##v#:V ,   06,5/ 34p $$If!vh5 555 #v #v#v#v :V 06,5555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5##v#:V 06,5/ 34$$If!vh5##v#:V ,   06,5/ 34p $$If!vh5 555 #v #v#v#v :V 06,5555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5##v#:V 06,5/ 34$$If!vh5##v#:V ,   06,5/ 34p $$If!vh5 555 #v #v#v#v :V 06,5555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 06,5555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5##v#:V ,   06,5/ 34p $$If!vh5 555 #v #v#v#v :V 06,5555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5##v#:V ,   06,5/ 34p $$If!vh5 555 #v #v#v#v :V 06,5555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34$$If!vh5 555 #v #v#v#v :V 065555/ 34^% 002 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH @`@ NormalCJ_HaJmH sH tH l@l  Heading 1-$$ & Fxx@&]^a$5>*CJ\aJN@"N  Heading 2dd@&[$\$5CJ$\aJ$N@2N  Heading 3dd@&[$\$5CJ\aJF@BF  Heading 4dd@&[$\$5\L@L  Heading 5$dd@&[$\$ 5>*\PP  Heading 6$@&56CJOJQJ\]aJVV  Heading 7$$@&a$56CJOJQJ\]aJHH  Heading 8$$@&a$5CJ \aJ < @<  Heading 9 $@&CJaJDA`D Default Paragraph FontVi@V  Table Normal :V 44 la (k (No List 2>@2 Title$a$5\HR@H Body Text Indent 2 H^HDC@D Body Text Indent X^X4 @"4 Footer  9r *W@1* Strong5\L^@BL 0 Normal (Web)dd[$\$ B*ph2B@R2 Body Text\:P@b: Body Text 2OJ QJ 6r6 textdd[$\$tHbob 0GDefault 7$8$H$-B*CJOJQJ^J_HaJmH phsH tH jj Z>C Table Grid7:V0>O> /Normal+1 7$8$H$OJQJBOB / TJtulo 6+1 7$8$H$OJQJBOB FA TJtulo 1+1 7$8$H$OJQJ>O> FA TJtulo 9+1 B*^JphPOP FA Texto independiente B*^JphVoV Q|Style1$7$8$H$$CJOJQJ^J_HaJmH sH tH BOB  Encabezado+1 B*^JphXOX Texto independiente 3+1! B*^Jphhh SangrJa 2 de t. independiente+1" B*^Jph4U@14 EX0 Hyperlink >*php@Bp EX List Paragraph!$$dA$^m$CJOJ PJ QJ ^JaJPK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] 16Vs50)312416Vs ]h#!$=1c8@ HKNRUW`,ux|A{JvܐNIМe([߮sƻ 8V*i n%)>@?n???@AAABGXdsgggh'hKhhh$mry~~~~7B1JfҌҍҕc0$8h-?Xu2&s /Ih 9HRx&g*..577779A9CpCCCCELLM&MGMMU\]_```.ajkknqq{0~Q~ԁ<pϐA,9&^m|@VK_ulrnPtHJyfVrdO ac~$LPFx"6)MuAtbĥ<VBԨ\F^OtHzܰB:x Auٳ 2iִ+j"bζ<f@$l>2V:2F6"Z\T421   !"#%&'(*/123456789:>?@ACEGHJKLNOSTUVXZ]^_adfghiklnoqtuvwxz|}~    !"#$%&'()*+,-./013456789:;<=>?@ABCDEFGHIJKLMNOPfghijklmopqrstuvwxyz{|}~x)))8***A+++,,,4----3.5....c///U000<==%====>>(>>>>>>>S?U?q????5@7@E@@@@ A AAwAyAAAAAGBIBWBBBBCC%C}CCCCCCNDPDpDDDE\E^EtEEEE9F;FMFFFF GG$G|G~GGHHHvHxHHHHHJILIUIIIIJJ'JJJJHKJKLfLhLLMM Z\rœ:MOĠ Ρԡ.BD  Teg@CtCtCtCtC4C4C4C4C4CTC4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4C4CXXXXXXXXXXX8@&fz&(  \B  S D"?\B  S D"?\B   S D"?\B ! S D"?\B " S D"?\B # S D"? \B $ S D"? \B % S D"? \B ' S D"?\B ( S D"?V ) # )"?# \B *@ S D"?$\B + S D"?)\B , S D"?'\B - S D"?&\B .@ S D"?%\B /@ S D"?(V 0 # 0"?" V 1 # 1"?+ V 2 # 2"?, V 3 # 3"?* V 4 # 4"?- V 5 # 5"?  \B 6 S D"?.\B 7 S D"?/\B 8 S D"?!\B 9 S D"?0\B : S D"?1\B ; S D"?2\B < S D"?3\B = S D"?4\B > S D"?5\B ? S D"?6VB A C D"?86B B "?6B C "?6r D@ "?\B E S D"?6B F "?VB G C D"?VB H C D"?\B I S D"?\B J S D"?\B r S D"? \B s S D"?\B t S D"?VB  C D"? \B  S D"?\B  S D"?\B  S D"?\B  S D"?\B  S D"?\B  S D"?\B  S D"?7\B  S D"?:\B  S D"?9\B  C D#" ?I\B  C D#" ?JhB  S D3"?AhB  S D3"?@hB  S D3"?=hB @ S D3"?<hB  S D3"?KhB  S D3"?MhB @ S D3"?LB2  3"?OB2  3"?N\B  C D#" ?R\B  C D#" ?QbB  S D#" ?UbB @ S D#" ?TbB  C D3"?PbB  C D3"?SB  3"??B  3"?>Bb  3"?HB  3"?EB  3"?DB2  3"?GB2  3"?FhB  S D3"?ChB @ S D3"?B<B  #" ?;bB  S D#" ?V\B  S D"?W\B  S D"?X\B  S D"?Y\B  S D"?ZbB  S D#" ?[VB  C D"?\\B  S D1"?dbB  S D#" ?]bB  S D#" ?^bB  S D#" ?_bB  S D#" ?`bB  S D#" ?abB  S D#" ?bbB  S D#" ?c\B  S D"?bB  c $D"?\B  S D"?B S  ?= :  [^hhhXipUvv#w cɀL֌،܌݌@ߔ&ƕǕɕʕ˕͕̕Εgp'(p   +,6eno()-CD=tGGUBVcy{^MNn t!t t> #tJ` t t t(t"P ::t# Xt$@t% txrr ts` tt t  t` t(0 t BBt` t tBH8tCtDPtEp8tF<tI(tH//tGnnt'8t(zXzt5` t8@ t0o"t)t*ett. t-Ct,t/xs t+s st3Lt1 !t2t4`t6p t7t9pt:P ht; t< t=@ t>t? !!txNNtAtpM Mtpd dt6ZVr,r,r-r} rrKr0`rP0!r`drdPr0!D!rD0r!%r0B0r>Z>r@$@r T@ r@T!t r br!2P"br})}r@PrB88r)rR Kr *Kr #r0 8t t t@ t}2}rTrR"rBrr,,rR!"!rr,,r<rO1<~O1LO1}O1O1O1$O1dO1O1O1$O1dO1O1O16O1$O1|}O1rO1O1ssx|ZZ~~ܕܕ..i i .     w{ZZ~~44o o . 8 *urn:schemas-microsoft-com:office:smarttagsCity=*urn:schemas-microsoft-com:office:smarttags PlaceType=*urn:schemas-microsoft-com:office:smarttags PlaceName9*urn:schemas-microsoft-com:office:smarttagsplace E    {BLmw   } # + 6 = Q_ /OTU]Wa)6zjq)3HQku LN%. ' E I } !!!!!">"N"##$$112&23344_4`4>>??9@C@AA{AAKBUBDDeErE=FKFFFGGGG_KqKsKKKKK LMMMMMNN N NN N,NnNwNNNNN OO$O,O-O8ODOLOhOpOOOOOOOPP#Q+Q,Q7QGQIQ{Q}QQQQQQQQQQQ RRRRRR'R*RUUWV_V`VkVVVnWvWwWWWWWWWW6X>X?XJXeXtX&Y1Y7Y@YjYyYYYzZ}Z~ZZZZ[[T\\\k^s^``0`;`B`N`````8a@a|aaccdef fefvfgg[ghgrgg hh&h0hhh+i2iuiiiiiiiikkPmRmmmnnpowooo{pppp q"q-q1qqqDrXrrrJuRuuuvwXwbwjwuwxxN{U{ |'|H|J|+}1}}}}}}}~~~~~~HLāˁ#-5@ĂȂQUVZ}΅Յ ?A#48gp8:Žeiݏuyőɑ (0bi>H +8JT͙ٙkr>Efh+-ޞIKɟ˟ן۟AIYbfnowASZcdl>@*7LYgq(1JS©̩  (DLMScks{ҫ׫٫1?LV̭ԭ?I*4LV)4>HʱԱT[.5VXϴѴ"$UW϶ٶKU"$r|%:<uw mwx9CkuŽ*1_dпBIMW(Ye!y Zaz| Y[(04<=Eoz%q{#PZ"*+38Clo{M_#3 v%(7DMdq +n{KUr|=G4= jrLU"#+7#-|lvV`is ;?dn>GIVy7CES"&EO_c"4>ju%bls}@J6@AIZcGP29jv,8FMnw_h02ln%'a g         [ n p x   uzfr\e:=#!$CJ>H ,;>) :     2"="""##$$$$.%5%L%N%%%%%& &$&-&M&R&&&'!'((((B)K)))))*)*1*:*I*R*********y++++0,9,,,,,-+-. .S/\/i/s///Y0d0t0000111*1?1K11111111111111282A2Z2f2u22222222C3L3a3j3t33333333*434n4x4n5w555|66Z7a777778888888899C9L9a9c9q9z9999:N:X:::::c<h<q<y<z<<<<<<<<<<K=X=g=o=p=}===V>^>_>j>?? ??P?]?l?s???6B=BC$C-C/CCCDDwDxDDDEE-F4F5FAFcFjFkFzFFFFFFFFFGG"G*GUGbGGGGGGGGGGGH HHHM&MNNNNNNO OZO[OPPQQRRRRRRRRTTTTTUGUPUVUcUzUUUUUUUUUUUUUUUV4V@VOV[VlVrVsVVVVVV[[\\\\!],]]]]]_$_`aAcGcTc]cectcuccccNd\d|dddde eWfifkffffff gg2g>g@gNgh%hiijjkkkk)m+mzm|mmmmmmm n nn#nDnFnZn^nnnnno(ooodpjpqqqqr rssssuu)u2uuu1v:vvvww+x2xTxVxHyNyyyyyz z@zBzPzTzqzszzzzzzz{ {0{;{_{j{{{{{{{|#|`|k|||}}} ~BLZe€ʀ̀NY҂ׂ$+,2QYZ`Յ \kˇ؇ ψވÌǍɍZeƎ "#)'=ELS/6=?"OY|]lYceo[dENjpYcQUHLw{*3]f-45Ctyÿпۿ',078H{!%/{48bf{~  U`  "*BDQU+.beitOTX`ag*/[gJNR]egvz~,2_g+6<>su!BEkm#13>@DM\^ikot"^b 8;CSacx|hvnrxBFLVRj !,48lpos??MMNNooppttuuSfn 3 < z > @ d m /fi"(IRZU\,0BN1;>Hqu29^eow ' 6 A } !!##e#}#####$$$T$b$%%((s)v)2*6***+++,_,d,0 060F0001111112333;;>'>>>>>W?p???9@D@@@AA{AAAAKBVBBBC$CCCCCRDoDDE`EsEEE=FLFFFG#GGGHHzHHHHNITIIIJ&JJJKKjLLM8MbMhMMMNNOOVQXQR R'R,RmVqVHYJY%Z*Z____aaeeeejiqicmm-n0nennxxxxyz}zz{;{{{n}r}5C̈́ԄiloyЇ9:?rYaŽĎ'TdBFu{zٓƕԕ ݘS{ՠޠ|}ʣΣlt,0Į߮ڶٷݷ#~&TZd!2?E A`[c?UV[LRPUD]*OY>E 8:=')!kp F L z          c n   8:|;GUWkw:>&4$ ##&&**++U,[,,,....11>11111123 4666688c=}={@@iAoApAtACBuBBBDDGGIIVKcKKKLLZOORRST[T^TU@VZ8Z*[,[#\&\]^aaa bcjpjjjjMkmmynnbsms1vJv(z2z{{|} ~N~R~9MNT)-KYI{| 6?FNP3333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333 h{$mq V q>?AX } !!!##$$''=(J(9)R)33 4,444 5 5:5R58-8"=$=:MFM,W5W_`0`<```aaShh6jQjmn?nUn^o{o|ooooqq#wwyzz<{{{,|M|T||'}e}y~~~~~~ɀ|Zc*T\]z"*zɐϐҐݐݚ,IJ @k>Բ:QR[b³@Hsȵ"vζ CO߿|3$2v0|@ y  {     /g:5M0/""1###^$$*%m++1144h556:667f7}77899+:-:8>P>@"@AASB'C)ChC^DlDEEEF1K>KL#LLLMVN^RRRRWSfSTT8WPWYYZ[.[Q[[\JcSccc'ikiiikkk5lllhnynnoZoo,p8px5x6xxҀӀR.OVlՌ78X2uؕ[+:SdOĠ[gǤ\?LNnpsu 2 #13344st\"\"$$KV+]3vK3}b"yuDH2ZF(Ac_V?!ysw]nKe֨ˇ! `*g'ӕ3W:&(VNXgwq~:HZ *Ib~o>Lrr!ŹrΈBh mYJ bU4 Du2 :MYI Qi%&D6+1BT7i]0LJP"$n;2hI,qH Kط$\ `1ho H*&j!B#}F"Y7_,&?Y (ˣv^+ B-n Rf-Q-3 '[Y0j7"N8<;0ko@h7wAb:CV5Ej0Hh~Ii(G'% JJt`+:J'NDt/Nz\SGYWhT.'(U+QXT_-qjYl 2\`{p&\F_:Da`Z?]bhc>8sp>t!dp0t7A:krTTw |O{A}QtՃ* ]^`CJOJQJo( ]^`CJOJQJo(o ppp]p^p`CJOJQJo( @ @ @ ]@ ^@ `CJOJQJo( ]^`CJOJQJo( ]^`CJOJQJo( ]^`CJOJQJo( ]^`CJOJQJo( PPP]P^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(  hhh]h^h`o(-  hhh]h^h`OJo(    ] ^ `o(.    ] ^ `. xxLx]x^x`L. HHH]H^H`. ]^`. L]^`L. ]^`. ]^`. X X LX ]X ^X `L. ]^`o(.    ] ^ `.   L ] ^ `L. xxx]x^x`. HHH]H^H`. L]^`L. ]^`. ]^`. L]^`L. ]^`o(- ]^`o() ppLp]p^p`L. @ @ @ ]@ ^@ `. ]^`. L]^`L. ]^`. ]^`. PPLP]P^P`L.    ] ^ `o(.    ] ^ `. xxLx]x^x`L. HHH]H^H`. ]^`. L]^`L. ]^`. ]^`. X X LX ]X ^X `L. ]^`OJPJQJ^Jo(    ] ^ `OJPJQJ^Jo(-    ] ^ `OJQJo( xxx]x^x`OJQJo( HHH]H^H`OJQJo(o ]^`OJQJo( ]^`OJQJo( ]^`OJQJo(o ]^`OJQJo( ]^`CJOJQJo( ]^`CJOJQJo(o ppp]p^p`CJOJQJo( @ @ @ ]@ ^@ `CJOJQJo( ]^`CJOJQJo( ]^`CJOJQJo( ]^`CJOJQJo( ]^`CJOJQJo( PPP]P^P`CJOJQJo( ]^`o(-    ] ^ `.   L ] ^ `L. xxx]x^x`. HHH]H^H`. L]^`L. ]^`. ]^`. L]^`L. ]^`o(-    ] ^ `. xxLx]x^x`L. HHH]H^H`. ]^`. L]^`L. ]^`. ]^`. X X LX ]X ^X `L.^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(    ] ^ `o(-    ] ^ `. xxLx]x^x`L. HHH]H^H`. ]^`. L]^`L. ]^`. ]^`. X X LX ]X ^X `L.  hhh]h^h`o(-^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo( 888]8^8`o(- ]^`.   L ] ^ `L.    ] ^ `. xxx]x^x`. HHLH]H^H`L. ]^`. ]^`. L]^`L.@OJQJ^Jo(. xxx]x^x`o(. ]^`o(.  ^ `o(-   L ] ^ `L. xxx]x^x`. HHH]H^H`. L]^`L. ]^`. ]^`. L]^`L. ]^`CJOJQJo( ]^`CJOJQJo(o ppp]p^p`CJOJQJo( @ @ @ ]@ ^@ `CJOJQJo( ]^`CJOJQJo( ]^`CJOJQJo( ]^`CJOJQJo( ]^`CJOJQJo( PPP]P^P`CJOJQJo( ]^`CJOJQJo( ]^`CJOJQJo(o ppp]p^p`CJOJQJo( @ @ @ ]@ ^@ `CJOJQJo( ]^`CJOJQJo( ]^`CJOJQJo( ]^`CJOJQJo( ]^`CJOJQJo( PPP]P^P`CJOJQJo(@OJQJ^Jo(.@OJQJ^Jo(.H ]^`OJPJQJ^Jo(- ]^`OJQJo(o P P P ]P ^P `OJQJo(    ] ^ `OJQJo( ]^`OJQJo(o ]^`OJQJo( ]^`OJQJo( ```]`^``OJQJo(o 000]0^0`OJQJo( 888]8^8`o(- ]^`.   L ] ^ `L.    ] ^ `. xxx]x^x`. HHLH]H^H`L. ]^`. ]^`. L]^`L. 888]8^8`o(. xxx]x^x`o(. 888]8^8`o(. @ @ 0@ ]@ ^@ `0o(.   L ] ^ `L. xxx]x^x`. HHH]H^H`. L]^`L. ]^`. ]^`. L]^`L.@OJQJ^Jo(. hhh]h^h`OJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo( ]^`. ]^`. ppp]p^p`. @ @ @ ]@ ^@ `. ]^`. ]^`. ]^`. ]^`. PPP]P^P`. hhh]h^h`o(-V+QXF_7wAV5E7i]Bh$\ '% J-qjYj7Tw B-AMYI Rf-i%{A}!dpp&\ho &j!]bhcqH &$n:C+1m'(U֨}F"NY (<:Ib~2Z7_,&8<;>+]uI\ShI*g':J~InA2\qb"J u2 /N8spko@WhTK| TWa`c_0HVtW:sw]HJ-4 [Y0A:krv^+%`@hhh]h^h`56CJOJQJo(WW,V~+ /b&K:x|" U        pF        YB       d        *zP       if{ (a:$`^j |]>ڂ&_N@        KX        <\w        VtՀ^Bvs$fTnr[<(tƈ:00bC=lD{~D0GOG K^CP5R >S T9W(XEXR\8r_6gP h[h7FiHj kndn%pNqAu z6{a{v|{Q|e}VN+wB# FU=3B SbSQ4TaieYl:FeTTX^'J)!&7Wd.+nn&`Hz/c+)O8H &E\%Z vr^U!?A@s`ZRssX !45QRS_aLLxx56k<k=k?5A5B5D5EcFcGcHcNcOcPcTcUcVe]e^ebeceewwwwwwwwwwwCCCCCCCCCCC>P@P(PT@P>P@P\P^P@PlP@PP@P PD@P$PL@PJP@PRPTP@PZP@P^P@PbPdP@PlPnP@PtPvP@PP@PP@PPP@PPh@PPp@PP@PP@PPP@PPPPP@PPPX @PPPd @PPPPP @PPP @Px @Unknown G* Times New Roman5Symbol3. * ArialA. Arial Narrow;Wingdings?= * Courier NewO.  k9?Lucida Sans Unicode5. *aTahomaINBradley Hand ITCABook Antiqua7.{ @CalibriA BCambria Math"1hD!Lj!5GnI{QI{Q!x24dCC 2QHX?0G2M! xxEstimation of Blood Glucose Dr.MahmoudnshaabandV                           ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U Oh+'0 $0 P \ h tEstimation of Blood Glucose Dr.Mahmoud Normal.dotm nshaaban4Microsoft Office Word@.!3@U@PZ&@AQI{՜.+,D՜.+,X hp  Faculty of MedicineC Estimation of Blood Glucose Title 8@ _PID_HLINKSAhB?a;http://www.nlm.nih.gov/medlineplus/ency/article/000898.htm ?l;http://www.nlm.nih.gov/medlineplus/ency/article/000895.htm 6e;http://www.nlm.nih.gov/medlineplus/ency/article/000206.htm 0`;http://www.nlm.nih.gov/medlineplus/ency/article/000263.htm 6e;http://www.nlm.nih.gov/medlineplus/ency/article/001216.htm 0c;http://www.nlm.nih.gov/medlineplus/ency/article/000260.htm 2c;http://www.nlm.nih.gov/medlineplus/ency/article/001557.htm 0g;http://www.nlm.nih.gov/medlineplus/ency/article/000264.htm 5e;http://www.nlm.nih.gov/medlineplus/ency/article/000236.htm >d;http://www.nlm.nih.gov/medlineplus/ency/article/000287.htm 1a;http://www.nlm.nih.gov/medlineplus/ency/article/002353.htm   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqstuvwxy{|}~Root Entry FdYData N1TableJWordDocument.SummaryInformation(rDocumentSummaryInformation8zCompObjy  F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q